Polyforms and salts of a 1,6-naphthyridine compound and their use for the treatment of cancer

Abstract

The present disclosure provides forms of Compound No. 1: (Compound No. 1), solvates thereof, hydrates thereof, and pharmaceutically acceptable salts thereof. The present disclosure also provides processes for preparing the forms and uses of the forms, e.g., in preventing or treating cancer.

Description

Attorney Docket No. ASET-042 / 001WO 325190-2274 FORMS AND SALTS OF 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES RELATED APPLICATIONS

[0001] This application claims priority to and the benefit of U.S. Provisional Application No.63 / 637,945, filed on April 24, 2024, which is incorporated by reference herein in its entirety. REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The contents of the electronic sequence listing (ASET- 042_001WO_ST26_SequenceListing.xml; Size: 2,530 bytes; and Date of Creation: April 18, 2025) are herein incorporated by reference in their entireties. BACKGROUND

[0003] Specific mutations in the human gene BRAF, which encodes for the protein B-Raf, are known to drive oncogenic activity in a variety of different cancers. Targeted inactivation of mutant B-Raf proteins by the administration of protein kinase inhibitors has been used to treat a number of different cancers in patients. However, there are subsets of patients administered these treatments that either fail to respond, eventually relapse or experience secondary lesions / pathway rebound. More specifically, many of the existing B-Raf-targeting kinase inhibitors either exhibit low specificity for B-Raf, leading to undesirable off-target effects, or only target a specific subset of BRAF / B-Raf mutation(s). Thus, there is a long-felt need in the art for new therapies that target specific oncogenic forms of B-Raf produced by mutations or alterations of the BRAF gene. The present disclosure provides morphic forms of Compound No.1 for preventing or treating cancer in patients with oncogenic mutations in the BRAF gene and B-Raf protein. SUMMARY

[0004] In some aspects, the present disclosure provides a morphic form of Compound No.1:a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0005] In some aspects, the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0006] In some aspects, the present disclosure provides a method of treating or preventing cancer in a subject, the method comprising administering to the subject a morphic form of Compound No. 1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof (e.g., in a therapeutically effective amount).

[0007] In some aspects, the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a morphic form of Compound No. 1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof (e.g., in a therapeutically effective amount).

[0008] In some aspects, the present disclosure provides a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, for treating or preventing cancer in a subject.

[0009] In some aspects, the present disclosure provides a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, for treating cancer in a subject.

[0010] In some aspects, the present disclosure provides a use of a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing cancer in a subject.

[0011] In some aspects, the present disclosure provides a use of a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a subject.

[0012] In some aspects, the present disclosure provides a combination comprising a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, and one or more inhibitors of the MAPK pathways.

[0013] In some aspects, the present disclosure provides a method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising a morphic form of Compound No. 1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof (e.g., in a therapeutically effective amount) and one or more inhibitors of the MAPK pathways (e.g., in a therapeutically effective amount).

[0014] In some aspects, the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject a combination comprising aAttorney Docket No. ASET-042 / 001WO 325190-2274 morphic form of Compound No. 1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof (e.g., in a therapeutically effective amount) and one or more inhibitors of the MAPK pathways (e.g., in a therapeutically effective amount).

[0015] In some aspects, the present disclosure provides a combination comprising a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, and one or more inhibitors of the MAPK pathways, for treating or preventing cancer in a subject.

[0016] In some aspects, the present disclosure provides a combination comprising a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, and one or more inhibitors of the MAPK pathways, for treating cancer in a subject.

[0017] In some aspects, the present disclosure provides a use of a combination comprising a morphic form of Compound No. 1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, and one or more inhibitors of the MAPK pathways, in the manufacture of a medicament for treating or preventing cancer in a subject.

[0018] In some aspects, the present disclosure provides a use of a combination comprising a morphic form of Compound No. 1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, and one or more inhibitors of the MAPK pathways, in the manufacture of a medicament for treating cancer in a subject.

[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the specification, the singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods and examples are illustrative only and are not intended to be limiting. In the case of conflict between the chemical structures and names of the compounds disclosed herein, the chemical structures will control.

[0020] Other features and advantages of the disclosure will be apparent from the following detailed description and claims.Attorney Docket No. ASET-042 / 001WO 325190-2274 BRIEF DESCRIPTIONS OF FIGURES

[0021] FIG.1 depicts the XRPD pattern of Form A of Compound No.1.

[0022] FIG.2 depicts the DSC thermogram of Form A of Compound No.1.

[0023] FIG.3 depicts the TGA thermogram of Form A of Compound No.1.

[0024] FIG.4 depicts the1H-NMR spectrum of Form A of Compound No.1.

[0025] FIG.5 depicts the DVS isotherm and kinetic plots of Form A of Compound No.1.

[0026] FIG.6 depicts the XRPD pattern of Form D of Compound No.1.

[0027] FIG.7 depicts the DSC thermogram of Form D of Compound No.1.

[0028] FIG.8 depicts the TGA thermogram of Form D of Compound No.1.

[0029] FIG.9 depicts the1H-NMR spectrum of Form D of Compound No.1.

[0030] FIG.10 depicts the DVS isotherm and kinetic plots of Form D of Compound No.1.

[0031] FIG.11 depicts the XRPD pattern of Form I of Compound No.1.

[0032] FIG.12 depicts the DSC thermogram of Form I of Compound No.1.

[0033] FIG.13 depicts the TGA thermogram of Form I of Compound No.1.

[0034] FIG.14 depicts the1H-NMR spectrum of Form I of Compound No.1.

[0035] FIG.15 depicts the XRPD pattern of Form J of Compound No.1.

[0036] FIG.16 depicts the DSC thermogram of Form J of Compound No.1.

[0037] FIG.17 depicts the TGA thermogram of Form J of Compound No.1.

[0038] FIG.18 depicts the1H-NMR spectrum of Form J of Compound No.1.

[0039] FIG.19 depicts the DVS isotherm and kinetic plots of Form J of Compound No.1.

[0040] FIG.20 depicts the XRPD pattern of Form L of Compound No.1.

[0041] FIG.21 depicts the DSC thermogram of Form L of Compound No.1.

[0042] FIG.22 depicts the TGA thermogram of Form L of Compound No.1.

[0043] FIG.23 depicts the1H-NMR spectrum of Form L of Compound No.1.

[0044] FIG.24 depicts the DVS isotherm and kinetic plots of Form L of Compound No.1.

[0045] FIG.25 depicts the XRPD pattern of Form C of Compound No.1.

[0046] FIG.26 depicts the DSC thermogram of Form C of Compound No.1.

[0047] FIG.27 depicts the TGA thermogram of Form C of Compound No.1.

[0048] FIG.28 depicts the1H-NMR spectrum of Form C of Compound No.1.

[0049] FIG.29 depicts the XRPD pattern of Form D of Compound No.1.

[0050] FIG.30 depicts the DSC thermogram of Form D of Compound No.1.

[0051] FIG.31 depicts the TGA thermogram of Form D of Compound No.1.

[0052] FIG.32 depicts the1H-NMR spectrum of Form D of Compound No.1.

[0053] FIG.33 depicts the XRPD pattern of Form E of Compound No.1.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0054] FIG.34 depicts the DSC thermogram of Form E of Compound No.1.

[0055] FIG.35 depicts the TGA thermogram of Form E of Compound No.1.

[0056] FIG.36 depicts the1H-NMR spectrum of Form E of Compound No.1.

[0057] FIG.37 depicts the XRPD pattern of Form F of Compound No.1.

[0058] FIG.38 depicts the DSC thermogram of Form F of Compound No.1.

[0059] FIG.39 depicts the TGA thermogram of Form F of Compound No.1.

[0060] FIG.40 depicts the1H-NMR spectrum of Form F of Compound No.1.

[0061] FIG.41 depicts the XRPD pattern of Form G of Compound No.1.

[0062] FIG.42 depicts the DSC thermogram of Form G of Compound No.1.

[0063] FIG.43 depicts the TGA thermogram of Form G of Compound No.1.

[0064] FIG.44 depicts the1H-NMR spectrum of Form G of Compound No.1.

[0065] FIG.45 depicts the XRPD pattern of Form H of Compound No.1.

[0066] FIG.46 depicts the DSC thermogram of Form H of Compound No.1.

[0067] FIG.47 depicts the TGA thermogram of Form H of Compound No.1.

[0068] FIG.48 depicts the1H-NMR spectrum of Form H of Compound No.1.

[0069] FIG.49 depicts the XRPD pattern of Form I of Compound No.1.

[0070] FIG.50 depicts the DSC thermogram of Form I of Compound No.1.

[0071] FIG.51 depicts the TGA thermogram of Form I of Compound No.1.

[0072] FIG.52 depicts the1H-NMR spectrum of Form I of Compound No.1.

[0073] FIG. 53 depicts the DSC thermogram of Form I of Compound No. 1 after the solid was heated to 170 °C.

[0074] FIG.54 depicts the XRPD pattern of Form J of Compound No.1.

[0075] FIG.55 depicts the DSC thermogram of Form J of Compound No.1.

[0076] FIG.56 depicts the TGA thermogram of Form J of Compound No.1.

[0077] FIG.57 depicts the1H-NMR spectrum of Form J of Compound No.1.

[0078] FIG.58 depicts the XRPD pattern of Form K of Compound No.1.

[0079] FIG.59 depicts the DSC thermogram of Form K of Compound No.1.

[0080] FIG.60 depicts the TGA thermogram of Form K of Compound No.1.

[0081] FIG.61 depicts the1H-NMR spectrum of Form K of Compound No.1.

[0082] FIG.62 depicts the XRPD pattern of Form L of Compound No.1.

[0083] FIG.63 depicts the DSC thermogram of Form L of Compound No.1.

[0084] FIG.64 depicts the TGA thermogram of Form L of Compound No.1.

[0085] FIG.65 depicts the1H-NMR spectrum of Form L of Compound No.1.

[0086] FIG.66 depicts the XRPD pattern of Form M of Compound No.1.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0087] FIG.67 depicts the DSC thermogram of Form M of Compound No.1.

[0088] FIG.68 depicts the TGA thermogram of Form M of Compound No.1.

[0089] FIG.69 depicts the1H-NMR spectrum of Form M of Compound No.1.

[0090] FIG.70 depicts the XRPD pattern of Form N of Compound No.1.

[0091] FIG.71 depicts the DSC thermogram of Form N of Compound No.1.

[0092] FIG.72 depicts the TGA thermogram of Form N of Compound No.1.

[0093] FIG.73 depicts the1H-NMR spectrum of Form N of Compound No.1.

[0094] FIG.74 depicts the XRPD pattern of Form O of Compound No.1.

[0095] FIG.75 depicts the DSC thermogram of Form O of Compound No.1.

[0096] FIG.76 depicts the TGA thermogram of Form O of Compound No.1.

[0097] FIG.77 depicts the1H-NMR spectrum of Form O of Compound No.1.

[0098] FIG.78 depicts the XRPD pattern of Form P of Compound No.1.

[0099] FIG.79 depicts the DSC thermogram of Form P of Compound No.1.

[0100] FIG.80 depicts the TGA thermogram of Form P of Compound No.1.

[0101] FIG.81 depicts the1H-NMR spectrum of Form P of Compound No.1.

[0102] FIG.82 depicts the XRPD pattern of Form B of Compound No.1.

[0103] FIG.83 depicts the DSC thermogram of Form B of Compound No.1.

[0104] FIG.84 depicts the TGA thermogram of Form B of Compound No.1.

[0105] FIG.85 depicts the1H-NMR spectrum of Form B of Compound No.1.

[0106] FIG. 86 depicts the TGA thermogram of a composition comprising an amorphous form of Compound No.1 and PVP VA64.

[0107] FIG. 87 depicts the TGA thermogram of a composition comprising an amorphous form of Compound No.1 and HPMC ASMG.

[0108] FIG. 88 depicts the TGA thermogram of a composition comprising an amorphous form of Compound No.1 and HPMC E3.

[0109] FIG. 89 depicts the TGA thermogram of a composition comprising an amorphous form of Compound No.1 and Eudragit E100.

[0110] FIG. 90 depicts the TGA thermogram of a composition comprising an amorphous form of Compound No.1 and Eudragit L100-55.

[0111] FIG. 91 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and PVP VA64.

[0112] FIG. 92 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and HPMC ASMG.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0113] FIG. 93 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and HPMC E3.

[0114] FIG. 94 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and Eudragit E100.

[0115] FIG. 95 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and Eudragit L100-55.

[0116] FIG. 96 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and PVP VA64.

[0117] FIG. 97 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and Soluplus.

[0118] FIG. 98 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and Kollidon 12 PF.

[0119] FIG. 99 depicts the mDSC thermogram of a composition comprising an amorphous form of Compound No.1 and HPMC ASMG.

[0120] FIG.100 depicts the XRPD patterns of, from top to bottom, a composition comprising an amorphous form of Compound No. 1 and Eudragit L100-55, a composition comprising an amorphous form of Compound No. 1 and Eudragit E100, a composition comprising an amorphous form of Compound No.1 and HPMC E3, a composition comprising an amorphous form of Compound No. 1 and HPMC ASMG, a composition comprising an amorphous form of Compound No.1 and PVP VA64, and crystalline Compound No.1 (Form A). DETAILED DESCRIPTION

[0121] Without wishing to be bound by theory, it is understood that a morphic form disclosed herein may possess one or more advantages, e.g., as compared to other forms of the compound. For example, a morphic form disclosed herein (e.g., Form A) may have higher stability (e.g., thermodynamic stability, stability in high heat and humidity with minimal water sorption, and / or long-term stability) as shown in Examples described hereinafter.

[0122] It is understood that the term “Compound No.1,” as used herein, refers to a compound having the following structure:(Compound No.1)Attorney Docket No. ASET-042 / 001WO 325190-2274

[0123] Compound No.1 or a pharmaceutically acceptable salt thereof can be prepared by any suitable technique known in the art or as described in PCT Application No. PCT / US2022 / 076164 (incorporated herein by reference).

[0124] In some aspects, the present disclosure provides a morphic form of Compound No.1, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.

[0125] In some embodiments, the morphic form is a crystalline form.

[0126] In some embodiments, the morphic form is a morphic form (e.g., crystalline form) of Compound No.1, the solvate thereof, or the hydrate thereof.

[0127] In some embodiments, the morphic form is a morphic form (e.g., crystalline form) of Compound No.1.

[0128] In some embodiments, the morphic form is a morphic form (e.g., crystalline form) of a solvate (e.g., heterosolvate) of Compound No.1.

[0129] In some embodiments, the morphic form is a morphic form (e.g., crystalline form) of a hydrate of Compound No.1.

[0130] In some embodiments, the morphic form is a morphic form (e.g., crystalline form) of Compound No.1 or the pharmaceutically acceptable salt thereof.

[0131] In some embodiments, the morphic form is a morphic form (e.g., crystalline form) of a pharmaceutically acceptable salt of Compound No.1.

[0132] In some embodiments, the morphic form is Form A of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0133] In some embodiments, the morphic form is Form B of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0134] In some embodiments, the morphic form is Form C of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0135] In some embodiments, the morphic form is Form D of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0136] In some embodiments, the morphic form is Form E of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0137] In some embodiments, the morphic form is Form F of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0138] In some embodiments, the morphic form is Form G of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0139] In some embodiments, the morphic form is Form H of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0140] In some embodiments, the morphic form is Form I of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0141] In some embodiments, the morphic form is Form J of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0142] In some embodiments, the morphic form is Form K of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0143] In some embodiments, the morphic form is Form L of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0144] In some embodiments, the morphic form is Form M of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0145] In some embodiments, the morphic form is Form N of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0146] In some embodiments, the morphic form is Form O of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0147] In some embodiments, the morphic form is Form P of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0148] In some aspects, the present disclosure provides a method of preparing a morphic form of Compound No.1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof. Form A

[0149] In some embodiments, the morphic form is Form A of Compound No.1, a salt thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.

[0150] In some embodiments, the morphic form is Form A of Compound No.1. X-Ray Powder Diffraction (XRPD) Characterization

[0151] In some embodiments, Form A is characterized by an X-ray diffraction (“XRPD”)pattern comprising signals (e.g., peaks) at 13.2±0.2, 22.3±0.2, and 25.3±0.2 °2 (e.g., 13.2±0.1,22.3±0.1, and 25.3±0.1 °2 (e.g., 13.2, 22.3, and 25.3 °2 )) using Cu K radiation.

[0152] In some embodiments, the XRPD pattern of Form A further comprises at least onesignal (e.g., peak) selected from 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 18.5±0.1,19.4±0.1, and 24.8±0.1 °2 (e.g., 18.5, 19.4, and 24.8 °2 )) using Cu K radiation.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0153] In some embodiments, the XRPD pattern of Form A further comprises at least twosignals (e.g., peaks) selected from 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 18.5±0.1,19.4±0.1, and 24.8±0.1 °2 (e.g., 18.5, 19.4, and 24.8 °2 )) using Cu K radiation.

[0154] In some embodiments, the XRPD pattern of Form A further comprises signals (e.g.,peaks) at 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 18.5±0.1, 19.4±0.1, and 24.8±0.1 °2(e.g., 18.5, 19.4, and 24.8 °2 )) using Cu K radiation.

[0155] In some embodiments, the XRPD pattern of Form A further comprises at least onesignal (e.g., peak) selected from 12.8±0.2, 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g.,12.8±0.1, 18.5±0.1, 19.4±0.1, and 24.8±0.1 °2 (e.g., 12.8, 18.5, 19.4, and 24.8 °2 )) using CuK radiation.

[0156] In some embodiments, the XRPD pattern of Form A further comprises at least twosignals (e.g., peaks) selected from 12.8±0.2, 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g.,12.8±0.1, 18.5±0.1, 19.4±0.1, and 24.8±0.1 °2 (e.g., 12.8, 18.5, 19.4, and 24.8 °2 )) using CuK radiation.

[0157] In some embodiments, the XRPD pattern of Form A further comprises signals (e.g.,peaks) at 12.8±0.2, 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 12.8±0.1, 18.5±0.1, 19.4±0.1,and 24.8±0.1 °2 (e.g., 12.8, 18.5, 19.4, and 24.8 °2 )) using Cu K radiation.

[0158] In some embodiments, Form A is characterized by an X-ray diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 13.2±0.2, 18.5±0.2,19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2 (e.g., 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1,24.8±0.1, and 25.3±0.1 °2 (e.g., 13.2, 18.5, 19.4, 22.3, 24.8, and 25.3 °2 )) using Cu Kradiation.

[0159] In some embodiments, the XRPD pattern of Form A comprises at least four signals(e.g., peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2(e.g., 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 13.2, 18.5,19.4, 22.3, 24.8, and 25.3 °2 ))using Cu K radiation.

[0160] In some embodiments, the XRPD pattern of Form A comprises at least five signals(e.g., peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2(e.g., 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 13.2, 18.5,19.4, 22.3, 24.8, and 25.3 °2 ))using Cu K radiation.

[0161] In some embodiments, the XRPD pattern of Form A comprises signals (e.g., peaks) at12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2 (e.g., 12.8±0.1,13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 12.8, 13.2, 18.5,19.4, 22.3, 24.8, and 25.3 °2 )) using Cu K radiation.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0162] In some embodiments, Form A is characterized by an X-ray diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 12.8±0.2, 13.2±0.2,18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2 (e.g., 12.8±0.1, 13.2±0.1, 18.5±0.1,19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 12.8, 13.2, 18.5, 19.4, 22.3, 24.8, and25.3 °2 )) using Cu K radiation.

[0163] In some embodiments, the XRPD pattern of Form A comprises at least four signals (e.g., peaks) selected from 12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and25.3±0.2 °2 (e.g., 12.8±0.1, 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1°2 (e.g., 12.8, 13.2, 18.5, 19.4, 22.3, 24.8, and 25.3 °2 )) using Cu K radiation.

[0164] In some embodiments, the XRPD pattern of Form A comprises at least five signals (e.g., peaks) selected from 12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and25.3±0.2 °2 (e.g., 12.8±0.1, 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1°2 (e.g., 12.8, 13.2, 18.5, 19.4, 22.3, 24.8, and 25.3 °2 )) using Cu K radiation.

[0165] In some embodiments, the XRPD pattern of Form A comprises signals (e.g., peaks) at12.8±0.2, 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2 (e.g., 12.8±0.1,13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 12.8, 13.2, 18.5,19.4, 22.3, 24.8, and 25.3 °2 )) using Cu K radiation.

[0166] In some embodiments, Form A is characterized by an XRPD profile substantially similar to that shown in FIG.1.

[0167] In some embodiments, Form A is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in the table below. It is understood that the values in the table are approximate and subject to instrumental and experimental variations. Table 1: Exemplary XRPD Signal List for Form AAttorney Docket No. ASET-042 / 001WO 325190-2274Attorney Docket No. ASET-042 / 001WO 325190-2274 Differential Scanning Calorimeter (DSC) Characterizations

[0168] In some embodiments, Form A is characterized by a DSC curve having an endothermic signal (e.g., peak) at 208 ± 20°C (e.g., 208 ± 10 °C (e.g., 208 ± 5 °C (e.g., 208 ± 4 °C (e.g., 208 ± 3 °C (e.g., 208 ± 2 °C (e.g., 208 ± 1 °C (e.g., 208 ± 0.5 °C))))))).

[0169] In some embodiments, Form A is characterized by a DSC curve having an endothermic signal (e.g., peak) at 208 °C.

[0170] In some embodiments, Form A is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 93 ± 9 J / g (e.g., 93 ± 8 J / g (e.g., 93 ± 7 J / g (e.g., 93 ± 6 J / g (e.g., 93 ± 5 J / g (e.g., 93 ± 4 J / g (e.g., 93 ± 3 J / g (e.g., 93 ± 2 J / g))))))).

[0171] In some embodiments, Form A is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 93 J / g.

[0172] In some embodiments, Form A is characterized by a DSC profile substantially similar to that shown in FIG.2. Thermogravimetric Analysis (TGA) Characterizations

[0173] In some embodiments, Form A shows a weight loss of from about 0.05% to about 0.5%, at a temperature ranging from about 35 ± 20 °C (e.g., 35 ± 10 °C (e.g., 35 ± 5 °C (e.g., 35 ± 4 °C (e.g., 35 ± 3 °C (e.g., 35 ± 2 °C (e.g., 35 ± 1 °C (e.g., 35 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA.

[0174] In some embodiments, Form A shows a weight loss of about 0.28%, at a temperature ranging from about 35 °C to about 200 °C, as measured by TGA.

[0175] In some embodiments, Form A is characterized by a TGA profile substantially similar to that shown in FIG.3.

[0176] In some embodiments, the purity of Form A is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0177] In some embodiments, the purity of Form A is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0178] In some embodiments, the purity of Form A is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 25°C / 92.5%RH in an open container for a week.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0179] In some embodiments, the purity of Form A is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 40°C / 75% RH in an open container for a week.

[0180] In some embodiments, the purity of Form A is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 60°C in a closed container for a week.

[0181] In some embodiments, Form A is non-hygroscopic.

[0182] In some embodiments, Form A undergoes less than 0.5%, less than 0.4%, less than 0.3 %, less than 0.2%, or less than 0.1% water uptake at 95% RH.

[0183] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95%.

[0184] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95% after being compressed for 5 minutes under 2MPa.

[0185] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95% after being compressed for 5 minutes under 5MPa.

[0186] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95% after being compressed for 5 minutes under 10MPa.

[0187] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95% after being ground manually with a mortar and pestle for 1 min.

[0188] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95% after being ground manually with a mortar and pestle for 2 min.

[0189] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95% after being ground manually with a mortar and pestle for 5 min.

[0190] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95% after being wet by water and ground manually with a mortar and pestle.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0191] In some embodiments, Form A has a crystallinity of over 50%, over 55%, over 60%, over 65%, 70%, over 75%, over 80%, over 85%, over 90%, or over 95% after being wet by ethanol and ground manually with a mortar and pestle.

[0192] In some embodiments, Form A has a solubility of over 80 g / mL, over 90 g / mL, over 100 g / mL, over 110 g / mL, over 120 g / mL, or over 130 g / mL, in pH 1.2 HCl solution (0.1 N) over 2 hours.

[0193] In some embodiments, Form A has a solubility of over 60 g / mL, over 70 g / mL, over 80 g / mL, over 90 g / mL, or over 95 g / mL, in pH 1.2 HCl solution (0.1 N) over 24 hours.

[0194] In some embodiments, Form A has a solubility of over 60 g / mL, over 70 g / mL, over 80 g / mL, over 90 g / mL, over 100 g / mL, or over 110 g / mL, in SGF, pH 2.0 over 2 hours.

[0195] In some embodiments, Form A has a solubility of over 60 g / mL, over 70 g / mL, over 80 g / mL, over 90 g / mL, over 100 g / mL, or over 110 g / mL, in SGF, pH 2.0 over 24 hours.

[0196] In some embodiments, Form A has a solubility of over 1 g / mL, over 2 g / mL, over 4 g / mL, over 6 g / mL, over 8 g / mL, or over 10 g / mL in FeSSIF-v1, pH 5.0 over 2 hours.

[0197] In some embodiments, Form A has a solubility of over 5 g / mL, over 10 g / mL, over 15 g / mL, or over 20 g / mL in FeSSIF-v1, pH 5.0 over 24 hours. Form B

[0198] In some embodiments, the morphic form is Form B of Compound No.1, a salt thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.

[0199] In some embodiments, the morphic form is Form B of Compound No.1. X-Ray Powder Diffraction (XRPD) Characterization

[0200] In some embodiments, Form B is characterized by an XRPD profile substantially similar to that shown in FIG.82. Differential Scanning Calorimeter (DSC) Characterizations

[0201] In some embodiments, Form B is characterized by a DSC curve having an endothermic signal (e.g., peak) at 208 ± 20°C (e.g., 208 ± 10 °C (e.g., 208 ± 5 °C (e.g., 208 ± 4 °C (e.g., 208 ± 3 °C (e.g., 208 ± 2 °C (e.g., 208 ± 1 °C (e.g., 208 ± 0.5 °C))))))).

[0202] In some embodiments, Form B is characterized by a DSC curve having an endothermic signal (e.g., peak) at 208 °C.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0203] In some embodiments, Form B is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 86 ± 9 J / g (e.g., 86 ± 8 J / g (e.g., 86 ± 7 J / g (e.g., 86 ± 6 J / g (e.g., 86 ± 5 J / g (e.g., 86 ± 4 J / g (e.g., 86 ± 3 J / g (e.g., 86 ± 2 J / g))))))).

[0204] In some embodiments, Form B is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 86 J / g.

[0205] In some embodiments, Form B is characterized by a DSC profile substantially similar to that shown in FIG.83. Thermogravimetric Analysis (TGA) Characterizations

[0206] In some embodiments, Form B shows a weight loss of from about 0.5% to about 4.0%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 180 ± 20 °C (e.g., 180 ± 10 °C (e.g., 180 ± 5 °C (e.g., 180 ± 4 °C (e.g., 180 ± 3 °C (e.g., 180 ± 2 °C (e.g., 180 ± 1 °C (e.g., 180 ± 0.5 °C))))))), as measured by TGA.

[0207] In some embodiments, Form B shows a weight loss of about 2.3%, at a temperature ranging from about 34 °C to about 180 °C, as measured by TGA.

[0208] In some embodiments, Form B is characterized by a TGA profile substantially similar to that shown in FIG.84. Form C

[0209] In some embodiments, the morphic form is Form C of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0210] In some embodiments, the morphic form is Form C of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0211] In some embodiments, the morphic form is Form C of a hydrochloride salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0212] In some embodiments, the morphic form is Form C of a hydrochloride salt of Compound No.1.

[0213] In some embodiments, the hydrochloride salt comprises Compound No. 1 and hydrochloric acid present at a ratio of about 1:1. In some embodiments, the hydrochloride salt comprises Compound No. 1 and hydrochloric acid present at a ratio of about 1:2. In some embodiments, the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 2:1.Attorney Docket No. ASET-042 / 001WO 325190-2274 X-Ray Powder Diffraction (XRPD) Characterization

[0214] In some embodiments, Form C is characterized by an XRPD profile substantially similar to that shown in FIG.25. Differential Scanning Calorimeter (DSC) Characterizations

[0215] In some embodiments, Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) at 56.6 ± 20°C (e.g., 56.6 ± 10 °C (e.g., 56.6 ± 5 °C (e.g., 56.6 ± 4 °C (e.g., 56.6 ± 3 °C (e.g., 56.6 ± 2 °C (e.g., 56.6 ± 1 °C (e.g., 56.6 ± 0.5 °C))))))).

[0216] In some embodiments, Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) at 56.6 °C.

[0217] In some embodiments, Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) at 188 ± 20°C (e.g., 188 ± 10 °C (e.g., 188 ± 5 °C (e.g., 188 ± 4 °C (e.g., 188 ± 3 °C (e.g., 188 ± 2 °C (e.g., 188 ± 1 °C (e.g., 188 ± 0.5 °C))))))).

[0218] In some embodiments, Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) at 188 °C.

[0219] In some embodiments, Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 4.09 ± 0.4 J / g (e.g., 4.09 ± 0.3 J / g (e.g., 4.09 ± 0.2 J / g (e.g., 4.09 ± 0.1 J / g (e.g., 4.09 ± 0.08 J / g (e.g., 4.09 ± 0.06 J / g (e.g., 4.09 ± 0.04 J / g (e.g., 4.09 ± 0.02 J / g))))))).

[0220] In some embodiments, Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 4.09 J / g.

[0221] In some embodiments, Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 111 ± 12 J / g (e.g., 111 ± 10 J / g (e.g., 111 ± 8 J / g (e.g., 111 ± 6 J / g (e.g., 111 ± 4 J / g (e.g., 111 ± 3 J / g (e.g., 111 ± 2 J / g (e.g., 111 ± 1 J / g))))))).

[0222] In some embodiments, Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 111 J / g.

[0223] In some embodiments, Form C is characterized by a DSC profile substantially similar to that shown in FIG.26. Thermogravimetric Analysis (TGA) Characterizations

[0224] In some embodiments, Form C shows a weight loss of from about 0.05% to about 2.5%, at a temperature ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C))))))) to about 100Attorney Docket No. ASET-042 / 001WO 325190-2274 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0225] In some embodiments, Form C shows a weight loss of about 0.9%, at a temperature ranging from about 33 °C to about 100 °C, as measured by TGA.

[0226] In some embodiments, Form C shows a weight loss of from about 1% to about 7%, at a temperature ranging from about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA.

[0227] In some embodiments, Form C shows a weight loss of about 4.4%, at a temperature ranging from about 100 °C to about 200 °C, as measured by TGA.

[0228] In some embodiments, Form C is characterized by a TGA profile substantially similar to that shown in FIG.27. Form D

[0229] In some embodiments, the morphic form is Form D of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0230] In some embodiments, the morphic form is Form D of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0231] In some embodiments, the morphic form is Form D of a hydrochloride salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0232] In some embodiments, the morphic form is Form D of a hydrochloride salt of Compound No.1.

[0233] In some embodiments, the hydrochloride salt comprises Compound No. 1 and hydrochloric acid present at a ratio of about 1:1. In some embodiments, the hydrochloride salt comprises Compound No. 1 and hydrochloric acid present at a ratio of about 1:2. In some embodiments, the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 1:3. In some embodiments, the hydrochloride salt comprises Compound No. 1 and hydrochloric acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0234] In some embodiments, Form D is characterized by an X-ray diffraction (“XRPD”)pattern comprising signals (e.g., peaks) at 7.7±0.2, 21.2±0.2, and 26.3±0.2 °2 (e.g., 7.7±0.1,21.2±0.1, and 26.3±0.1 °2 (e.g., 7.7, 21.2, and 26.3 °2 )) using Cu K radiation.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0235] In some embodiments, the XRPD pattern of Form D further comprises at least onesignal (e.g., peak) selected from 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 27.8±0.1,28.7±0.1, and 30.2±0.1 °2 (e.g., 27.8, 28.7, and 30.2 °2 )) using Cu K radiation.

[0236] In some embodiments, the XRPD pattern of Form D further comprises at least twosignals (e.g., peaks) selected from 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 27.8±0.1,28.7±0.1, and 30.2±0.1 °2 (e.g., 27.8, 28.7, and 30.2 °2 )) using Cu K radiation.

[0237] In some embodiments, the XRPD pattern of Form D further comprises signals (e.g.,peaks) at 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2(e.g., 27.8, 28.7, and 30.2 °2 )) using Cu K radiation.

[0238] In some embodiments, Form D is characterized by an X-ray diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2,27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1,and 30.2±0.1 °2 (e.g., 7.7, 21.2, 26.3, 27.8, 28.7, and 30.2 °2 )) using Cu K radiation.

[0239] In some embodiments, the XRPD pattern of Form D comprises at least four signals(e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2(e.g., 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2 (e.g., 7.7, 21.2, 26.3,27.8, 28.7, and 30.2 °2 )) using Cu K radiation.

[0240] In some embodiments, the XRPD pattern of Form D comprises at least five signals(e.g., peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2(e.g., 7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2 (e.g., 7.7, 21.2, 26.3,27.8, 28.7, and 30.2 °2 )) using Cu K radiation.

[0241] In some embodiments, the XRPD pattern of Form D comprises signals (e.g., peaks) at7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 7.7±0.1, 21.2±0.1,26.3±0.1, 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2 (e.g., 7.7, 21.2, 26.3, 27.8, 28.7, and 30.2 °2 ))using Cu K radiation.

[0242] In some embodiments, Form D is characterized by an XRPD pattern substantially similar to those shown in FIGs.6 or 29.

[0243] In some embodiments, Form D is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in the table below. It is understood that the values in the table are approximate and subject to instrumental and experimental variations.Attorney Docket No. ASET-042 / 001WO 325190-2274 Table 2: Exemplary XRPD Signal List for Form DAttorney Docket No. ASET-042 / 001WO 325190-2274 Differential Scanning Calorimeter (DSC) Characterizations

[0244] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 61.5 ± 20°C (e.g., 61.5 ± 10 °C (e.g., 61.5 ± 5 °C (e.g., 61.5 ± 4 °C (e.g., 61.5 ± 3 °C (e.g., 61.5 ± 2 °C (e.g., 61.5 ± 1 °C (e.g., 61.5 ± 0.5 °C))))))).

[0245] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 61.5 °C.

[0246] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 141 ± 20°C (e.g., 141 ± 10 °C (e.g., 141 ± 5 °C (e.g., 141 ± 4 °C (e.g., 141 ± 3 °C (e.g., 141 ± 2 °C (e.g., 141 ± 1 °C (e.g., 141 ± 0.5 °C))))))).

[0247] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 141 °C.

[0248] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 67 ± 20°C (e.g., 67 ± 10 °C (e.g., 67 ± 5 °C (e.g., 67 ± 4 °C (e.g., 67 ± 3 °C (e.g., 67 ± 2 °C (e.g., 67 ± 1 °C (e.g., 67 ± 0.5 °C))))))).

[0249] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 67 °C.

[0250] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 145 ± 20°C (e.g., 145 ± 10 °C (e.g., 145 ± 5 °C (e.g., 145 ± 4 °C (e.g., 145 ± 3 °C (e.g., 145 ± 2 °C (e.g., 145 ± 1 °C (e.g., 145 ± 0.5 °C))))))).

[0251] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 145 °C.

[0252] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 8.48 ± 0.8 J / g (e.g., 8.48 ± 0.7 J / g (e.g., 8.48 ± 0.6 J / g (e.g., 8.48 ± 0.5 J / g (e.g., 8.48 ± 0.4 J / g (e.g., 8.48 ± 0.3 J / g (e.g., 8.48 ± 0.2 J / g (e.g., 8.48 ± 0.1 J / g))))))).

[0253] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 8.48 J / g.

[0254] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 354 ± 35 J / g (e.g., 354 ± 30 J / g (e.g., 354 ± 25 J / g (e.g., 354 ± 20 J / g (e.g., 354 ± 15 J / g (e.g., 354 ± 10 J / g (e.g., 354 ± 5 J / g (e.g., 354 ± 3 J / g))))))).

[0255] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 354 J / g.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0256] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 16.2 ± 2 J / g (e.g., 16.2 ± 1.5 J / g (e.g., 16.2 ± 1 J / g (e.g., 16.2 ± 0.8 J / g (e.g., 16.2 ± 0.6 J / g (e.g., 16.2 ± 0.4 J / g (e.g., 16.2 ± 0.2 J / g (e.g., 16.2 ± 0.1 J / g))))))).

[0257] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 16.2 J / g.

[0258] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 255 ± 25 J / g (e.g., 255 ± 20 J / g (e.g., 255 ± 15 J / g (e.g., 255 ± 10 J / g (e.g., 255 ± 5 J / g (e.g., 255 ± 4 J / g (e.g., 255 ± 2 J / g (e.g., 255 ± 1 J / g))))))).

[0259] In some embodiments, Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 255 J / g.

[0260] In some embodiments, Form D is characterized by a DSC profile substantially similar to those shown in FIGs.7 or 30. Thermogravimetric Analysis (TGA) Characterizations

[0261] In some embodiments, Form D shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 90 ± 20 °C (e.g., 90 ± 10 °C (e.g., 90 ± 5 °C (e.g., 90 ± 4 °C (e.g., 90 ± 3 °C (e.g., 90 ± 2 °C (e.g., 90 ± 1 °C (e.g., 90 ± 0.5 °C))))))), as measured by TGA.

[0262] In some embodiments, Form D shows a weight loss of about 1.8%, at a temperature ranging from about 34 °C to about 90 °C, as measured by TGA.

[0263] In some embodiments, Form D shows a weight loss of from about 10% to about 25%, at a temperature ranging from about 90 ± 20 °C (e.g., 90 ± 10 °C (e.g., 90 ± 5 °C (e.g., 90 ± 4 °C (e.g., 90 ± 3 °C (e.g., 90 ± 2 °C (e.g., 90 ± 1 °C (e.g., 90 ± 0.5 °C))))))) to about 170 ± 20 °C (e.g., 170 ± 10 °C (e.g., 170 ± 5 °C (e.g., 170 ± 4 °C (e.g., 170 ± 3 °C (e.g., 170 ± 2 °C (e.g., 170 ± 1 °C (e.g., 170 ± 0.5 °C))))))), as measured by TGA.

[0264] In some embodiments, Form D shows a weight loss of about 17%, at a temperature ranging from about 90 °C to about 170 °C, as measured by TGA.

[0265] In some embodiments, Form D shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20Attorney Docket No. ASET-042 / 001WO 325190-2274 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0266] In some embodiments, Form D shows a weight loss of about 2.6%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA.

[0267] In some embodiments, Form D shows a weight loss of from about 8% to about 25%, at a temperature ranging from about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA.

[0268] In some embodiments, Form D shows a weight loss of about 15%, at a temperature ranging from about 100 °C to about 200 °C, as measured by TGA.

[0269] In some embodiments, Form D is characterized by a TGA profile substantially similar to those shown in FIGs.8 or 31.

[0270] In some embodiments, the purity of Form D is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0271] In some embodiments, the purity of Form D is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0272] In some embodiments, the purity of Form D is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 25°C / 92.5%RH in an open container for a week.

[0273] In some embodiments, the purity of Form D is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 40°C / 75% RH in an open container for a week.

[0274] In some embodiments, the purity of Form D is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 60°C in a closed container for a week.

[0275] In some embodiments, Form D has a solubility of over 80 g / mL, over 100 g / mL, over 120 g / mL, over 140 g / mL, or over 160 g / mL, in pH 1.2 HCl solution (0.1 N) over 2 hours.

[0276] In some embodiments, Form D has a solubility of over 50 g / mL, over 60 g / mL, over 70 g / mL, over 80 g / mL, or over 90 g / mL, in pH 1.2 HCl solution (0.1 N) over 24 hours.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0277] In some embodiments, Form D has a solubility of over 60 g / mL, over 70 g / mL, over 80 g / mL, over 90 g / mL, over 100 g / mL, over 110 g / mL, or over 120 g / mL, in SGF, pH 2.0 over 2 hours.

[0278] In some embodiments, Form D has a solubility of over 60 g / mL, over 70 g / mL, over 80 g / mL, over 90 g / mL, over 100 g / mL, or over 110 g / mL, in SGF, pH 2.0 over 24 hours.

[0279] In some embodiments, Form D has a solubility of over 1 g / mL, over 2 g / mL, over 3 g / mL, over 4 g / mL, over 5 g / mL, or over 7 g / mL in FaSSIF-v1, pH 6.5 over 2 hours.

[0280] In some embodiments, Form D has a solubility of 2 g / mL, over 4 g / mL, over 6 g / mL, over 8 g / mL, over 10 g / mL, or over 12 g / mL in FaSSIF-v1, pH 6.5 over 24 hours.

[0281] In some embodiments, Form D has a solubility of over 50 g / mL, over 100 g / mL, over 150 g / mL, over 200 g / mL, or over 250 g / mL in FeSSIF-v1, pH 5.0 over 2 hours.

[0282] In some embodiments, Form D has a solubility of 10 g / mL, over 20 g / mL, over 30 g / mL, or over 40 g / mL in FeSSIF-v1, pH 5.0 over 24 hours.

[0283] In some embodiments, Form D has a solubility of over 60 g / mL, over 80 g / mL, over 100 g / mL, over 120 g / mL, over 140 g / mL, or over 160 g / mL, in water over 2 hours.

[0284] In some embodiments, Form D has a solubility of over 60 g / mL, over 80 g / mL, over 100 g / mL, over 120 g / mL, over 140 g / mL, or over 160 g / mL, in water over 24 hours. Form E

[0285] In some embodiments, the morphic form is Form E of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0286] In some embodiments, the morphic form is Form E of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0287] In some embodiments, the morphic form is Form E of a sulfate salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0288] In some embodiments, the morphic form is Form E of a sulfate salt of Compound No. 1.

[0289] In some embodiments, the sulfate salt comprises Compound No. 1 and sulfuric acid present at a ratio of about 1:1. In some embodiments, the sulfate salt comprises Compound No. 1 and sulfuric acid present at a ratio of about 1:2. In some embodiments, the sulfate salt comprises Compound No.1 and sulfuric acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) CharacterizationAttorney Docket No. ASET-042 / 001WO 325190-2274

[0290] In some embodiments, Form E is characterized by an XRPD profile substantially similar to that shown in FIG.33. Differential Scanning Calorimeter (DSC) Characterizations

[0291] In some embodiments, Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) at 65.9 ± 20°C (e.g., 65.9 ± 10 °C (e.g., 65.9 ± 5 °C (e.g., 65.9 ± 4 °C (e.g., 65.9 ± 3 °C (e.g., 65.9 ± 2 °C (e.g., 65.9 ± 1 °C (e.g., 65.9 ± 0.5 °C))))))).

[0292] In some embodiments, Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) at 65.9 °C.

[0293] In some embodiments, Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) at 200 ± 20°C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))).

[0294] In some embodiments, Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) at 200 °C.

[0295] In some embodiments, Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 19.3 ± 2.0 J / g (e.g., 19.3 ± 1.5 J / g (e.g., 19.3 ± 1.0 J / g (e.g., 19.3 ± 0.8 J / g (e.g., 19.3 ± 0.6 J / g (e.g., 19.3 ± 0.4 J / g (e.g., 19.3 ± 0.2 J / g (e.g., 19.3 ± 0.1 J / g))))))).

[0296] In some embodiments, Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 19.3 J / g.

[0297] In some embodiments, Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 64.3 ± 6.5 J / g (e.g., 64.3 ± 4.0 J / g (e.g., 64.3 ± 2.0 J / g (e.g., 64.3 ± 1.0 J / g (e.g., 64.3 ± 0.8 J / g (e.g., 64.3 ± 0.6 J / g (e.g., 64.3 ± 0.4 J / g (e.g., 64.3 ± 0.2 J / g))))))).

[0298] In some embodiments, Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 64.3 J / g.

[0299] In some embodiments, Form E is characterized by a DSC profile substantially similar to that shown in FIG.34. Thermogravimetric Analysis (TGA) Characterizations

[0300] In some embodiments, Form E shows a weight loss of from about 0.05% to about 4.5%, at a temperature ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C))))))) to about 100Attorney Docket No. ASET-042 / 001WO 325190-2274 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0301] In some embodiments, Form E shows a weight loss of about 1.3%, at a temperature ranging from about 33 °C to about 100 °C, as measured by TGA.

[0302] In some embodiments, Form E is characterized by a TGA profile substantially similar to that shown in FIG.35. Form F

[0303] In some embodiments, the morphic form is Form F of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0304] In some embodiments, the morphic form is Form F of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0305] In some embodiments, the morphic form is Form F of a phosphate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0306] In some embodiments, the morphic form is Form F of a phosphate salt of Compound No.1.

[0307] In some embodiments, the phosphate salt comprises Compound No.1 and phosphoric acid present at a ratio of about 1:1. In some embodiments, the phosphate salt comprises Compound No. 1 and phosphoric acid present at a ratio of about 1:2. In some embodiments, the phosphate salt comprises Compound No. 1 and phosphoric acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0308] In some embodiments, Form F is characterized by an XRPD profile substantially similar to that shown in FIG.37. Differential Scanning Calorimeter (DSC) Characterizations

[0309] In some embodiments, Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) at 72.2 ± 20°C (e.g., 72.2 ± 10 °C (e.g., 72.2 ± 5 °C (e.g., 72.2 ± 4 °C (e.g., 72.2 ± 3 °C (e.g., 72.2 ± 2 °C (e.g., 72.2 ± 1 °C (e.g., 72.2 ± 0.5 °C))))))).

[0310] In some embodiments, Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) at 72.2 °C.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0311] In some embodiments, Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) at 159 ± 20°C (e.g., 159 ± 10 °C (e.g., 159 ± 5 °C (e.g., 159 ± 4 °C (e.g., 159 ± 3 °C (e.g., 159 ± 2 °C (e.g., 159 ± 1 °C (e.g., 159 ± 0.5 °C))))))).

[0312] In some embodiments, Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) at 159 °C.

[0313] In some embodiments, Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 64.4 ± 6.5 J / g (e.g., 64.4 ± 5.0 J / g (e.g., 64.4 ± 4.0 J / g (e.g., 64.4 ± 3.0 J / g (e.g., 64.4 ± 2.0 J / g (e.g., 64.4 ± 1.0 J / g (e.g., 64.4 ± 0.8 J / g (e.g., 64.4 ± 0.5 J / g))))))).

[0314] In some embodiments, Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 64.4 J / g.

[0315] In some embodiments, Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 33.6 ± 3.5 J / g (e.g., 33.6 ± 3.0 J / g (e.g., 33.6 ± 2.5 J / g (e.g., 33.6 ± 2.0 J / g (e.g., 33.6 ± 1.5 J / g (e.g., 33.6 ± 1.0 J / g (e.g., 33.6 ± 0.5 J / g (e.g., 33.6 ± 0.3 J / g))))))).

[0316] In some embodiments, Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 33.6 J / g.

[0317] In some embodiments, Form F is characterized by a DSC profile substantially similar to that shown in FIG.38. Thermogravimetric Analysis (TGA) Characterizations

[0318] In some embodiments, Form F shows a weight loss of from about 0.5% to about 7.5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0319] In some embodiments, Form F shows a weight loss of about 3.6%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA.

[0320] In some embodiments, Form F is characterized by a TGA profile substantially similar to that shown in FIG.39. Form G

[0321] In some embodiments, the morphic form is Form G of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0322] In some embodiments, the morphic form is Form G of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0323] In some embodiments, the morphic form is Form G of a phosphate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0324] In some embodiments, the morphic form is Form G of a phosphate salt of Compound No.1.

[0325] In some embodiments, the phosphate salt comprises Compound No.1 and phosphoric acid present at a ratio of about 1:1. In some embodiments, the phosphate salt comprises Compound No. 1 and phosphoric acid present at a ratio of about 1:2. In some embodiments, the phosphate salt comprises Compound No. 1 and phosphoric acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0326] In some embodiments, Form G is characterized by an XRPD profile substantially similar to that shown in FIG.41. Differential Scanning Calorimeter (DSC) Characterizations

[0327] In some embodiments, Form G is characterized by a DSC curve having an endothermic signal (e.g., peak) at 75.1 ± 20°C (e.g., 75.1 ± 10 °C (e.g., 75.1 ± 5 °C (e.g., 75.1 ± 4 °C (e.g., 75.1 ± 3 °C (e.g., 75.1 ± 2 °C (e.g., 75.1 ± 1 °C (e.g., 75.1 ± 0.5 °C))))))).

[0328] In some embodiments, Form G is characterized by a DSC curve having an endothermic signal (e.g., peak) at 75.1 °C.

[0329] In some embodiments, Form G is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 58.4 ± 6.0 J / g (e.g., 58.4 ± 5.0 J / g (e.g., 58.4 ± 4.0 J / g (e.g., 58.4 ± 3.0 J / g (e.g., 58.4 ± 2.0 J / g (e.g., 58.4 ± 1.5 J / g (e.g., 58.4 ± 1.0 J / g (e.g., 58.4 ± 0.5 J / g))))))).

[0330] In some embodiments, Form G is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 58.4 J / g.

[0331] In some embodiments, Form G is characterized by a DSC profile substantially similar to that shown in FIG.42. Thermogravimetric Analysis (TGA) Characterizations

[0332] In some embodiments, Form G shows a weight loss of from about 2.0% to about 7.5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4Attorney Docket No. ASET-042 / 001WO 325190-2274 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0333] In some embodiments, Form G shows a weight loss of about 4.1%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA.

[0334] In some embodiments, Form G is characterized by a TGA profile substantially similar to that shown in FIG.43. Form H

[0335] In some embodiments, the morphic form is Form H of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0336] In some embodiments, the morphic form is Form H of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0337] In some embodiments, the morphic form is Form H of a mesylate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0338] In some embodiments, the morphic form is Form H of a mesylate salt of Compound No.1.

[0339] In some embodiments, the mesylate salt comprises Compound No. 1 and methanesulfonic acid present at a ratio of about 1:1. In some embodiments, the mesylate salt comprises Compound No.1 and methanesulfonic acid present at a ratio of about 1:2. In some embodiments, the mesylate salt comprises Compound No.1 and methanesulfonic acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0340] In some embodiments, Form H is characterized by an XRPD profile substantially similar to that shown in FIG.45. Differential Scanning Calorimeter (DSC) Characterizations

[0341] In some embodiments, Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) at 72.4 ± 20°C (e.g., 72.4 ± 10 °C (e.g., 72.4 ± 5 °C (e.g., 72.4 ± 4 °C (e.g., 72.4 ± 3 °C (e.g., 72.4 ± 2 °C (e.g., 72.4 ± 1 °C (e.g., 72.4 ± 0.5 °C))))))).

[0342] In some embodiments, Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) at 72.4 °C.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0343] In some embodiments, Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) at 163 ± 20°C (e.g., 163 ± 10 °C (e.g., 163 ± 5 °C (e.g., 163 ± 4 °C (e.g., 163 ± 3 °C (e.g., 163 ± 2 °C (e.g., 163 ± 1 °C (e.g., 163 ± 0.5 °C))))))).

[0344] In some embodiments, Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) at 163 °C.

[0345] In some embodiments, Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 49.3 ± 5.0 J / g (e.g., 49.3 ± 4.5 J / g (e.g., 49.3 ± 4.0 J / g (e.g., 49.3 ± 3.5 J / g (e.g., 49.3 ± 3.0 J / g (e.g., 49.3 ± 2.5 J / g (e.g., 49.3 ± 2.0 J / g (e.g., 49.3 ± 1.0 J / g))))))).

[0346] In some embodiments, Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 49.3 J / g.

[0347] In some embodiments, Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 59.1 ± 6.0 J / g (e.g., 59.1 ± 4.0 J / g (e.g., 59.1 ± 3.0 J / g (e.g., 59.1 ± 2.0 J / g (e.g., 59.1 ± 1.5 J / g (e.g., 59.1 ± 1.0 J / g (e.g., 59.1 ± 0.5 J / g (e.g., 59.1 ± 0.3 J / g))))))).

[0348] In some embodiments, Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 59.1 J / g.

[0349] In some embodiments, Form H is characterized by a DSC profile substantially similar to that shown in FIG.46. Thermogravimetric Analysis (TGA) Characterizations

[0350] In some embodiments, Form H shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0351] In some embodiments, Form H shows a weight loss of about 2.4%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA.

[0352] In some embodiments, Form H is characterized by a TGA profile substantially similar to that shown in FIG.47. Form I

[0353] In some embodiments, the morphic form is Form I of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0354] In some embodiments, the morphic form is Form I of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0355] In some embodiments, the morphic form is Form I of a besylate salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0356] In some embodiments, the morphic form is Form I of a besylate salt of Compound No. 1.

[0357] In some embodiments, the besylate salt comprises Compound No. 1 and benzenesulfonic acid present at a ratio of about 1:1. In some embodiments, the besylate salt comprises Compound No. 1 and benzenesulfonic acid present at a ratio of about 1:2. In some embodiments, the besylate salt comprises Compound No. 1 and benzenesulfonic acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0358] In some embodiments, Form I is characterized by an X-ray diffraction (“XRPD”)pattern comprising signals (e.g., peaks) at 12.4±0.2, 16.6±0.2, and 23.4±0.2 °2 (e.g., 12.4±0.1,16.6±0.1, and 23.4±0.1 °2 (e.g., 12.4, 16.6, and 23.4 °2 )) using Cu K radiation.

[0359] In some embodiments, the XRPD pattern of Form I further comprises at least onesignal (e.g., peak) selected from 19.3±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 19.3±0.1,26.3±0.1, and 27.2±0.1 °2 (e.g., 19.3, 26.3, and 27.2 °2 )) using Cu K radiation.

[0360] In some embodiments, the XRPD pattern of Form I further comprises at least twosignals (e.g., peaks) selected from 19.3±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 19.3±0.1,26.3±0.1, and 27.2±0.1 °2 (e.g., 19.3, 26.3, and 27.2 °2 )) using Cu K radiation.

[0361] In some embodiments, the XRPD pattern of Form I further comprises signals (e.g.,peaks) at 19.3±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 19.3±0.1, 26.3±0.1, and 27.2±0.1 °2(e.g., 19.3, 26.3, and 27.2 °2 )) using Cu K radiation.

[0362] In some embodiments, Form I is characterized by an X-ray diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 12.4±0.2, 16.6±0.2,19.3±0.2, 23.4±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1,26.3±0.1, and 27.2±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6 °2 )) using Cu Kradiation.

[0363] In some embodiments, the XRPD pattern of Form I comprises at least four signals(e.g., peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2, and 27.2±0.2 °2(e.g., 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1, and 27.2±0.1 °2 (e.g., 6.7, 12.1, 15.1,17.5, 24.2, and 24.6 °2 )) using Cu K radiation.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0364] In some embodiments, the XRPD pattern of Form I comprises at least five signals (e.g.,peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g.,12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1, and 27.2±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5,24.2, and 24.6 °2 )) using Cu K radiation.

[0365] In some embodiments, the XRPD pattern of Form I comprises signals (e.g., peaks) at12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 12.4±0.1, 16.6±0.1,19.3±0.1, 23.4±0.1, 26.3±0.1, and 27.2±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6 °2 ))using Cu K radiation.

[0366] In some embodiments, Form I is characterized by an XRPD pattern substantially similar to that shown in FIGs.11 or 49.

[0367] In some embodiments, Form I is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in the table below. It is understood that the values in the table are approximate and subject to instrumental and experimental variations. Table 3: Exemplary XRPD Signal List for Form IAttorney Docket No. ASET-042 / 001WO 325190-2274Differential Scanning Calorimeter (DSC) Characterizations

[0368] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 233 ± 20°C (e.g., 233 ± 10 °C (e.g., 233 ± 5 °C (e.g., 233 ± 4 °C (e.g., 233 ± 3 °C (e.g., 233 ± 2 °C (e.g., 233 ± 1 °C (e.g., 233 ± 0.5 °C))))))).

[0369] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 233 °C.

[0370] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 128 ± 20°C (e.g., 128 ± 10 °C (e.g., 128 ± 5 °C (e.g., 128 ± 4 °C (e.g., 128 ± 3 °C (e.g., 128 ± 2 °C (e.g., 128 ± 1 °C (e.g., 128 ± 0.5 °C))))))).Attorney Docket No. ASET-042 / 001WO 325190-2274

[0371] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 128 °C.

[0372] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 235 ± 20°C (e.g., 235 ± 10 °C (e.g., 235 ± 5 °C (e.g., 235 ± 4 °C (e.g., 235 ± 3 °C (e.g., 235 ± 2 °C (e.g., 235 ± 1 °C (e.g., 235 ± 0.5 °C))))))).

[0373] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 235 °C.

[0374] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 96 ± 9 J / g (e.g., 96 ± 8 J / g (e.g., 96 ± 7 J / g (e.g., 96 ± 6 J / g (e.g., 96 ± 5 J / g (e.g., 96 ± 4 J / g (e.g., 96 ± 2 J / g (e.g., 96 ± 1 J / g))))))).

[0375] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 96 J / g.

[0376] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 40 ± 4 J / g (e.g., 40 ± 3 J / g (e.g., 40 ± 2 J / g (e.g., 40 ± 1 J / g (e.g., 40 ± 0.75 J / g (e.g., 40 ± 0.5 J / g (e.g., 40 ± 0.2 J / g (e.g., 40 ± 0.1 J / g))))))).

[0377] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 40 J / g.

[0378] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 88 ± 9 J / g (e.g., 88 ± 8 J / g (e.g., 88 ± 7 J / g (e.g., 88 ± 6 J / g (e.g., 88 ± 5 J / g (e.g., 88 ± 4 J / g (e.g., 88 ± 2 J / g (e.g., 88 ± 1 J / g))))))).

[0379] In some embodiments, Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 88 J / g.

[0380] In some embodiments, Form I is characterized by a DSC profile substantially similar to those shown in FIGs.12 or 50. Thermogravimetric Analysis (TGA) Characterizations

[0381] In some embodiments, Form I shows a weight loss of from about 0.1% to about 2%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 230 ± 20 °C (e.g., 230 ± 10 °C (e.g., 230 ± 5 °C (e.g., 230 ± 4 °C (e.g., 230 ± 3 °C (e.g., 230 ± 2 °C (e.g., 230 ± 1 °C (e.g., 230 ± 0.5 °C))))))), as measured by TGA.

[0382] In some embodiments, Form I shows a weight loss of about 0.5%, at a temperature ranging from about 34 °C to about 230 °C, as measured by TGA.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0383] In some embodiments, Form I is characterized by a TGA profile substantially similar to those shown in FIGs.13 or 51.

[0384] In some embodiments, the purity of Form I is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%. Form J

[0385] In some embodiments, the morphic form is Form J of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0386] In some embodiments, the morphic form is Form J of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0387] In some embodiments, the morphic form is Form J of a tosylate salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0388] In some embodiments, the morphic form is Form J of a tosylate salt of Compound No.

[0389] In some embodiments, the tosylate salt comprises Compound No. 1 and p- toluenesulfonic acid present at a ratio of about 1:1. In some embodiments, the tosylate salt comprises Compound No.1 and p-toluenesulfonic acid present at a ratio of about 1:2. In some embodiments, the tosylate salt comprises Compound No.1 and p-toluenesulfonic acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0390] In some embodiments, Form J is characterized by an X-ray diffraction (“XRPD”)pattern comprising signals (e.g., peaks) at 6.7±0.2, 12.1±0.2, and 15.1±0.2 °2 (e.g., 6.7±0.1,12.1±0.1, and 15.1±0.1 °2 (e.g., 6.7, 12.1, and 15.1 °2 )) using Cu K radiation.

[0391] In some embodiments, the XRPD pattern of Form J further comprises at least onesignal (e.g., peak) selected from 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 17.5±0.1,24.2±0.1, and 24.6±0.1 °2 (e.g., 17.5, 24.2, and 24.6 °2 )) using Cu K radiation.

[0392] In some embodiments, the XRPD pattern of Form J further comprises at least twosignals (e.g., peaks) selected from 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 17.5±0.1,24.2±0.1, and 24.6±0.1 °2 (e.g., 17.5, 24.2, and 24.6 °2 )) using Cu K radiation.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0393] In some embodiments, the XRPD pattern of Form J further comprises signals (e.g.,peaks) at 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2(e.g., 17.5, 24.2, and 24.6 °2 )) using Cu K radiation.

[0394] In some embodiments, Form J is characterized by an X-ray diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2,17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1,and 24.6±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6 °2 )) using Cu K radiation.

[0395] In some embodiments, the XRPD pattern of Form J comprises at least four signals(e.g., peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2(e.g., 6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2 (e.g., 6.7, 12.1, 15.1,17.5, 24.2, and 24.6 °2 )) using Cu K radiation.

[0396] In some embodiments, the XRPD pattern of Form J comprises at least five signals (e.g.,peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g.,6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5,24.2, and 24.6 °2 )) using Cu K radiation.

[0397] In some embodiments, the XRPD pattern of Form J comprises signals (e.g., peaks) at6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 6.7±0.1, 12.1±0.1,15.1±0.1, 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6 °2 ))using Cu K radiation.

[0398] In some embodiments, Form J is characterized by an XRPD pattern substantially similar to those shown in FIGs.15 or 54.

[0399] In some embodiments, Form J is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in the table below. It is understood that the values in the table are approximate and subject to instrumental and experimental variations. Table 4: Exemplary XRPD Signal List for Form JAttorney Docket No. ASET-042 / 001WO 325190-2274Differential Scanning Calorimeter (DSC) Characterizations

[0400] In some embodiments, Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) at 204 ± 20°C (e.g., 204 ± 10 °C (e.g., 204 ± 5 °C (e.g., 204 ± 4 °C (e.g., 204 ± 3 °C (e.g., 204 ± 2 °C (e.g., 204 ± 1 °C (e.g., 204 ± 0.5 °C))))))).Attorney Docket No. ASET-042 / 001WO 325190-2274

[0401] In some embodiments, Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) at 204 °C.

[0402] In some embodiments, Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 76 ± 8 J / g (e.g., 76 ± 7 J / g (e.g., 76 ± 6 J / g (e.g., 76 ± 5 J / g (e.g., 76 ± 4 J / g (e.g., 76 ± 3 J / g (e.g., 76 ± 2 J / g (e.g., 76 ± 1 J / g))))))).

[0403] In some embodiments, Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 76 J / g.

[0404] In some embodiments, Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) at 205 ± 20°C (e.g., 205 ± 10 °C (e.g., 205 ± 5 °C (e.g., 205 ± 4 °C (e.g., 205 ± 3 °C (e.g., 205 ± 2 °C (e.g., 205 ± 1 °C (e.g., 205 ± 0.5 °C))))))).

[0405] In some embodiments, Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) at 205 °C.

[0406] In some embodiments, Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 62 ± 6 J / g (e.g., 62 ± 5 J / g (e.g., 62 ± 4 J / g (e.g., 62 ± 3 J / g (e.g., 62 ± 2 J / g (e.g., 62 ± 1 J / g (e.g., 62 ± 0.75 J / g (e.g., 62 ± 0.5 J / g))))))).

[0407] In some embodiments, Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 62 J / g.

[0408] In some embodiments, Form J is characterized by a DSC profile substantially similar to those shown in FIGs.16 or 55. Thermogravimetric Analysis (TGA) Characterizations

[0409] In some embodiments, Form J shows a weight loss of from about 0.1% to about 2%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA.

[0410] In some embodiments, Form J shows a weight loss of about 0.7%, at a temperature ranging from about 34 °C to about 200 °C, as measured by TGA.

[0411] In some embodiments, Form J shows a weight loss of from about 0.1% to about 2.5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0412] In some embodiments, Form J shows a weight loss of about 0.9%, at a temperature ranging from about 34 °C to about 200 °C, as measured by TGA.

[0413] In some embodiments, Form J is characterized by a TGA profile substantially similar to those shown in FIGs.17 or 56.

[0414] In some embodiments, the purity of Form J is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0415] In some embodiments, Form J undergoes less than 2.0%, less than 1.5%, less than 1.0 %, less than 0.75%, or less than 0.5% water uptake at 95% RH.

[0416] In some embodiments, the purity of Form J is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 25°C / 92.5%RH in an open container for a week.

[0417] In some embodiments, the purity of Form J is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 40°C / 75% RH in an open container for a week.

[0418] In some embodiments, the purity of Form J is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 60°C in a closed container for a week.

[0419] In some embodiments, Form J has a solubility of over 20 g / mL, over 40 g / mL, over 60 g / mL, over 80 g / mL, over 100 g / mL, or over 110 g / mL, in pH 1.2 HCl solution (0.1 N) over 2 hours.

[0420] In some embodiments, Form J has a solubility of over 50 g / mL, over 60 g / mL, over 70 g / mL, over 80 g / mL, or over 90 g / mL, in pH 1.2 HCl solution (0.1 N) over 24 hours.

[0421] In some embodiments, Form J has a solubility of over 20 g / mL, over 40 g / mL, over 60 g / mL, over 80 g / mL, or over 100 g / mL, in SGF, pH 2.0 over 2 hours.

[0422] In some embodiments, Form J has a solubility of over 50 g / mL, over 60 g / mL, over 70 g / mL, over 80 g / mL, or over 90 g / mL, in SGF, pH 2.0 over 24 hours.

[0423] In some embodiments, Form J has a solubility of over 20 g / mL, over 40 g / mL, over 60 g / mL, over 80 g / mL, or over 100 g / mL, in FeSSIF-v1, pH 5.0 over 2 hours.

[0424] In some embodiments, Form J has a solubility of over 5 g / mL, over 10 g / mL, over 15 g / mL, or over 20 g / mL in FeSSIF-v1, pH 5.0 over 24 hours.

[0425] In some embodiments, Form J has a solubility of over 2 g / mL, over 4 g / mL, over 8 g / mL, over 12 g / mL, or over 16 g / mL in water over 2 hours.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0426] In some embodiments, Form J has a solubility of over 2 g / mL, over 4 g / mL, over 8 g / mL, over 12 g / mL, over 16 g / mL, or over 20 g / mL in water over 24 hours. Form K

[0427] In some embodiments, the morphic form is Form K of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0428] In some embodiments, the morphic form is Form K of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0429] In some embodiments, the morphic form is Form K of a maleate salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0430] In some embodiments, the morphic form is Form K of a maleate salt of Compound No.

[0431] In some embodiments, the maleate salt comprises Compound No. 1 and maleic acid present at a ratio of about 1:1. In some embodiments, the maleate salt comprises Compound No. 1 and maleic acid present at a ratio of about 1:2. In some embodiments, the maleate salt comprises Compound No.1 and maleic acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0432] In some embodiments, Form K is characterized by an XRPD profile substantially similar to that shown in FIG.58. Differential Scanning Calorimeter (DSC) Characterizations

[0433] In some embodiments, Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) at 57.1 ± 20°C (e.g., 57.1 ± 10 °C (e.g., 57.1 ± 5 °C (e.g., 57.1 ± 4 °C (e.g., 57.1 ± 3 °C (e.g., 57.1 ± 2 °C (e.g., 57.1 ± 1 °C (e.g., 57.1 ± 0.5 °C))))))).

[0434] In some embodiments, Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) at 57.1 °C.

[0435] In some embodiments, Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) at 121 ± 20°C (e.g., 121 ± 10 °C (e.g., 121 ± 5 °C (e.g., 121 ± 4 °C (e.g., 121 ± 3 °C (e.g., 121 ± 2 °C (e.g., 121 ± 1 °C (e.g., 121 ± 0.5 °C))))))).

[0436] In some embodiments, Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) at 121 °C.

[0437] In some embodiments, Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 12.9 ± 1.5 J / g (e.g., 12.9 ± 1.3 J / g (e.g.,Attorney Docket No. ASET-042 / 001WO 325190-2274 12.9 ± 1.0 J / g (e.g., 12.9 ± 0.8 J / g (e.g., 12.9 ± 0.6 J / g (e.g., 12.9 ± 0.4 J / g (e.g., 12.9 ± 0.2 J / g (e.g., 12.9 ± 0.1 J / g))))))).

[0438] In some embodiments, Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 12.9 J / g.

[0439] In some embodiments, Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 91.9 ± 10 J / g (e.g., 91.9 ± 8 J / g (e.g., 91.9 ± 6 J / g (e.g., 91.9 ± 5 J / g (e.g., 91.9 ± 4 J / g (e.g., 91.9 ± 3 J / g (e.g., 91.9 ± 2 J / g (e.g., 91.9 ± 1 J / g))))))).

[0440] In some embodiments, Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 91.9 J / g.

[0441] In some embodiments, Form K is characterized by a DSC profile substantially similar to that shown in FIG.59. Thermogravimetric Analysis (TGA) Characterizations

[0442] In some embodiments, Form K shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 80 ± 20 °C (e.g., 80 ± 10 °C (e.g., 80 ± 5 °C (e.g., 80 ± 4 °C (e.g., 80 ± 3 °C (e.g., 80 ± 2 °C (e.g., 80 ± 1 °C (e.g., 80 ± 0.5 °C))))))), as measured by TGA.

[0443] In some embodiments, Form K shows a weight loss of about 2.0%, at a temperature ranging from about 34 °C to about 80 °C, as measured by TGA.

[0444] In some embodiments, Form K shows a weight loss of from about 8% to about 25%, at a temperature ranging from about 80 ± 20 °C (e.g., 80 ± 10 °C (e.g., 80 ± 5 °C (e.g., 80 ± 4 °C (e.g., 80 ± 3 °C (e.g., 80 ± 2 °C (e.g., 80 ± 1 °C (e.g., 80 ± 0.5 °C))))))) to about 250 ± 20 °C (e.g., 250 ± 10 °C (e.g., 250 ± 5 °C (e.g., 250 ± 4 °C (e.g., 250 ± 3 °C (e.g., 250 ± 2 °C (e.g., 250 ± 1 °C (e.g., 250 ± 0.5 °C))))))), as measured by TGA.

[0445] In some embodiments, Form K shows a weight loss of about 15%, at a temperature ranging from about 80 °C to about 250 °C, as measured by TGA.

[0446] In some embodiments, Form K is characterized by a TGA profile substantially similar to that shown in FIG.60. Form L

[0447] In some embodiments, the morphic form is Form L of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0448] In some embodiments, the morphic form is Form L of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0449] In some embodiments, the morphic form is Form L of a fumarate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0450] In some embodiments, the morphic form is Form L of a fumarate salt of Compound No.1.

[0451] In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:1. In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:2. In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0452] In some embodiments, Form L is characterized by an X-ray diffraction (“XRPD”)pattern comprising signals (e.g., peaks) at 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2 (e.g., 12.5±0.1,15.6±0.1, and 27.0±0.1 °2 (e.g., 12.5, 15.6, and 27.0 °2 )) using Cu K radiation.

[0453] In some embodiments, the XRPD pattern of Form L further comprises at least onesignal (e.g., peak) selected from 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2 (e.g., 12.5±0.1,15.6±0.1, and 27.0±0.1 °2 (e.g., 12.5, 15.6, and 27.0 °2 )) using Cu K radiation.

[0454] In some embodiments, the XRPD pattern of Form L further comprises at least twosignals (e.g., peaks) selected from 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2 (e.g., 12.5±0.1,15.6±0.1, and 27.0±0.1 °2 (e.g., 12.5, 15.6, and 27.0 °2 )) using Cu K radiation.

[0455] In some embodiments, the XRPD pattern of Form L further comprises signals (e.g.,peaks) at 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2 (e.g., 12.5±0.1, 15.6±0.1, and 27.0±0.1 °2(e.g., 12.5, 15.6, and 27.0 °2 )) using Cu K radiation.

[0456] In some embodiments, Form L is characterized by an X-ray diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 12.0±0.2, 14.5±0.2,15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2 (e.g., 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1,27.0±0.1, and 27.2±0.1 °2 (e.g., 12.0, 14.5, 15.6, 18.7, 27.0, and 27.2 °2 )) using Cu Kradiation.

[0457] In some embodiments, the XRPD pattern of Form L comprises at least four signals(e.g., peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2(e.g., 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1, and 27.2±0.1 °2 (e.g., 12.0, 14.5,15.6, 18.7, 27.0, and 27.2 °2 )) using Cu K radiation.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0458] In some embodiments, the XRPD pattern of Form L comprises at least five signals(e.g., peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2(e.g., 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1, and 27.2±0.1 °2 (e.g., 12.0, 14.5,15.6, 18.7, 27.0, and 27.2 °2 )) using Cu K radiation.

[0459] In some embodiments, the XRPD pattern of Form L comprises signals (e.g., peaks) at12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2 (e.g., 12.0±0.1, 14.5±0.1,15.6±0.1, 18.7±0.1, 27.0±0.1, and 27.2±0.1 °2 (e.g., 12.0, 14.5, 15.6, 18.7, 27.0, and 27.2°2 )) using Cu K radiation.

[0460] In some embodiments, Form L is characterized by an XRPD pattern substantially similar those shown in FIGs.20 or 62.

[0461] In some embodiments, Form L is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in the table below. It is understood that the values in the table are approximate and subject to instrumental and experimental variations. Table 5: Exemplary XRPD Signal List for Form LAttorney Docket No. ASET-042 / 001WO 325190-2274Differential Scanning Calorimeter (DSC) Characterizations

[0462] In some embodiments, Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) at 195 ± 20°C (e.g., 195 ± 10 °C (e.g., 195 ± 5 °C (e.g., 195 ± 4 °C (e.g., 195 ± 3 °C (e.g., 195 ± 2 °C (e.g., 195 ± 1 °C (e.g., 195 ± 0.5 °C))))))).

[0463] In some embodiments, Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) at 195 °C.

[0464] In some embodiments, Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 111 ± 11 J / g (e.g., 111 ± 10 J / g (e.g., 111 ± 8 J / g (e.g., 111 ± 6 J / g (e.g., 111 ± 4 J / g (e.g., 111 ± 3 J / g (e.g., 111 ± 2 J / g (e.g., 111 ± 1 J / g))))))).

[0465] In some embodiments, Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 111 J / g.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0466] In some embodiments, Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) at 196 ± 20°C (e.g., 196 ± 10 °C (e.g., 196 ± 5 °C (e.g., 196 ± 4 °C (e.g., 196 ± 3 °C (e.g., 196 ± 2 °C (e.g., 196 ± 1 °C (e.g., 196 ± 0.5 °C))))))).

[0467] In some embodiments, Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) at 196 °C.

[0468] In some embodiments, Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 99 ± 10 J / g (e.g., 99 ± 9 J / g (e.g., 99 ± 8 J / g (e.g., 99 ± 6 J / g (e.g., 99 ± 4 J / g (e.g., 99 ± 3 J / g (e.g., 99 ± 2 J / g (e.g., 99 ± 1 J / g))))))).

[0469] In some embodiments, Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 99 J / g.

[0470] In some embodiments, Form L is characterized by a DSC profile substantially similar to those shown in FIGs.21 or 63. Thermogravimetric Analysis (TGA) Characterizations

[0471] In some embodiments, Form L shows a weight loss of from about 0.1% to about 2%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 180 ± 20 °C (e.g., 180 ± 10 °C (e.g., 180 ± 5 °C (e.g., 180 ± 4 °C (e.g., 180 ± 3 °C (e.g., 180 ± 2 °C (e.g., 180 ± 1 °C (e.g., 180 ± 0.5 °C))))))), as measured by TGA.

[0472] In some embodiments, Form L shows a weight loss of about 0.8%, at a temperature ranging from about 34 °C to about 180 °C, as measured by TGA.

[0473] In some embodiments, Form L shows a weight loss of from about 0.05% to about 2%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 185 ± 20 °C (e.g., 185 ± 10 °C (e.g., 185 ± 5 °C (e.g., 185 ± 4 °C (e.g., 185 ± 3 °C (e.g., 185 ± 2 °C (e.g., 185 ± 1 °C (e.g., 185 ± 0.5 °C))))))), as measured by TGA.

[0474] In some embodiments, Form L shows a weight loss of about 0.5%, at a temperature ranging from about 34 °C to about 185 °C, as measured by TGA.

[0475] In some embodiments, Form L is characterized by a TGA profile substantially similar to those shown in FIGs.22 or 64.

[0476] In some embodiments, the purity of Form L is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0477] In some embodiments, Form L undergoes less than 1.0%, less than 0.8%, less than 0.6 %, less than 0.4%, or less than 0.2% water uptake at 95% RH.

[0478] In some embodiments, the purity of Form L is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 25°C / 92.5%RH in an open container for a week.

[0479] In some embodiments, the purity of Form L is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 40°C / 75% RH in an open container for a week.

[0480] In some embodiments, the purity of Form L is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, after being placed at 60°C in a closed container for a week.

[0481] In some embodiments, Form L has a solubility of over 20 g / mL, over 40 g / mL, over 60 g / mL, over 80 g / mL, over 100 g / mL, over 110 g / mL, or over 130 g / mL in pH 1.2 HCl solution (0.1 N) over 2 hours.

[0482] In some embodiments, Form L has a solubility of over 20 g / mL, over 40 g / mL, over 60 g / mL, over 80 g / mL, over 100 g / mL, or over 110 g / mL, in pH 1.2 HCl solution (0.1 N) over 24 hours.

[0483] In some embodiments, Form L has a solubility of over 40 g / mL, over 80 g / mL, over 100 g / mL, over 120 g / mL, or over 140 g / mL, in SGF, pH 2.0 over 2 hours.

[0484] In some embodiments, Form L has a solubility of over 20 g / mL, over 40 g / mL, over 60 g / mL, over 80 g / mL, or over 100 g / mL, in SGF, pH 2.0 over 24 hours.

[0485] In some embodiments, Form L has a solubility of over 40 g / mL, over 80 g / mL, over 100 g / mL, over 120 g / mL, over 140 g / mL, or over 160 g / mL, in FeSSIF-v1, pH 5.0 over 2 hours.

[0486] In some embodiments, Form L has a solubility of over 5 g / mL, over 10 g / mL, over 15 g / mL, or over 20 g / mL in FeSSIF-v1, pH 5.0 over 24 hours. Form M

[0487] In some embodiments, the morphic form is Form M of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0488] In some embodiments, the morphic form is Form M of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0489] In some embodiments, the morphic form is Form M of a fumarate salt of Compound No.1, a solvate thereof, or a hydrate thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0490] In some embodiments, the morphic form is Form M of a fumarate salt of Compound No.1.

[0491] In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:1. In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:2. In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0492] In some embodiments, Form M is characterized by an XRPD profile substantially similar to that shown in FIG.66. Differential Scanning Calorimeter (DSC) Characterizations

[0493] In some embodiments, Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) at 54.0 ± 20°C (e.g., 54.0 ± 10 °C (e.g., 54.0 ± 5 °C (e.g., 54.0 ± 4 °C (e.g., 54.0 ± 3 °C (e.g., 54.0 ± 2 °C (e.g., 54.0 ± 1 °C (e.g., 54.0 ± 0.5 °C))))))).

[0494] In some embodiments, Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) at 54.0 °C.

[0495] In some embodiments, Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) at 125 ± 20°C (e.g., 125 ± 10 °C (e.g., 125 ± 5 °C (e.g., 125 ± 4 °C (e.g., 125 ± 3 °C (e.g., 125 ± 2 °C (e.g., 125 ± 1 °C (e.g., 125 ± 0.5 °C))))))).

[0496] In some embodiments, Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) at 125 °C.

[0497] In some embodiments, Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 26.1 ± 2.5 J / g (e.g., 26.1 ± 2.0 J / g (e.g., 26.1 ± 1.5 J / g (e.g., 26.1 ± 1.0 J / g (e.g., 26.1 ± 0.8 J / g (e.g., 26.1 ± 0.6 J / g (e.g., 26.1 ± 0.4 J / g (e.g., 26.1 ± 0.2 J / g))))))).

[0498] In some embodiments, Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 26.1 J / g.

[0499] In some embodiments, Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 34.9 ± 3.5 J / g (e.g., 34.9 ± 3.0 J / g (e.g., 34.9 ± 2.5 J / g (e.g., 34.9 ± 2.0 J / g (e.g., 34.9 ± 1.5 J / g (e.g., 34.9 ± 1.0 J / g (e.g., 34.9 ± 0.5 J / g (e.g., 34.9 ± 0.3 J / g))))))).

[0500] In some embodiments, Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 34.9 J / g.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0501] In some embodiments, Form M is characterized by a DSC profile substantially similar to that shown in FIG.67. Thermogravimetric Analysis (TGA) Characterizations

[0502] In some embodiments, Form M shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0503] In some embodiments, Form M shows a weight loss of about 1.6%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA.

[0504] In some embodiments, Form M is characterized by a TGA profile substantially similar to that shown in FIG.68. Form N

[0505] In some embodiments, the morphic form is Form N of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0506] In some embodiments, the morphic form is Form N of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0507] In some embodiments, the morphic form is Form N of a fumarate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0508] In some embodiments, the morphic form is Form N of a fumarate salt of Compound No.1.

[0509] In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:1. In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:2. In some embodiments, the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0510] In some embodiments, Form N is characterized by an XRPD profile substantially similar to that shown in FIG.70. Differential Scanning Calorimeter (DSC) CharacterizationsAttorney Docket No. ASET-042 / 001WO 325190-2274

[0511] In some embodiments, Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) at 62.0 ± 20°C (e.g., 62.0 ± 10 °C (e.g., 62.0 ± 5 °C (e.g., 62.0 ± 4 °C (e.g., 62.0 ± 3 °C (e.g., 62.0 ± 2 °C (e.g., 62.0 ± 1 °C (e.g., 62.0 ± 0.5 °C))))))).

[0512] In some embodiments, Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) at 62.0 °C.

[0513] In some embodiments, Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) at 107 ± 20°C (e.g., 107 ± 10 °C (e.g., 107 ± 5 °C (e.g., 107 ± 4 °C (e.g., 107 ± 3 °C (e.g., 107 ± 2 °C (e.g., 107 ± 1 °C (e.g., 107 ± 0.5 °C))))))).

[0514] In some embodiments, Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) at 107 °C.

[0515] In some embodiments, Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 37.8 ± 3.8 J / g (e.g., 37.8 ± 3.4 J / g (e.g., 37.8 ± 3.0 J / g (e.g., 37.8 ± 2.5 J / g (e.g., 37.8 ± 2.0 J / g (e.g., 37.8 ± 1.5 J / g (e.g., 37.8 ± 1.0 J / g (e.g., 37.8 ± 0.5 J / g))))))).

[0516] In some embodiments, Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 37.8 J / g.

[0517] In some embodiments, Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 22.1 ± 2.5 J / g (e.g., 22.1 ± 2.0 J / g (e.g., 22.1 ± 1.5 J / g (e.g., 22.1 ± 1.0 J / g (e.g., 22.1 ± 0.8 J / g (e.g., 22.1 ± 0.6 J / g (e.g., 22.1 ± 0.4 J / g (e.g., 22.1 ± 0.2 J / g))))))).

[0518] In some embodiments, Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 22.1 J / g.

[0519] In some embodiments, Form N is characterized by a DSC profile substantially similar to that shown in FIG.71. Thermogravimetric Analysis (TGA) Characterizations

[0520] In some embodiments, Form N shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 110 ± 20 °C (e.g., 110 ± 10 °C (e.g., 110 ± 5 °C (e.g., 110 ± 4 °C (e.g., 110 ± 3 °C (e.g., 110 ± 2 °C (e.g., 110 ± 1 °C (e.g., 110 ± 0.5 °C))))))), as measured by TGA.

[0521] In some embodiments, Form N shows a weight loss of about 1.8%, at a temperature ranging from about 34 °C to about 110 °C, as measured by TGA.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0522] In some embodiments, Form N is characterized by a TGA profile substantially similar to that shown in FIG.72. Form O

[0523] In some embodiments, the morphic form is Form O of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0524] In some embodiments, the morphic form is Form O of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0525] In some embodiments, the morphic form is Form O of a L-tartrate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0526] In some embodiments, the morphic form is Form O of a L-tartrate salt of Compound No.1.

[0527] In some embodiments, the L-tartrate salt comprises Compound No. 1 and L-tartaric acid present at a ratio of about 1:1. In some embodiments, the L-tartrate salt comprises Compound No. 1 and L-tartaric acid present at a ratio of about 1:2. In some embodiments, the L-tartrate salt comprises Compound No.1 and L-tartaric acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0528] In some embodiments, Form O is characterized by an XRPD profile substantially similar to that shown in FIG.74. Differential Scanning Calorimeter (DSC) Characterizations

[0529] In some embodiments, Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) at 52.7 ± 20°C (e.g., 52.7 ± 10 °C (e.g., 52.7 ± 5 °C (e.g., 52.7 ± 4 °C (e.g., 52.7 ± 3 °C (e.g., 52.7 ± 2 °C (e.g., 52.7 ± 1 °C (e.g., 52.7 ± 0.5 °C))))))).

[0530] In some embodiments, Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) at 52.7 °C.

[0531] In some embodiments, Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) at 129 ± 20°C (e.g., 129 ± 10 °C (e.g., 129 ± 5 °C (e.g., 129 ± 4 °C (e.g., 129 ± 3 °C (e.g., 129 ± 2 °C (e.g., 129 ± 1 °C (e.g., 129 ± 0.5 °C))))))).

[0532] In some embodiments, Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) at 129 °C.

[0533] In some embodiments, Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 24.5 ± 2.5 J / g (e.g., 24.5 ± 2.0 J / g (e.g.,Attorney Docket No. ASET-042 / 001WO 325190-2274 24.5 ± 1.5 J / g (e.g., 24.5 ± 1.0 J / g (e.g., 24.5 ± 0.8 J / g (e.g., 24.5 ± 0.6 J / g (e.g., 24.5 ± 0.4 J / g (e.g., 24.5 ± 0.2 J / g))))))).

[0534] In some embodiments, Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 24.5 J / g.

[0535] In some embodiments, Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 34.8 ± 3.5 J / g (e.g., 34.8 ± 3.0 J / g (e.g., 34.8 ± 2.5 J / g (e.g., 34.8 ± 2.0 J / g (e.g., 34.8 ± 1.5 J / g (e.g., 34.8 ± 1.0 J / g (e.g., 34.8 ± 0.5 J / g (e.g., 34.8 ± 0.3 J / g))))))).

[0536] In some embodiments, Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 34.8 J / g.

[0537] In some embodiments, Form O is characterized by a DSC profile substantially similar to that shown in FIG.75. Thermogravimetric Analysis (TGA) Characterizations

[0538] In some embodiments, Form O shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0539] In some embodiments, Form O shows a weight loss of about 1.6%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA.

[0540] In some embodiments, Form O shows a weight loss of from about 0.3% to about 2.5%, at a temperature ranging from about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) to about 140 ± 20 °C (e.g., 140 ± 10 °C (e.g., 140 ± 5 °C (e.g., 140 ± 4 °C (e.g., 140 ± 3 °C (e.g., 140 ± 2 °C (e.g., 140 ± 1 °C (e.g., 140 ± 0.5 °C))))))), as measured by TGA.

[0541] In some embodiments, Form O shows a weight loss of about 1.0%, at a temperature ranging from about 100 °C to about 140 °C, as measured by TGA.

[0542] In some embodiments, Form O is characterized by a TGA profile substantially similar to that shown in FIG.76. Form P

[0543] In some embodiments, the morphic form is Form P of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0544] In some embodiments, the morphic form is Form P of a salt of Compound No. 1, a solvate thereof, or a hydrate thereof.

[0545] In some embodiments, the morphic form is Form P of a L-malate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0546] In some embodiments, the morphic form is Form P of a L-malate salt of Compound No.1.

[0547] In some embodiments, the L-malate salt comprises Compound No.1 and L-malic acid present at a ratio of about 1:1. In some embodiments, the L-malate salt comprises Compound No.1 and L-malic acid present at a ratio of about 1:2. In some embodiments, the L-malate salt comprises Compound No.1 and L-malic acid present at a ratio of about 2:1. X-Ray Powder Diffraction (XRPD) Characterization

[0548] In some embodiments, Form P is characterized by an XRPD profile substantially similar to that shown in FIG.78. Differential Scanning Calorimeter (DSC) Characterizations

[0549] In some embodiments, Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) at 109 ± 20°C (e.g., 109 ± 10 °C (e.g., 109 ± 5 °C (e.g., 109 ± 4 °C (e.g., 109 ± 3 °C (e.g., 109 ± 2 °C (e.g., 109 ± 1 °C (e.g., 109 ± 0.5 °C))))))).

[0550] In some embodiments, Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) at 109 °C.

[0551] In some embodiments, Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) at 169 ± 20°C (e.g., 169 ± 10 °C (e.g., 169 ± 5 °C (e.g., 169 ± 4 °C (e.g., 169 ± 3 °C (e.g., 169 ± 2 °C (e.g., 169 ± 1 °C (e.g., 169 ± 0.5 °C))))))).

[0552] In some embodiments, Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) at 169 °C.

[0553] In some embodiments, Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 57.5 ± 6.0 J / g (e.g., 57.5 ± 5.0 J / g (e.g., 57.5 ± 4.0 J / g (e.g., 57.5 ± 3.0 J / g (e.g., 57.5 ± 2.0 J / g (e.g., 57.5 ± 1.5 J / g (e.g., 57.5 ± 1.0 J / g (e.g., 57.5 ± 0.5 J / g))))))).

[0554] In some embodiments, Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 57.5 J / g.

[0555] In some embodiments, Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 21.5 ± 2.5 J / g (e.g., 21.5 ± 2.0 J / g (e.g.,Attorney Docket No. ASET-042 / 001WO 325190-2274 21.5 ± 1.5 J / g (e.g., 21.5 ± 1.0 J / g (e.g., 21.5 ± 0.8 J / g (e.g., 21.5 ± 0.6 J / g (e.g., 21.5 ± 0.4 J / g (e.g., 21.5 ± 0.2 J / g))))))).

[0556] In some embodiments, Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 21.5 J / g.

[0557] In some embodiments, Form P is characterized by a DSC profile substantially similar to that shown in FIG.79. Thermogravimetric Analysis (TGA) Characterizations

[0558] In some embodiments, Form P shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 130 ± 20 °C (e.g., 130 ± 10 °C (e.g., 130 ± 5 °C (e.g., 130 ± 4 °C (e.g., 130 ± 3 °C (e.g., 130 ± 2 °C (e.g., 130 ± 1 °C (e.g., 130 ± 0.5 °C))))))), as measured by TGA.

[0559] In some embodiments, Form P shows a weight loss of about 2.1%, at a temperature ranging from about 34 °C to about 130 °C, as measured by TGA.

[0560] In some embodiments, Form P shows a weight loss of from about 15% to about 30%, at a temperature ranging from about 130 ± 20 °C (e.g., 130 ± 10 °C (e.g., 130 ± 5 °C (e.g., 130 ± 4 °C (e.g., 130 ± 3 °C (e.g., 130 ± 2 °C (e.g., 130 ± 1 °C (e.g., 130 ± 0.5 °C))))))) to about 300 ± 20 °C (e.g., 300 ± 10 °C (e.g., 300 ± 5 °C (e.g., 300 ± 4 °C (e.g., 300 ± 3 °C (e.g., 300 ± 2 °C (e.g., 300 ± 1 °C (e.g., 300 ± 0.5 °C))))))), as measured by TGA.

[0561] In some embodiments, Form P shows a weight loss of about 21%, at a temperature ranging from about 130 °C to about 300 °C, as measured by TGA.

[0562] In some embodiments, Form P is characterized by a TGA profile substantially similar to that shown in FIG.80. Methods of Preparing the Crystalline Forms

[0563] In some aspects, the present disclosure features a method of preparing a crystalline form of Compound No.1 or a pharmaceutically acceptable salt thereof.

[0564] In some aspects, the present disclosure provides a method of preparing a crystalline form of Compound No.1 or a pharmaceutically acceptable salt thereof, comprising one or more steps as described herein.

[0565] In some aspects, the present disclosure provides a compound obtainable by, or obtained by, or directly obtained by a method for preparing a crystalline form of Compound No. 1 or a pharmaceutically acceptable salt thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0566] Compound No. 1 or the pharmaceutically acceptable salt thereof can be prepared by any suitable technique known in the art or as described in PCT Application No. PCT / US2022 / 076164 (incorporated herein by reference). Particular processes for the preparation of these compounds are described further in the accompanying examples.

[0567] In some embodiments, the crystalline form of Compound No. 1 can be prepared by equilibration of Compound No. 1 in a suitable amount of solvent at 25 °C for 2 weeks with a stirring plate.

[0568] In some embodiments, the crystalline form of Compound No. 1 can be prepared by equilibration of Compound No. 1 in a suitable amount of solvent at 50 °C for 1 week with a stirring plate.

[0569] In some embodiments, the crystalline form of Compound No. 1 can be prepared by equilibration of Compound No. 1 in a suitable amount of solvent under a temperature cycle between 5 °C to 50 °C at a heating / cooling rate of 0.1°C / min for 10 cycles.

[0570] In some embodiments, the crystalline form of Compound No. 1 can be prepared by dissolving Compound No. 1 in a suitable amount of solvent, filtering the obtained solution through a 0.45μm syringe nylon membrane filter, and slowly evaporating the filtered solution under ambient conditions.

[0571] In some embodiments, the crystalline form of Compound No. 1 can be prepared by dissolving Compound No. 1 in a suitable amount of solvent, filtering the obtained solution through a 0.45μm syringe nylon membrane filter, and fast evaporating the filtered solution under nitrogen flow.

[0572] In some embodiments, the crystalline form of Compound No. 1 can be prepared by dissolving Compound No. 1 in a minimal amount of solvent at 50 °C, filtering the obtained solution through a 0.45μm syringe nylon membrane filter, and cooling the filtered solution to 5 °C at 0.1°C / min.

[0573] In some embodiments, the crystalline form of Compound No. 1 can be prepared by dissolving Compound No. 1 in a minimal amount of solvent at 50 °C, filtering the obtained solution through a 0.45μm syringe nylon membrane filter, and cooling the filtered solution to -20 °C at 0.1°C / min.

[0574] In some embodiments, the crystalline form of Compound No. 1 can be prepared by dissolving Compound No. 1 in a minimal amount of solvent at 50 °C, filtering the obtained solution through a 0.45μm syringe nylon membrane filter, and agitating the filtered solution inside of a 0°C ice bath.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0575] In some embodiments, the crystalline form of Compound No. 1 can be prepared by dissolving Compound No.1 in a minimal amount of solvent at ambient temperature (about 20- 25°C), filtering the obtained solution through a 0.45μm syringe nylon membrane filter, and slowly adding 1-4 folds of anti-solvent into the filtered solution until a large amount of solids precipitate out.

[0576] In some embodiments, the crystalline form of Compound No. 1 can be prepared by dissolving Compound No.1 in a minimal amount of solvent at ambient temperature (about 20- 25°C), filtering the obtained solution through a 0.45μm syringe nylon membrane filter, and quickly adding the filtered solution into 4 folds of anti-solvent.

[0577] In some embodiments, the crystalline form of Compound No. 1 can be prepared by dissolving Compound No.1 in a minimal amount of solvent at ambient temperature (about 20- 25°C), filtering the obtained solution through a 0.45μm syringe nylon membrane filter, and undergoing vapor diffusion using anti-solvents at ambient temperature for up to 14 days.

[0578] In some embodiments, the crystalline form of Compound No. 1 can be prepared by adding a suitable amount of solvent to Compound No.1, stirring the suspension at 50°C for 2 hours, chilling to 25°C and stirring at 25°C for 4 days, filtering the obtained solution through a 0.45μm syringe nylon membrane filter by centrifugation at 14,000 rpm, and drying the solids at 50°C under vacuum for 2h.

[0579] In some embodiments, the crystalline form of Compound No. 1 can be prepared by adding a suitable amount of solvent to Compound No.1, stirring the suspension at 50°C for 2 hours, chilling to 25°C and stirring at 25°C for 4 days, cooling the solution to 5°C, filtering the obtained solution through a 0.45μm syringe nylon membrane filter by centrifugation at 14,000 rpm, and drying the solids at 50°C under vacuum for 2h.

[0580] In some embodiments, the crystalline form of Compound No. 1 can be prepared by adding a suitable amount of solvent to Compound No.1, stirring the suspension at 25°C for 4 days, filtering the obtained solution through a 0.45μm syringe nylon membrane filter by centrifugation at 14,000 rpm, and drying the solids at 50°C under vacuum for 2h.

[0581] In some embodiments, the crystalline form of Compound No. 1 can be prepared by adding a suitable amount of solvent to Compound No.1, stirring the suspension at 25°C for 4 days, cooling the solution to 5°C, filtering the obtained solution through a 0.45μm syringe nylon membrane filter by centrifugation at 14,000 rpm, and drying the solids at 50°C under vacuum for 2h.Attorney Docket No. ASET-042 / 001WO 325190-2274 Amorphous Forms and Combinations thereof

[0582] In some aspects, the present disclosure provides an amorphous form of Compound No.1, a salt thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.

[0583] In some aspects, the present disclosure provides an amorphous form of Compound No.1.

[0584] In some aspects, the present disclosure provides a combination comprising: an amorphous form of Compound No.1, a salt thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a polymer.

[0585] In some aspects, the present disclosure provides a composition (e.g., a pharmaceutical composition) comprising the combination disclosed herein.

[0586] In some embodiments, the polymer is polyvinylpyrrolidone (PVP).

[0587] In some embodiments, the polymer comprises a copolymer of N-vinylpyrrolidone and vinyl acetate.

[0588] In some embodiments, the polymer comprises a polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer.

[0589] In some embodiments, the polymer is PVP VA64, Soluplus, Kollidon 12 PF, HPMC ASMG, HPMC E3, Eudragit E100, or Eudragit L100-55.

[0590] In some embodiments, the polymer is sold as Eudragit®.

[0591] In some embodiments, the polymer is sold as Soluplus®.

[0592] In some embodiments, the polymer is sold as Kollidon®.

[0593] In some embodiments, the polymer is sold as Kollidon®12 PF.

[0594] In some embodiments, the polymer is sold as PVP VA64.

[0595] In some embodiments, the polymer is sold as HPMC ASMG.

[0596] In some embodiments, the polymer is sold as HPMC E3.

[0597] In some embodiments, the polymer is sold as Eudragit®E100.

[0598] In some embodiments, the polymer is sold as Eudragit®L100-55.

[0599] In some embodiments, the polymer is hydroxypropyl methylcellulose (HPMC).

[0600] In some embodiments, the polymer is a polymethacrylate-based copolymer.

[0601] In some embodiments, the polymer is PVP VA64.

[0602] In some embodiments, the polymer is HPMC ASMG.

[0603] In some embodiments, the polymer is HPMC E3.

[0604] In some embodiments, the polymer is Eudragit®E100.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0605] In some embodiments, the polymer is Eudragit®L100-55.

[0606] In some embodiments, the amorphous form is combined with a polymer at a ratio of about 1:0.5 (w / w), about 1:1 (w / w), about 1:2 (w / w), about 1:3 (w / w), about 1:4 (w / w), or about 1:5 (w / w).

[0607] In some embodiments, the amorphous form is combined with a polymer at a ratio of about 1:1 (w / w).

[0608] In some embodiments, the amorphous form is combined with a polymer at a ratio of about 1:4 (w / w).

[0609] In some embodiments, the composition is a solid dispersion.

[0610] In some aspects, the composition is a solid dispersion prepared by spray drying.

[0611] In some aspects, the composition is a solid dispersion prepared by hot melt extrusion (HME).

[0612] In some embodiments, the composition is prepared from Form A of Compound No.1. Thermogravimetric Analysis (TGA) Characterizations

[0613] In some embodiments, the combination (e.g., the composition) shows a weight loss of from about 2.5% to about 10%, at a temperature ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0614] In some embodiments, the combination (e.g., the composition) shows a weight loss of about 5.2%, at a temperature ranging from about 33 °C to about 100 °C, as measured by TGA.

[0615] In some embodiments, the combination (e.g., the composition) is characterized by a TGA profile substantially similar to that shown in FIG.86.

[0616] In some embodiments, the combination (e.g., the composition) shows a weight loss of from about 0.5% to about 5%, at a temperature ranging from about 32 ± 20 °C (e.g., 32 ± 10 °C (e.g., 32 ± 5 °C (e.g., 32 ± 4 °C (e.g., 32 ± 3 °C (e.g., 32 ± 2 °C (e.g., 32 ± 1 °C (e.g., 32 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0617] In some embodiments, the combination (e.g., the composition) shows a weight loss of about 1.7%, at a temperature ranging from about 32 °C to about 100 °C, as measured by TGA.

[0618] In some embodiments, the combination (e.g., the composition) is characterized by a TGA profile substantially similar to that shown in FIG.87.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0619] In some embodiments, the combination (e.g., the composition) shows a weight loss of from about 0.5% to about 5%, at a temperature ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0620] In some embodiments, the combination (e.g., the composition) shows a weight loss of about 2.8%, at a temperature ranging from about 33 °C to about 100 °C, as measured by TGA.

[0621] In some embodiments, the combination (e.g., the composition) is characterized by a TGA profile substantially similar to that shown in FIG.88.

[0622] In some embodiments, the combination (e.g., the composition) shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0623] In some embodiments, the combination (e.g., the composition) shows a weight loss of about 1.0%, at a temperature ranging from about 33 °C to about 100 °C, as measured by TGA. In some embodiments, the combination (e.g., the composition) is characterized by a TGA profile substantially similar to that shown in FIG.89.

[0624] In some embodiments, the combination (e.g., the composition) shows a weight loss of from about 0.5% to about 10%, at a temperature ranging from about 32 ± 20 °C (e.g., 32 ± 10 °C (e.g., 32 ± 5 °C (e.g., 32 ± 4 °C (e.g., 32 ± 3 °C (e.g., 32 ± 2 °C (e.g., 32 ± 1 °C (e.g., 32 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA.

[0625] In some embodiments, the combination (e.g., the composition) shows a weight loss of about 3.2%, at a temperature ranging from about 32 °C to about 100 °C, as measured by TGA.

[0626] In some embodiments, the combination (e.g., the composition) is characterized by a TGA profile substantially similar to that shown in FIG.90. Modulated Differential Scanning Calorimetry (mDSC) Characterizations

[0627] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 106 ± 20°C (e.g., 106 ± 10 °C (e.g., 106 ± 5 °C (e.g., 106 ± 4 °C (e.g., 106 ± 3 °C (e.g., 106 ± 2 °C (e.g., 106 ± 1 °C (e.g., 106 ± 0.5 °C))))))).Attorney Docket No. ASET-042 / 001WO 325190-2274

[0628] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 106 °C.

[0629] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.91.

[0630] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0631] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0632] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 102 ± 20°C (e.g., 102 ± 10 °C (e.g., 102 ± 5 °C (e.g., 102 ± 4 °C (e.g., 102 ± 3 °C (e.g., 102 ± 2 °C (e.g., 102 ± 1 °C (e.g., 102 ± 0.5 °C))))))).

[0633] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 102 °C.

[0634] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.92.

[0635] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0636] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0637] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 104 ± 20°C (e.g., 104 ± 10 °C (e.g., 104 ± 5 °C (e.g., 104 ± 4 °C (e.g., 104 ± 3 °C (e.g., 104 ± 2 °C (e.g., 104 ± 1 °C (e.g., 104 ± 0.5 °C))))))).

[0638] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 104 °C.

[0639] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.93.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0640] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0641] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0642] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 48 ± 20°C (e.g., 48 ± 10 °C (e.g., 48 ± 5 °C (e.g., 48 ± 4 °C (e.g., 48 ± 3 °C (e.g., 48± 2 °C (e.g., 48 ± 1 °C (e.g., 48 ± 0.5 °C))))))).

[0643] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 48 °C.

[0644] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.94.

[0645] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0646] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0647] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 181 ± 20°C (e.g., 181 ± 10 °C (e.g., 181 ± 5 °C (e.g., 181 ± 4 °C (e.g., 181 ± 3 °C (e.g., 181± 2 °C (e.g., 181 ± 1 °C (e.g., 181 ± 0.5 °C))))))).

[0648] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 181 °C.

[0649] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.95.

[0650] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0651] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0652] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 107 ± 20°C (e.g., 107 ± 10 °C (e.g., 107 ± 5 °C (e.g., 107 ± 4 °C (e.g., 107 ± 3 °C (e.g., 107 ± 2 °C (e.g., 107 ± 1 °C (e.g., 107 ± 0.5 °C))))))).

[0653] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 107 °C.

[0654] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.96.

[0655] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0656] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0657] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 72 ± 20°C (e.g., 72 ± 10 °C (e.g., 72 ± 5 °C (e.g., 72 ± 4 °C (e.g., 72 ± 3 °C (e.g., 72 ± 2 °C (e.g., 72 ± 1 °C (e.g., 72 ± 0.5 °C))))))).

[0658] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 72 °C.

[0659] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.97.

[0660] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0661] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0662] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 107 ± 20°C (e.g., 107 ± 10 °C (e.g., 107 ± 5 °C (e.g., 107 ± 4 °C (e.g., 107 ± 3 °C (e.g., 107 ± 2 °C (e.g., 107 ± 1 °C (e.g., 107 ± 0.5 °C))))))).

[0663] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 107 °C.

[0664] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.98.

[0665] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0666] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%.

[0667] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at 91 ± 20°C (e.g., 91 ± 10 °C (e.g., 91 ± 5 °C (e.g., 91 ± 4 °C (e.g., 91 ± 3 °C (e.g., 91 ± 2 °C (e.g., 91 ± 1 °C (e.g., 91 ± 0.5 °C))))))).

[0668] In some embodiments, the combination (e.g., the composition) is characterized by a glass transition temperature (Tg) as measured by mDSC at about 91 °C.

[0669] In some embodiments, the combination (e.g., the composition) is characterized by an mDSC profile substantially similar to that shown in FIG.99.

[0670] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%.

[0671] In some embodiments, the purity of the amorphous form in the combination (e.g., the composition) is more than 99.0%, more than 99.1%, more than 99.2%, more than 99.3%, more than 99.4%, more than 99.5%, more than 99.6%, more than 99.7%, more than 99.8%, or more than 99.9%. Pharmaceutical Compositions

[0672] In some aspects, the present disclosure features pharmaceutical compositions comprising a morphic form of Compound No.1, the solvate thereof, the hydrate thereof, or theAttorney Docket No. ASET-042 / 001WO 325190-2274 pharmaceutically acceptable salt thereof described herein, and one or more pharmaceutically acceptable carriers or excipients.

[0673] The pharmaceutical compositions containing active compounds of the present disclosure may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and / or auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.

[0674] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol and sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0675] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In theAttorney Docket No. ASET-042 / 001WO 325190-2274 case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0676] Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and / or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0677] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0678] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0679] The active compounds can be prepared with pharmaceutically acceptable carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.

[0680] It may be especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form asAttorney Docket No. ASET-042 / 001WO 325190-2274 used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.

[0681] In therapeutic applications, the dosages of the pharmaceutical compositions used in accordance with the disclosure vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage. Generally, the dose should be sufficient to result in slowing, and preferably regressing, the symptoms of the disease and also preferably causing complete regression of the disease.

[0682] It is understood that the pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. Methods of Use

[0683] In some aspects, the present disclosure provides a method of treating or preventing cancer in a subject, comprising administering to the subject a pharmaceutically effective amount of a form of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0684] In some aspects, the present disclosure provides a method of treating or preventing cancer in a subject, comprising administering to the subject a pharmaceutically effective amount of a form of Compound No.1 (e.g., Form A, Form, B, Form C, Form, D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form O, or Form P) , the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0685] In some aspects, the present disclosure provides a form of Compound No.1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof for use in treating or preventing cancer in a subject.

[0686] In some aspects, the present disclosure provides a form of Compound No.1 (e.g., Form A, Form, B, Form C, Form, D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form O, or Form P), the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof for use in treating or preventing cancer in a subject.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0687] In some aspects, the present disclosure provides use of a form of Compound No.1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing cancer in a subject.

[0688] In some aspects, the present disclosure provides use of a form of Compound No. 1 (e.g., Form A, Form, B, Form C, Form, D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form O, or Form P), the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing cancer in a subject.

[0689] In some embodiments, Form A of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0690] In some embodiments, Form B of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0691] In some embodiments, Form C of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0692] In some embodiments, Form D of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0693] In some embodiments, Form E of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0694] In some embodiments, Form F of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0695] In some embodiments, Form G of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0696] In some embodiments, Form H of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0697] In some embodiments, Form I of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0698] In some embodiments, Form J of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0699] In some embodiments, Form K of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0700] In some embodiments, Form L of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0701] In some embodiments, Form M of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0702] In some embodiments, Form N of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0703] In some embodiments, Form O of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered.

[0704] In some embodiments, Form P of Compound No. 1, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof is administered. Suitable Subjects and Diseases

[0705] In some embodiments, the subject is a mammal.

[0706] In some embodiments, the subject is a human.

[0707] In some embodiments, the subject is a mouse.

[0708] In some embodiments, the subject is a rat.

[0709] In some embodiments, the subject is a dog.

[0710] In some embodiments, the subject is a monkey.

[0711] In some embodiments, the cancer is characterized by at least one oncogenic mutation in the BRAF gene.

[0712] It is understood that a cancer that is characterized by at least one oncogenic mutation in the BRAF gene is a cancer that is typically associated with at least one oncogenic mutation in the BRAF gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the BRAF gene.

[0713] In some embodiments, the cancer is characterized by at least one oncogenic variant of B-Raf.

[0714] It is understood that a cancer that is characterized by least one oncogenic variant of B- Raf is a cancer that is typically associated with at least one oncogenic variant of B-Raf, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of B-Raf.

[0715] It is understood that an oncogenic variant of B-Raf is a B-Raf protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a BRAF gene that comprises at least one oncogenic mutation.

[0716] In some embodiments, the subject has at least one oncogenic mutation in the BRAF gene.

[0717] In some embodiments, the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0718] As would be appreciated by the skilled artisan, in the context of a gene (e.g. BRAF), an oncogenic mutation can include, but is not limited to a mutation that results in the substitution of one amino acid for another at a specific position within B-Raf, a mutation that results in the substitution of one or more amino acids for one or more amino acids between two specific positions within B-Raf, a mutation that results in an insertion of one or more amino acids between two positions within B-Raf, a mutation that results in the deletion of one more amino acids between two positions within B-Raf, and mutation that results in a fusion of B- Raf, or portion thereof, with another protein, or portion thereof, or any combination thereof. As would be appreciated by the skilled artisan, in the context of a gene, an oncogenic mutation can include, but is not limited to, a missense mutation, a nonsynonymous mutation, an insertion of one or more nucleotides, a deletion of one or more nucleotides, an inversion and a deletion- insertion. As would be appreciated by the skilled artisan, in the context of a gene (e.g. BRAF), the gene can have one or more of the aforementioned types of oncogenic mutations, including combinations of different types of oncogenic mutations.

[0719] As would be appreciated by the skilled artisan, in the context of a protein (e.g. B-Raf), an oncogenic mutation can include, but is not limited to, the substitution of one amino acid for another at a specific position within B-Raf, the substitution of one or more amino acids for one or more amino acids between two specific positions within B-Raf, an insertion of one or more amino acids between two positions within B-Raf, a deletion of one more amino acids between two positions within B-Raf, and a fusion of B-Raf, or portion thereof, with another protein, or portion thereof, or any combination thereof. As would be appreciated by the skilled artisan, in the context of a protein (e.g. B-Raf), the protein can have one or more of the aforementioned types of oncogenic mutations, including combinations of different types of oncogenic mutations.

[0720] In some embodiments, an oncogenic mutation of B-Raf can be any of the B-Raf mutations put forth in Table 6. An oncogenic variant of B-Raf can comprise any combination of the oncogenic mutations put forth in Table 6. In a non-limiting example, an oncogenic variant of B-Raf can comprise the oncogenic mutations K601E and S363F.Attorney Docket No. ASET-042 / 001WO 325190-2274 Table 6. B-Raf mutations (numbering corresponding to SEQ ID NO: 1)

[0721] As would be appreciated by the skilled Artisan, L485-P490>Y and L485-P490Y refers to the substitution residues L485 through P490 of B-Raf (SEQ ID NO: 1) with a Tyrosine (Y) residue.

[0722] In some embodiments, an oncogenic mutation of B-Raf can comprise a deletion of any combination of one or more amino acids between L485 and P490 of B-Raf (SEQ ID NO: 1). In some embodiments, an oncogenic mutation of B-Raf can comprise a deletion of any combination of one or more amino acids between L485 and Q494 of B-Raf (SEQ ID NO: 1). In some embodiments, an oncogenic mutation of B-Raf can comprise a deletion of any combination of one or more amino acids between A481 and Q494 of B-Raf (SEQ ID NO: 1). In some embodiments, an oncogenic mutation of B-Raf can comprise a deletion of any combination of one or more amino acids between K475 and N500 of B-Raf (SEQ ID NO: 1). In some embodiments, any of the preceding deletions can further comprise any combination of one or more substitutions and / or insertions within the range of residues indicated.

[0723] A wild type B-Raf sequence of the present disclosure may comprise, consist essentially of, or consist of the amino acid sequence of: 1 MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI 51 KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL 101 ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK 151 SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI 201 QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF 251 CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI 301 PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD 351 EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA 401 TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW 451 EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN 501 EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM 551 IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV 601 KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELMAttorney Docket No. ASET-042 / 001WO 325190-2274 651 TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK 701 RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS 751 PKTPIQAGGY GAFPVH (SEQ ID NO: 1)

[0724] In some embodiments, the oncogenic mutation is a class I mutation. Accordingly, in some embodiments, the oncogenic variant of B-Raf comprises a class I mutation.

[0725] In some embodiments, the oncogenic mutation is a class II mutation. Accordingly, in some embodiments, the oncogenic variant of B-Raf comprises a class II mutation.

[0726] In some embodiments, the oncogenic mutation is a class III mutation. Accordingly, in some embodiments, the oncogenic variant of B-Raf comprises a class III mutation.

[0727] In some embodiments, the oncogenic variant of B-Raf can be any of the B-Raf variants put forth in Table 7. Table 7. B-Raf oncogenic variants (numbering corresponding to SEQ ID NO: 1)

[0728] In some embodiments, an oncogenic variant of B-Raf can comprise a deletion of any combination of one or more amino acids between L485 and P490 of B-Raf (SEQ ID NO: 1). In some embodiments, an oncogenic variant of B-Raf can comprise a deletion of any combination of one or more amino acids between L485 and Q494 of B-Raf (SEQ ID NO: 1). In some embodiments, an oncogenic variant of B-Raf can comprise a deletion of any combination of one or more amino acids between A481 and Q494 of B-Raf (SEQ ID NO: 1).Attorney Docket No. ASET-042 / 001WO 325190-2274 In some embodiments, an oncogenic variant of B-Raf can comprise a deletion of any combination of one or more amino acids between K475 and N500 of B-Raf (SEQ ID NO: 1). In some embodiments, any of the preceding deletions can further comprise any combination of one or more substitutions and / or insertions within the range of residues indicated.

[0729] In some embodiments, a subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf and at least one additional protein in the RAF and / or MAPK / ERK signaling pathways that comprises at least one mutation. In some embodiments, the at least one additional protein can be selected from N-Ras, K-Ras, Neurofibromin 1 (NF1). In some embodiments, the at least one mutation in the at least one additional protein can be an oncogenic mutation.

[0730] In some embodiments, a subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf and an N-Ras protein comprising at least one mutation. In some as embodiments, an N-Ras protein comprising at least one mutation can be N-Ras-G12D, N-Ras-Q61K, and / or N-Ras-Q61R. In some embodiment, an N-Ras protein comprising at least one mutation can be N-Ras-Q61L and / or N-Ras-G13D. In a non-limiting example, a subject can have at least one tumor and / or cancerous cell that expresses B-Raf- D594G and N-Ras-G12D.

[0731] In some embodiments, a subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf and a K-Ras protein comprising at least one mutation. In some embodiments, a K-Ras protein comprising at least one mutation can be K-Ras-G12V, K-Ras-G12D, K-Ras-G12A, K-Ras-G12S, K-Ras-G12C, K-Ras-Q61H, K-Ras-Q61L, K-Ras- G13C and / or K-Ras-G13D.

[0732] In some embodiments, a subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf and an NF1 protein comprising at least one mutation. Exemplary mutations within NF1 proteins include, but are not limited to missense mutations, nonsense mutations, frameshift mutations, and splice site mutations, insertions, deletions, and translocations.

[0733] In some embodiments, the cancer is characterized by at least one oncogenic mutation in at least one protein in the RAF and / or MAPK / ERK signaling pathways. In some embodiments, the at least one protein in the RAF and / or MAPK / ERK signaling pathways can be selected from N-Ras, K-Ras, and NF1.

[0734] In some embodiments, the cancer is characterized by at least one oncogenic mutation in the KRAS gene.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0735] It is understood that a cancer that is characterized by at least one oncogenic mutation in the KRAS gene is a cancer that is typically associated with at least one oncogenic mutation in the KRAS gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the KRAS gene.

[0736] In some embodiments, the cancer is characterized by at least one oncogenic variant of K-Ras.

[0737] It is understood that a cancer that is characterized by least one oncogenic variant of K- Ras is a cancer that is typically associated with at least one oncogenic variant of K-Ras, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of K-Ras.

[0738] It is understood that an oncogenic variant of K-Ras is a K-Ras protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a KRAS gene that comprises at least one oncogenic mutation.

[0739] In some embodiments, the subject has at least one oncogenic mutation in the KRAS gene.

[0740] In some embodiments, the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of K-Ras.

[0741] In some embodiments, an oncogenic mutation of K-Ras can be selected from K-Ras- G12V, K-Ras-G12D, K-Ras-G12A, K-Ras-G12S, K-Ras-G12C, K-Ras-Q61H, K-Ras-Q61L, K-Ras-G13C and K-Ras-G13D. In some embodiments, an oncogenic mutation of K-Ras can be a mutation that induces constitutive RAF dimer activation. In some embodiments, an oncogenic mutation of K-Ras is a mutation that is not K-Ras-G12C. In some embodiments, an oncogenic mutation of K-Ras can be K-Ras-G12D. In some embodiments, an oncogenic mutation of K-ras can be K-Ras-G12V.

[0742] In some embodiments, the cancer is characterized by at least one oncogenic mutation in the NRAS gene.

[0743] It is understood that a cancer that is characterized by at least one oncogenic mutation in the NRAS gene is a cancer that is typically associated with at least one oncogenic mutation in the NRAS gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the NRAS gene.

[0744] In some embodiments, the cancer is characterized by at least one oncogenic variant of N-Ras.

[0745] It is understood that a cancer that is characterized by least one oncogenic variant of N- Ras is a cancer that is typically associated with at least one oncogenic variant of N-Ras,Attorney Docket No. ASET-042 / 001WO 325190-2274 including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of N-Ras.

[0746] It is understood that an oncogenic variant of N-Ras is a N-Ras protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a NRAS gene that comprises at least one oncogenic mutation.

[0747] In some embodiments, the subject has at least one oncogenic mutation in the NRAS gene.

[0748] In some embodiments, the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of N-Ras.

[0749] In some embodiments, an oncogenic mutation of N-Ras can be selected from N-Ras- G12D, N-Ras-Q61K, N-Ras-Q61R, N-Ras-Q61L and N-Ras-G13D. In some embodiments, an oncogenic mutation of N-Ras can be a mutation that induces constitutive RAF dimer activation.

[0750] In some embodiments, the cancer is characterized by at least one oncogenic mutation in the NF1 gene. In some embodiments, an oncogenic mutation in the NF1 gene can be a loss- of-function mutation.

[0751] It is understood that a cancer that is characterized by at least one oncogenic mutation in the NF1 gene is a cancer that is typically associated with at least one oncogenic mutation in the NF1 gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the NF1 gene.

[0752] In some embodiments, the cancer is characterized by at least one oncogenic variant of NF1.

[0753] It is understood that a cancer that is characterized by least one oncogenic variant of NF1 is a cancer that is typically associated with at least one oncogenic variant of NF1, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of N-Ras.

[0754] It is understood that an oncogenic variant of NF1 is a NF1 protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a NF1 gene that comprises at least one oncogenic mutation. In some aspects, an oncogenic mutation in an NF1 protein can be a loss-of-function mutation in the NF1 protein.

[0755] In some embodiments, the subject has at least one oncogenic mutation in the NF1 gene.

[0756] In some embodiments, the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of NF1.

[0757] In some embodiments, the cancer is characterized by any combination of: at least one oncogenic mutation in the NRAS gene, at least one oncogenic mutation in the KRAS gene, andAttorney Docket No. ASET-042 / 001WO 325190-2274 at least one oncogenic mutation in the NF1 gene. The oncogenic mutations in can be any of the oncogenic mutations described herein.

[0758] Accordingly, in some embodiments, the cancer is characterized by any combination of at least one oncogenic variant of K-Ras, at least one oncogenic variant of N-Ras, and at least one oncogenic variant of NF1.

[0759] In some embodiments, the cancer is characterized by at least one oncogenic mutation in a gene encoding a RAS GTPase.

[0760] It is understood that a cancer that is characterized by at least one oncogenic mutation in a gene encoding a RAS GTPase is a cancer that is typically associated with at least one oncogenic mutation in a gene encoding a RAS GTPase, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation the gene encoding a RAS GTPase.

[0761] In some embodiments, the cancer is characterized by at least one oncogenic variant of a RAS GTPase.

[0762] It is understood that a cancer that is characterized by least one oncogenic variant of a RAS GTPase is a cancer that is typically associated with at least one oncogenic variant of a RAS GTPase, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of a RAS GTPase.

[0763] It is understood that an oncogenic variant of a RAS GTPase is a RAS GTPase protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a gene encoding a RAS GTPase that comprises at least one oncogenic mutation.

[0764] In some embodiments, the subject has at least one oncogenic mutation in a gene encoding a RAS GTPase.

[0765] In some embodiments, the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of a RAS GTPase.

[0766] In some embodiments, a RAS GTPase can be NRAS, KRAS or HRAS.

[0767] In some embodiments, the cancer is characterized by at least one oncogenic mutation in the HRAS gene.

[0768] It is understood that a cancer that is characterized by at least one oncogenic mutation in the HRAS gene is a cancer that is typically associated with at least one oncogenic mutation in the HRAS gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the HRAS gene.

[0769] In some embodiments, the cancer is characterized by at least one oncogenic variant of H-Ras.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0770] It is understood that a cancer that is characterized by least one oncogenic variant of H- Ras is a cancer that is typically associated with at least one oncogenic variant of H-Ras, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant of H-Ras.

[0771] It is understood that an oncogenic variant of H-Ras is a H-Ras protein that comprises at least one oncogenic mutation and that is produced as the result of the expression of a HRAS gene that comprises at least one oncogenic mutation.

[0772] In some embodiments, the subject has at least one oncogenic mutation in the HRAS gene.

[0773] In some embodiments, the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of H-Ras.

[0774] In some embodiments, the cancer is a carcinoma, a lymphoma, a blastoma, a sarcoma, a leukemia, a brain cancer, a breast cancer, a blood cancer, a bone cancer, a lung cancer, a skin cancer, a liver cancer, an ovarian cancer, a bladder cancer, a renal cancer, a kidney cancer, a gastric cancer, a thyroid cancer, a pancreatic cancer, an esophageal cancer, a prostate cancer, a cervical cancer, a uterine cancer, a stomach cancer, a soft tissue cancer, a laryngeal cancer, a small intestine cancer, a testicular cancer, an anal cancer, a vulvar cancer, a joint cancer, an oral cancer, a pharynx cancer or a colorectal cancer.

[0775] In some embodiments, the cancer is adrenocortical carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma, endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, acute myeloid leukemia, brain lower grade glioma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma, paraganglioma, prostate adenocarcinoma, rectum adenocarcinoma, sarcoma, skin cutaneous melanoma, stomach adenocarcinoma, testicular germ cell tumors, thyroid carcinoma, thymoma, uterine carcinosarcoma, uveal melanoma. Other examples include breast cancer, lung cancer, lymphoma, melanoma, liver cancer, colorectal cancer, ovarian cancer, bladder cancer, renal cancer or gastric cancer. Further examples of cancer include neuroendocrine cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, thyroid cancer, endometrial cancer, biliary cancer, esophageal cancer, anal cancer, salivary, cancer, vulvar cancer, cervical cancer, Acute lymphoblastic leukemia (ALL), Acute myeloidAttorney Docket No. ASET-042 / 001WO 325190-2274 leukemia (AML), Adrenal gland tumors, Anal cancer, Bile duct cancer, Bladder cancer, Bone cancer, Bowel cancer, Brain tumors, Breast cancer, Cancer of unknown primary (CUP), Cancer spread to bone, Cancer spread to brain, Cancer spread to liver, Cancer spread to lung, Carcinoid, Cervical cancer, Children's cancers, Chronic lymphocytic leukemia (CLL), Chrome myeloid leukemia (CML), Colorectal cancer, Ear cancer, Endometrial cancer, Eye cancer, Follicular dendritic cell sarcoma, Gallbladder cancer, Gastric cancer, Gastro esophageal junction cancers, Germ cell tumors, Gestational trophoblastic disease (GIT)), Hairy cell leukemia, Head and neck cancer, Hodgkin lymphoma, Kaposi’s sarcoma, Kidney cancer, Laryngeal cancer, Leukemia, Gastric linitis plastica, Liver cancer, Lung cancer, Lymphoma, Malignant schwannoma, Mediastinal germ cell tumors, Melanoma skin cancer, Men's cancer, Merkel cell skin cancer, Mesothelioma, Molar pregnancy, Mouth and oropharyngeal cancer, Myeloma, Nasal and paranasal sinus cancer, Nasopharyngeal cancer, Neuroblastoma, Neuroendocrine tumors, Non-Hodgkin lymphoma (NHL), Esophageal cancer, Ovarian cancer, Pancreatic cancer, Penile cancer, Persistent trophoblastic disease and choriocarcinoma, Pheochromocytoma, Prostate cancer, Pseudomyxoma peritonei, Rectal cancer. Retinoblastoma, Salivary gland cancer, Secondary' cancer, Signet cell cancer, Skin cancer, Small bowel cancer, Soft tissue sarcoma, Stomach cancer, T cell childhood non Hodgkin lymphoma (NHL), Testicular cancer, Thymus gland cancer, Thyroid cancer, Tongue cancer, Tonsil cancer, Tumors of the adrenal gland, Uterine cancer. Vaginal cancer, Vulval cancer, Wilms' tumor, Womb cancer and Gynaecological cancer. Examples of cancer also include, but are not limited to, Hematologic malignancies, Lymphoma, Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, Multiple myeloma, Chrome lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, Myelodysplastic syndromes, Myelofibrosis, Biliary tract cancer, Hepatocellular cancer, Colorectal cancer, Breast cancer, Lung cancer, Non-small cell lung cancer, Ovarian cancer, Thyroid Carcinoma, Renal Cell Carcinoma, Pancreatic cancer, Bladder cancer, skin cancer, malignant melanoma, merkel cell carcinoma, Uveal Melanoma or Glioblastoma multiforme.

[0776] In some embodiments, the cancer is a hematological cancer.

[0777] In some embodiments, the cancer is a solid cancer (also referred to as a solid malignancy or a solid tumor).

[0778] In some embodiments, the cancer is melanoma, breast cancer, head and neck cancer, esophagogastric cancer, stomach and small intestine cancer, lung cancer, mesothelioma, hepatobiliary cancer, pancreatic cancer, kidney cancer, colorectal cancer, endometrial cancer,Attorney Docket No. ASET-042 / 001WO 325190-2274 cervical cancer, ovarian cancer, bladder cancer, prostate cancer, soft tissue sarcoma, CNS and brain cancer, or thyroid cancer.

[0779] In some embodiments, the cancer is non-small cell lung cancer (NSCLC), colorectal cancer, melanoma, thyroid cancer, histiocytosis, small bowel cancer, gastrointestinal neuroendocrine cancer, carcinoma of unknown primary, non-melanoma skin cancer, prostate cancer, gastric cancer, non-Hodgkin's lymphoma, papillary thyroid carcinoma or glioblastoma.

[0780] In some embodiments, the cancer is NSCLC. In some embodiments, the NSCLC has not undergone small cell lung cancer transformation.

[0781] In some embodiments, the cancer is a histiocytic neoplasm. In some embodiments, the histiocytic neoplasm is Langerhans cell histiocytosis (LCH). In some embodiments, the histiocytic neoplasm is Erdheim Chester disease (ECD).

[0782] In some embodiments, the cancer is melanoma.

[0783] In some embodiments, the cancer is thyroid carcinoma.

[0784] In some embodiments, the cancer is colorectal carcinoma.

[0785] In some embodiments, the cancer is glioma.

[0786] In some embodiments, the cancer is astrocytoma, brain stem glioma, ependymoma, oligo-astrocytoma, oligodendroglioma, or optic pathway glioma.

[0787] In some embodiments, the cancer is low-grade glioma (e.g., glioma arising from astrocytes and / or oligodendrocytes).

[0788] In some embodiments, the cancer is glioma (e.g., low-grade glioma) in a subject having an age of 18 years or older.

[0789] In some embodiments, the cancer is glioma (e.g., low-grade glioma) in a subject having an age of younger than 18 years.

[0790] In some embodiments, the cancer is glioblastoma.

[0791] In some embodiments, any of the cancers described herein can be a recurrent cancer.

[0792] In some embodiments, any of the cancers described herein can be an advanced cancer.

[0793] In some embodiments, any of the cancers described herein can be a metastatic cancer.

[0794] In some embodiments, any of the tumors described herein can be a recurrent tumor.

[0795] In some embodiments, any of the tumors described herein can be an advanced tumor.

[0796] In some embodiments, any of the tumors described herein can be a metastatic tumor.

[0797] In some embodiments, the cancer is NSCLC and the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class I mutation. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class IIAttorney Docket No. ASET-042 / 001WO 325190-2274 mutation. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class III mutation. In some embodiments, the oncogenic variant of B-Raf-V600E. In some embodiments, the NSCLC can be recurrent, advanced, metastatic, or any combination thereof.

[0798] In some embodiments, the cancer is NSCLC and the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of K-Ras. In some embodiments, the oncogenic variant of K-Ras is a K-Ras protein comprising an oncogenic mutation that is not K-Ras-G12C. In some embodiments, the NSCLC can be recurrent, advanced, metastatic, or any combination thereof.

[0799] In some embodiments, the cancer is a histiocytic neoplasm, and the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class I mutation, at least one class II mutation, at least one class III mutation, or any combination thereof. In some embodiments, the cancer is a histiocytic neoplasm, and the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of N-Ras. In some embodiments, the histiocytic neoplasm can be recurrent.

[0800] In some embodiments, the cancer is melanoma and the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class I mutation, at least one class II mutation, at least one class III mutation, or any combination thereof. In some embodiments, the oncogenic variant of B-Raf-V600E. In some embodiments, the melanoma can be recurrent, advanced, metastatic, or any combination thereof.

[0801] In some embodiments, the cancer is melanoma and the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of N-Ras. In some embodiments, the melanoma can be recurrent, advanced, metastatic, or any combination thereof.

[0802] In some embodiments, the cancer is thyroid carcinoma and the subject has at least one tumor and / or cancerous cell that expresses and oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class I mutation, at least one class II mutation, at least one class III mutation, or any combination thereof.

[0803] In some embodiments, the cancer is colorectal carcinoma and the subject has at least one tumor and / or cancerous cell that expresses and oncogenic variant of B-Raf. In some aspects, the oncogenic variant of B-Raf is a B-Raf protein comprising at least one class II mutation, at least one class III mutation, or any combination thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0804] In some embodiments, the administration of a compound of the present disclosure does not induce paradoxical activation of wild-type B-Raf.

[0805] In some embodiments, the administration of a compound of the present disclosure does not substantially increase the amount of p-ERK in the subject.

[0806] In some embodiments, the administration of a compound of the present disclosure results in an amount of p-ERK in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, at least about 80% lower, at least about 90% lower, or at least about 95% lower as compared to a comparable subject being administered with vemurafenib or encorafenib.

[0807] In some embodiments, the administration of a compound of the present disclosure results in an amount of p-ERK in the subject that is at least about 10% lower, at least about 20% lower, at least about 30% lower, at least about 40% lower, at least about 50% lower, at least about 60% lower, at least about 70% lower, at least about 80% lower, at least about 90% lower, or at least about 95% lower as compared to a comparable subject without administration.

[0808] In some embodiments, the administration of a compound of the present disclosure reduces the tumor volume in the subject by at least about 10% lower, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%.

[0809] In some embodiments, the cancer is insensitive or resistant to treatment with one or more inhibitors of the MAPK pathways.

[0810] In some embodiments, the cancer is insensitive or resistant to treatment with a BRAF inhibitor, a MEK inhibitor, or a combination thereof.

[0811] In some embodiments, the cancer is insensitive or resistant to treatment with a combination comprising a BRAF inhibitor and a MEK inhibitor.

[0812] In some embodiments, the cancer is insensitive to treatment with a combination comprising a BRAF inhibitor and a MEK inhibitor.

[0813] In some embodiments, the cancer is resistant to treatment with a combination comprising a BRAF inhibitor and a MEK inhibitor.

[0814] In some embodiments, the subject has an adverse reaction to treatment with one or more inhibitors of the MAPK pathways.

[0815] In some embodiments, the subject has an adverse reaction to treatment with a BRAF inhibitor, a MEK inhibitor, or a combination thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0816] In some embodiments, the subject has an adverse reaction to treatment with a combination comprising a BRAF inhibitor and a MEK inhibitor.

[0817] In some embodiments, the adverse reaction is a new cancer (e.g., skin cancer), bleeding, a gastrointestinal effect, an effect on the kidney and / or liver, an ocular issue, a lung issue, a fever, or any combination thereof.

[0818] In some embodiments, the subject has been previously administered one or more inhibitors of the MAPK pathways, and the subject has experienced disease progression despite the previous administration.

[0819] In some embodiments, the subject has been previously administered a BRAF inhibitor, a MEK inhibitor, or a combination thereof, and the subject has experienced disease progression despite the previous administration.

[0820] In some embodiments, the subject has been previously administered a combination comprising a BRAF inhibitor and a MEK inhibitor, and the subject has experienced disease progression despite the previous administration.

[0821] In some embodiments, the subject has at least one brain metastases.

[0822] In some embodiments, the subject has no brain metastases. Inhibitors of MAPK Pathways

[0823] In some embodiments, the one or more inhibitors of the MAPK pathways comprise a BRAF inhibitor, a MEK inhibitor, or any combination thereof.

[0824] In some embodiments, the one or more inhibitors of the MAPK pathways comprise a combination comprising a BRAF inhibitor and a MEK inhibitor.

[0825] In some embodiments, the BRAF inhibitor is vemurafenib, dabrafenib, or encorafenib.

[0826] In some embodiments, the BRAF inhibitor is vemurafenib.

[0827] In some embodiments, the BRAF inhibitor is dabrafenib.

[0828] In some embodiments, the BRAF inhibitor is encorafenib.

[0829] In some embodiments, the MEK inhibitor is trametinib, cobimetinib, or binimetinib.

[0830] In some embodiments, the MEK inhibitor is trametinib.

[0831] In some embodiments, the MEK inhibitor is cobimetinib.

[0832] In some embodiments, the MEK inhibitor is binimetinib. Definitions

[0833] It is understood that the compounds described herein include the compounds themselves, as well as their salts, and their solvates, if applicable. A salt, for example, can beAttorney Docket No. ASET-042 / 001WO 325190-2274 formed between an anion and a positively charged group (e.g., amino) on a substituted benzene compound. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).

[0834] Unless explicitly indicated otherwise, the terms “approximately” and “about” are synonymous. In some embodiments, “approximately” and “about” refer to the recited amount, value, dose, or duration ± 20%, ± 15%, ± 10%, ± 8%, ± 6%, ± 5%, ± 4%, ± 2%, ± 1%, or ± 0.5%. In some embodiments, “approximately” and “about” refer to the listed amount or duration ± 10%, ± 8%, ± 6%, ± 5%, ± 4%, or ± 2%. In some embodiments, “approximately” and “about” refer to the listed amount, value, dose, or duration ± 5%. In some embodiments, “approximately” and “about” refer to the listed amount, value, dose, or duration ± 2%. In some embodiments, “approximately” and “about” refer to the listed amount, value, dose, or duration

[0835] As used herein, the term “pharmaceutically acceptable anion” refers to an anion suitable for forming a pharmaceutically acceptable salt. Likewise, a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a substituted benzene compound. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion. The substituted benzene compounds also include those salts containing quaternary nitrogen atoms.

[0836] It is understood that the compounds of the present disclosure, for example, the salts of the compounds, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules. Nonlimiting examples of hydrates include monohydrates and dihydrates. Nonlimiting examples of solvates include ethanol solvates and acetone solvates.

[0837] As used herein, the expressions “one or more of A, B, or C,” “one or more A, B, or C,” “one or more of A, B, and C,” “one or more A, B, and C,” “selected from the group consisting of A, B, and C”, “selected from A, B, and C”, and the like are used interchangeably and all refer to a selection from a group consisting of A, B, and / or C, i.e., one or more As, one or more Bs, one or more Cs, or any combination thereof, unless indicated otherwise.

[0838] It is understood that, throughout the description, where compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components. Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps. Further, itAttorney Docket No. ASET-042 / 001WO 325190-2274 should be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions can be conducted simultaneously.

[0839] It is understood that compounds of the present disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or which will be apparent to the skilled artisan in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B., March, J., March’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5thedition, John Wiley & Sons: New York, 2001; Greene, T.W., Wuts, P.G. M., Protective Groups in Organic Synthesis, 3rdedition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser’s Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), incorporated by reference herein, are useful and recognized reference textbooks of organic synthesis known to those in the art.

[0840] It is to be understood that, unless otherwise stated, any description of a method of treatment or prevention includes use of a crystalline form of Compound No. 1 or a pharmaceutically acceptable salt thereof to provide such treatment or prevention as is described herein. It is to be further understood, unless otherwise stated, any description of a method of treatment or prevention includes use of a crystalline form of Compound No. 1 or a pharmaceutically acceptable salt thereof to prepare a medicament to treat or prevent such condition. The treatment or prevention includes treatment or prevention of human or non- human animals including rodents and other disease models.

[0841] It is to be understood that, unless otherwise stated, any description of a method of treatment includes use of a crystalline form of Compound No. 1 or a pharmaceutically acceptable salt thereof to provide such treatment as is described herein. It is to be further understood, unless otherwise stated, any description of a method of treatment includes use of a crystalline form of Compound No.1 or a pharmaceutically acceptable salt thereof to prepare a medicament to treat such condition. The treatment includes treatment of human or non-human animals including rodents and other disease models.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0842] As used herein, the term “subject” refers to a subject having a disease or having an increased risk of developing the disease. A “subject” includes a mammal. The mammal can be e.g., a human or appropriate non-human mammal, such as primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or a pig. The subject can also be a bird or fowl. In one embodiment, the mammal is a human.

[0843] In some embodiments, the term “subject in need thereof” can be one who has been previously diagnosed or identified as having a disease or disorder disclosed herein. A subject in need thereof can also be one who is suffering from a disease or disorder disclosed herein. Alternatively, a subject in need thereof can be one who has an increased risk of developing such disease or disorder relative to the population at large (i.e., a subject who is predisposed to developing such disorder relative to the population at large). A subject in need thereof can have a refractory or resistant a disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment). The subject in need thereof may be resistant at start of treatment or may become resistant during treatment. In some embodiments, the subject in need thereof received and failed all known effective therapies for a disease or disorder disclosed herein. In some embodiments, the subject in need thereof received at least one prior therapy.

[0844] As used herein, the term “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder. The term “treat” can also include treatment of a cell in vitro or an animal model.

[0845] It is to be understood that a crystalline form of Compound No.1 or a pharmaceutically acceptable salt thereof, can or may also be used to prevent a relevant disease, condition or disorder, or used to identify suitable candidates for such purposes.

[0846] As used herein, the term “preventing,” “prevent,” or “protecting against” describes reducing or eliminating the onset of the symptoms or complications of such disease, condition or disorder.

[0847] It is to be understood that “solubility” or “solubility rating” refers to the property of a polymorph (e.g., Form A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, or P) disclosed herein to dissolve in a liquid solvent and form a homogeneous solution. In some embodiments, solubility is expressed as a concentration, either by mass of solute per unit volume of solvent (e.g., g of solute per kg of solvent, g per dL (100 mL), mg / ml, etc.), molarity, molality, mole fraction, orAttorney Docket No. ASET-042 / 001WO 325190-2274 other similar descriptions of concentration. A person of skill in the art may understand that the maximum equilibrium amount of solute that can dissolve per amount of solvent is the solubility of that solute in that solvent under the specified conditions, including temperature, pressure, pH, and the nature of the solvent.

[0848] As used herein, “stable” refers to a polymorph that maintains purity, appearance, and / or analytical parameters over a defined time and temperature as compared to the polymorph as isolated. In some embodiments, the “stable” polymorph exhibits less than about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, or about 0.1% impurity over a set period of time (e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks, one month, two months, three months, or four months).

[0849] As used herein, the term “pharmaceutical composition” is a formulation containing the compounds of the present disclosure in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler or a vial. The quantity of active ingredient (e.g., a formulation of the disclosed compound or salt, hydrate, solvate or isomer thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved. One skilled in the art will appreciate that it is sometimes necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalational, buccal, sublingual, intrapleural, intrathecal, intranasal, and the like. Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.

[0850] As used herein, the term “pharmaceutically acceptable” refers to those compounds, anions, cations, materials, compositions, carriers, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0851] As used herein, the term “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.

[0852] As used herein, the term “therapeutically effective amount”, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.

[0853] It is understood that, for the compounds of the present disclosure being capable of further forming salts, all of these forms are also contemplated within the scope of the claimed disclosure.

[0854] As used herein, the term “pharmaceutically acceptable salts” refer to derivatives of the compounds of the present disclosure wherein the parent compound is modified by making acid or base salts thereof. In some embodiments, the pharmaceutically acceptable salt of a compound is also a prodrug of the compound. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic, 2- hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, 1,2-ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicylic, stearic, subacetic, succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, toluene sulfonic, and the commonly occurring amine acids, e.g., glycine, alanine, phenylalanine, arginine, etc.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0855] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentane propionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3- phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, muconic acid, and the like. The present disclosure also encompasses salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. In the salt form, it is understood that the ratio of the compound to the cation or anion of the salt can be 1:1, or any ration other than 1:1, e.g., 3:1, 2:1, 1:2, or 1:3.

[0856] It is understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.

[0857] The compounds, or pharmaceutically acceptable salts thereof, are administered orally, nasally, transdermally, pulmonary, inhalationally, buccally, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally and parenterally. In one embodiment, the compound is administered orally. One skilled in the art will recognize the advantages of certain routes of administration.

[0858] The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

[0859] Techniques for formulation and administration of the disclosed compounds of the disclosure can be found in Remington: the Science and Practice of Pharmacy, 19thedition, Mack Publishing Co., Easton, PA (1995). In an embodiment, the compounds described herein, and the pharmaceutically acceptable salts thereof, are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein.

[0860] All percentages and ratios used herein, unless otherwise indicated, are by weight. Other features and advantages of the present disclosure are apparent from the differentAttorney Docket No. ASET-042 / 001WO 325190-2274 examples. The provided examples illustrate different components and methodology useful in practicing the present disclosure. The examples do not limit the claimed disclosure. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present disclosure.

[0861] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents is not intended as an admission that any is pertinent prior art, nor does it constitute any admission as to the contents or date of the same. The invention having now been described by way of written description, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments and that the foregoing description and examples below are for purposes of illustration and not limitation of the claims that follow. Exemplary Embodiments

[0862] Exemplary Embodiment No.1. A morphic form of Compound No.1:a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.

[0863] Exemplary Embodiment No.2. The morphic form of Exemplary Embodiment No. 1, wherein the morphic form is a crystalline form.

[0864] Exemplary Embodiment No.3. The morphic form of Exemplary Embodiment Nos. 1 or 2, wherein the morphic form is Form A, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0865] Exemplary Embodiment No.4. The morphic form of any of the preceding Exemplary Embodiments, wherein Form A is characterized by an X-ray powder diffraction(“XRPD”) pattern comprising signals (e.g., peaks) at 13.2±0.2, 22.3±0.2, and 25.3±0.2 °2(e.g., 13.2±0.1, 22.3±0.1, and 25.3±0.1 °2 (e.g., 13.2, 22.3, and 25.3 °2 )) using Cu Kradiation.

[0866] Exemplary Embodiment No.5. The morphic form of any of the preceding Exemplary Embodiments, wherein the XRPD pattern of Form A further comprises at leastone signal (e.g., peak) selected from 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 18.5±0.1,19.4±0.1, and 24.8±0.1 °2 (e.g., 18.5, 19.4, and 24.8 °2 )) using Cu K radiation;Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein the XRPD pattern of Form A further comprises at least twosignals (e.g., peaks) selected from 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 18.5±0.1,19.4±0.1, and 24.8±0.1 °2 (e.g., 18.5, 19.4, and 24.8 °2 ))using Cu K radiation;optionally, wherein the XRPD pattern of Form A further comprises signals (e.g.,peaks) at 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 18.5±0.1, 19.4±0.1, and 24.8±0.1 °2(e.g., 18.5, 19.4, and 24.8 °2 )) using Cu K radiation.

[0867] Exemplary Embodiment No.6. The morphic form of any of the preceding Exemplary Embodiments, wherein Form A is characterized by an X-ray powder diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 13.2±0.2,18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2 (e.g., 13.2±0.1, 18.5±0.1, 19.4±0.1,22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 13.2, 18.5, 19.4, 22.3, 24.8, and 25.3 °2 )) usingCu K radiation;optionally, wherein the XRPD pattern of Form A comprises at least four signals (e.g.,peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2(e.g., 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 13.2, 18.5,19.4, 22.3, 24.8, and 25.3 °2 ))using Cu K radiation;optionally, wherein the XRPD pattern of Form A comprises at least five signals (e.g.,peaks) selected from 13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2(e.g., 13.2±0.1, 18.5±0.1, 19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 13.2, 18.5,19.4, 22.3, 24.8, and 25.3 °2 ))using Cu K radiation;optionally, wherein the XRPD pattern of Form A comprises signals (e.g., peaks) at13.2±0.2, 18.5±0.2, 19.4±0.2, 22.3±0.2, 24.8±0.2, and 25.3±0.2 °2 (e.g., 13.2±0.1, 18.5±0.1,19.4±0.1, 22.3±0.1, 24.8±0.1, and 25.3±0.1 °2 (e.g., 13.2, 18.5, 19.4, 22.3, 24.8, and 25.3°2 )) using Cu K radiation.

[0868] Exemplary Embodiment No.7. The morphic form of any of the preceding Exemplary Embodiments, wherein Form A is characterized by an XRPD profile substantially similar to that shown in FIG.1.

[0869] Exemplary Embodiment No.8. The morphic form of any of the preceding Exemplary Embodiments, wherein Form A is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in Table 1.

[0870] Exemplary Embodiment No.9. The morphic form of any of the preceding Exemplary Embodiments, wherein Form A is characterized by a DSC curve having an endothermic signal (e.g., peak) at 208 ± 20°C (e.g., 208 ± 10 °C (e.g., 208 ± 5 °C (e.g., 208 ± 4 °C (e.g., 208 ± 3 °C (e.g., 208 ± 2 °C (e.g., 208 ± 1 °C (e.g., 208 ± 0.5 °C)))))));Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein Form A is characterized by a DSC curve having an endothermic signal (e.g., peak) at 208 °C.

[0871] Exemplary Embodiment No.10. The morphic form of any of the preceding Exemplary Embodiments, wherein Form A is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 93 ± 9 J / g (e.g., 93 ± 8 J / g (e.g., 93 ± 7 J / g (e.g., 93 ± 6 J / g (e.g., 93 ± 5 J / g (e.g., 93 ± 4 J / g (e.g., 93 ± 3 J / g (e.g., 93 ± 2 J / g))))))); optionally, wherein Form A is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 93 J / g; optionally, wherein Form A is characterized by a DSC profile substantially similar to that shown in FIG.2.

[0872] Exemplary Embodiment No.11. The morphic form of any of the preceding Exemplary Embodiments, wherein Form A shows a weight loss of from about 0.05% to about 0.5%, at a temperature ranging from about 35 ± 20 °C (e.g., 35 ± 10 °C (e.g., 35 ± 5 °C (e.g., 35 ± 4 °C (e.g., 35 ± 3 °C (e.g., 35 ± 2 °C (e.g., 35 ± 1 °C (e.g., 35 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form A shows a weight loss of about 0.28%, at a temperature ranging from about 35 °C to about 200 °C, as measured by TGA; optionally, wherein Form A is characterized by a TGA profile substantially similar to that shown in FIG.3.

[0873] Exemplary Embodiment No.12. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form B, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0874] Exemplary Embodiment No.13. The morphic form of any of the preceding Exemplary Embodiments, wherein Form B is characterized by an XRPD profile substantially similar to that shown in FIG.82.

[0875] Exemplary Embodiment No.14. The morphic form of any of the preceding Exemplary Embodiments, wherein Form B is characterized by a DSC curve having an endothermic signal (e.g., peak) at 208 ± 20°C (e.g., 208 ± 10 °C (e.g., 208 ± 5 °C (e.g., 208 ± 4 °C (e.g., 208 ± 3 °C (e.g., 208 ± 2 °C (e.g., 208 ± 1 °C (e.g., 208 ± 0.5 °C))))))); optionally, wherein Form B is characterized by a DSC curve having an endothermic signal (e.g., peak) at 208 °C.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0876] Exemplary Embodiment No.15. The morphic form of any of the preceding Exemplary Embodiments, wherein Form B is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 86 ± 9 J / g (e.g., 86 ± 8 J / g (e.g., 86 ± 7 J / g (e.g., 86 ± 6 J / g (e.g., 86 ± 5 J / g (e.g., 86 ± 4 J / g (e.g., 86 ± 3 J / g (e.g., 86 ± 2 J / g))))))); optionally, wherein Form B is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 86 J / g; optionally, wherein Form B is characterized by a DSC profile substantially similar to that shown in FIG.83.

[0877] Exemplary Embodiment No.16. The morphic form of any of the preceding Exemplary Embodiments, wherein Form B shows a weight loss of from about 0.5% to about 4.0%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 180 ± 20 °C (e.g., 180 ± 10 °C (e.g., 180 ± 5 °C (e.g., 180 ± 4 °C (e.g., 180 ± 3 °C (e.g., 180 ± 2 °C (e.g., 180 ± 1 °C (e.g., 180 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form B shows a weight loss of about 2.3%, at a temperature ranging from about 34 °C to about 180 °C, as measured by TGA; optionally, wherein Form B is characterized by a TGA profile substantially similar to that shown in FIG.84.

[0878] Exemplary Embodiment No.17. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form C, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0879] Exemplary Embodiment No.18. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form C of a hydrochloride salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0880] Exemplary Embodiment No.19. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form C of a hydrochloride salt of Compound No.1.

[0881] Exemplary Embodiment No.20. The morphic form of any of the preceding Exemplary Embodiments, wherein the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 1:1.

[0882] Exemplary Embodiment No.21. The morphic form of any of the preceding Exemplary Embodiments, wherein the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 1:2.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0883] Exemplary Embodiment No.22. The morphic form of any of the preceding Exemplary Embodiments, wherein the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 2:1.

[0884] Exemplary Embodiment No.23. The morphic form of any of the preceding Exemplary Embodiments, wherein Form C is characterized by an XRPD profile substantially similar to that shown in FIG.25.

[0885] Exemplary Embodiment No.24. The morphic form of any of the preceding Exemplary Embodiments, wherein Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) at 56.6 ± 20°C (e.g., 56.6 ± 10 °C (e.g., 56.6 ± 5 °C (e.g., 56.6 ± 4 °C (e.g., 56.6 ± 3 °C (e.g., 56.6 ± 2 °C (e.g., 56.6 ± 1 °C (e.g., 56.6 ± 0.5 °C))))))); optionally, wherein Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) at 56.6 °C.

[0886] Exemplary Embodiment No.25. The morphic form of any of the preceding Exemplary Embodiments, wherein Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) at 188 ± 20°C (e.g., 188 ± 10 °C (e.g., 188 ± 5 °C (e.g., 188 ± 4 °C (e.g., 188 ± 3 °C (e.g., 188 ± 2 °C (e.g., 188 ± 1 °C (e.g., 188 ± 0.5 °C))))))); optionally, wherein Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) at 188 °C.

[0887] Exemplary Embodiment No.26. The morphic form of any of the preceding Exemplary Embodiments, wherein Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 4.09 ± 0.4 J / g (e.g., 4.09 ± 0.3 J / g (e.g., 4.09 ± 0.2 J / g (e.g., 4.09 ± 0.1 J / g (e.g., 4.09 ± 0.08 J / g (e.g., 4.09 ± 0.06 J / g (e.g., 4.09 ± 0.04 J / g (e.g., 4.09 ± 0.02 J / g))))))); optionally, wherein Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 4.09 J / g.

[0888] Exemplary Embodiment No.27. The morphic form of any of the preceding Exemplary Embodiments, wherein Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 111 ± 12 J / g (e.g., 111 ± 10 J / g (e.g., 111 ± 8 J / g (e.g., 111 ± 6 J / g (e.g., 111 ± 4 J / g (e.g., 111 ± 3 J / g (e.g., 111 ± 2 J / g (e.g., 111 ± 1 J / g))))))); optionally, wherein Form C is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 111 J / g; optionally, wherein Form C is characterized by a DSC profile substantially similar to that shown in FIG.26.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0889] Exemplary Embodiment No.28. The morphic form of any of the preceding Exemplary Embodiments, wherein Form C shows a weight loss of from about 0.05% to about 2.5%, at a temperature ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form C shows a weight loss of about 0.9%, at a temperature ranging from about 33 °C to about 100 °C, as measured by TGA.

[0890] Exemplary Embodiment No.29. The morphic form of any of the preceding Exemplary Embodiments, wherein Form C shows a weight loss of from about 1% to about 7%, at a temperature ranging from about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form C shows a weight loss of about 4.4%, at a temperature ranging from about 100 °C to about 200 °C, as measured by TGA; optionally, wherein Form C is characterized by a TGA profile substantially similar to that shown in FIG.27.

[0891] Exemplary Embodiment No.30. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form D, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0892] Exemplary Embodiment No.31. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form D of a hydrochloride salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0893] Exemplary Embodiment No.32. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form D of a hydrochloride salt of Compound No.1.

[0894] Exemplary Embodiment No.33. The morphic form of any of the preceding Exemplary Embodiments, wherein the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 1:1.

[0895] Exemplary Embodiment No.34. The morphic form of any of the preceding Exemplary Embodiments, wherein the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 1:2.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0896] Exemplary Embodiment No.35. The morphic form of any of the preceding Exemplary Embodiments, wherein the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 1:3.

[0897] Exemplary Embodiment No.36. The morphic form of any of the preceding Exemplary Embodiments, wherein the hydrochloride salt comprises Compound No.1 and hydrochloric acid present at a ratio of about 2:1.

[0898] Exemplary Embodiment No.37. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by an X-ray powder diffraction(“XRPD”) pattern comprising signals (e.g., peaks) at 7.7±0.2, 21.2±0.2, and 26.3±0.2 °2(e.g., 7.7±0.1, 21.2±0.1, and 26.3±0.1 °2 (e.g., 7.7, 21.2, and 26.3 °2 )) using Cu Kradiation; optionally, wherein the XRPD pattern of Form D further comprises at least one signal(e.g., peak) selected from 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 27.8±0.1, 28.7±0.1, and30.2±0.1 °2 (e.g., 27.8, 28.7, and 30.2 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form D further comprises at least twosignals (e.g., peaks) selected from 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 27.8±0.1,28.7±0.1, and 30.2±0.1 °2 (e.g., 27.8, 28.7, and 30.2 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form D further comprises signals (e.g.,peaks) at 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2(e.g., 27.8, 28.7, and 30.2 °2 )) using Cu K radiation.

[0899] Exemplary Embodiment No.38. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by an X-ray powder diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 7.7±0.2,21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 7.7±0.1, 21.2±0.1, 26.3±0.1,27.8±0.1, 28.7±0.1, and 30.2±0.1 °2 (e.g., 7.7, 21.2, 26.3, 27.8, 28.7, and 30.2 °2 )) usingCu K radiation;optionally, wherein the XRPD pattern of Form D comprises at least four signals (e.g.,peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g.,7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2 (e.g., 7.7, 21.2, 26.3, 27.8,28.7, and 30.2 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form D comprises at least five signals (e.g.,peaks) selected from 7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g.,7.7±0.1, 21.2±0.1, 26.3±0.1, 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2 (e.g., 7.7, 21.2, 26.3, 27.8,28.7, and 30.2 °2 )) using Cu K radiation;Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein the XRPD pattern of Form D comprises signals (e.g., peaks) at7.7±0.2, 21.2±0.2, 26.3±0.2, 27.8±0.2, 28.7±0.2, and 30.2±0.2 °2 (e.g., 7.7±0.1, 21.2±0.1,26.3±0.1, 27.8±0.1, 28.7±0.1, and 30.2±0.1 °2 (e.g., 7.7, 21.2, 26.3, 27.8, 28.7, and 30.2°2 )) using Cu K radiation.

[0900] Exemplary Embodiment No.39. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by an XRPD pattern substantially similar to those shown in FIG.6 or FIG.29.

[0901] Exemplary Embodiment No.40. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in Table 2.

[0902] Exemplary Embodiment No.41. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 61.5 ± 20°C (e.g., 61.5 ± 10 °C (e.g., 61.5 ± 5 °C (e.g., 61.5 ± 4 °C (e.g., 61.5 ± 3 °C (e.g., 61.5 ± 2 °C (e.g., 61.5 ± 1 °C (e.g., 61.5 ± 0.5 °C))))))); optionally, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 61.5 °C.

[0903] Exemplary Embodiment No.42. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 141 ± 20°C (e.g., 141 ± 10 °C (e.g., 141 ± 5 °C (e.g., 141 ± 4 °C (e.g., 141 ± 3 °C (e.g., 141 ± 2 °C (e.g., 141 ± 1 °C (e.g., 141 ± 0.5 °C))))))); optionally, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 141 °C.

[0904] Exemplary Embodiment No.43. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 67 ± 20°C (e.g., 67 ± 10 °C (e.g., 67 ± 5 °C (e.g., 67 ± 4 °C (e.g., 67 ± 3 °C (e.g., 67 ± 2 °C (e.g., 67 ± 1 °C (e.g., 67 ± 0.5 °C))))))); optionally, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 67 °C.

[0905] Exemplary Embodiment No.44. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 145 ± 20°C (e.g., 145 ± 10 °C (e.g., 145 ± 5 °C (e.g., 145 ± 4 °C (e.g., 145 ± 3 °C (e.g., 145 ± 2 °C (e.g., 145 ± 1 °C (e.g., 145 ± 0.5 °C))))))); optionally, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) at 145 °C.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0906] Exemplary Embodiment No.45. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 8.48 ± 0.8 J / g (e.g., 8.48 ± 0.7 J / g (e.g., 8.48 ± 0.6 J / g (e.g., 8.48 ± 0.5 J / g (e.g., 8.48 ± 0.4 J / g (e.g., 8.48 ± 0.3 J / g (e.g., 8.48 ± 0.2 J / g (e.g., 8.48 ± 0.1 J / g))))))); optionally, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 8.48 J / g.

[0907] Exemplary Embodiment No.46. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 354 ± 35 J / g (e.g., 354 ± 30 J / g (e.g., 354 ± 25 J / g (e.g., 354 ± 20 J / g (e.g., 354 ± 15 J / g (e.g., 354 ± 10 J / g (e.g., 354 ± 5 J / g (e.g., 354 ± 3 J / g))))))); optionally, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 354 J / g.

[0908] Exemplary Embodiment No.47. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 16.2 ± 2 J / g (e.g., 16.2 ± 1.5 J / g (e.g., 16.2 ± 1 J / g (e.g., 16.2 ± 0.8 J / g (e.g., 16.2 ± 0.6 J / g (e.g., 16.2 ± 0.4 J / g (e.g., 16.2 ± 0.2 J / g (e.g., 16.2 ± 0.1 J / g))))))); optionally, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 16.2 J / g.

[0909] Exemplary Embodiment No.48. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 255 ± 25 J / g (e.g., 255 ± 20 J / g (e.g., 255 ± 15 J / g (e.g., 255 ± 10 J / g (e.g., 255 ± 5 J / g (e.g., 255 ± 4 J / g (e.g., 255 ± 2 J / g (e.g., 255 ± 1 J / g))))))); optionally, wherein Form D is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 255 J / g; optionally, wherein Form D is characterized by a DSC profile substantially similar to those shown in FIG.7 or FIG.30.

[0910] Exemplary Embodiment No.49. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 90Attorney Docket No. ASET-042 / 001WO 325190-2274 ± 20 °C (e.g., 90 ± 10 °C (e.g., 90 ± 5 °C (e.g., 90 ± 4 °C (e.g., 90 ± 3 °C (e.g., 90 ± 2 °C (e.g., 90 ± 1 °C (e.g., 90 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form D shows a weight loss of about 1.8%, at a temperature ranging from about 34 °C to about 90 °C, as measured by TGA.

[0911] Exemplary Embodiment No.50. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D shows a weight loss of from about 10% to about 25%, at a temperature ranging from about 90 ± 20 °C (e.g., 90 ± 10 °C (e.g., 90 ± 5 °C (e.g., 90 ± 4 °C (e.g., 90 ± 3 °C (e.g., 90 ± 2 °C (e.g., 90 ± 1 °C (e.g., 90 ± 0.5 °C))))))) to about 170 ± 20 °C (e.g., 170 ± 10 °C (e.g., 170 ± 5 °C (e.g., 170 ± 4 °C (e.g., 170 ± 3 °C (e.g., 170 ± 2 °C (e.g., 170 ± 1 °C (e.g., 170 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form D shows a weight loss of about 17%, at a temperature ranging from about 90 °C to about 170 °C, as measured by TGA.

[0912] Exemplary Embodiment No.51. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form D shows a weight loss of about 2.6%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA.

[0913] Exemplary Embodiment No.52. The morphic form of any of the preceding Exemplary Embodiments, wherein Form D shows a weight loss of from about 8% to about 25%, at a temperature ranging from about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form D shows a weight loss of about 15%, at a temperature ranging from about 100 °C to about 200 °C, as measured by TGA; optionally, wherein Form D is characterized by a TGA profile substantially similar to those shown in FIG.8 or FIG.31.

[0914] Exemplary Embodiment No.53. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form E, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0915] Exemplary Embodiment No.54. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form E of a sulfate salt of Compound No.1.

[0916] Exemplary Embodiment No.55. The morphic form of any of the preceding Exemplary Embodiments, wherein the sulfate salt comprises Compound No.1 and sulfuric acid present at a ratio of about 1:1.

[0917] Exemplary Embodiment No.56. The morphic form of any of the preceding Exemplary Embodiments, wherein the sulfate salt comprises Compound No.1 and sulfuric acid present at a ratio of about 1:2.

[0918] Exemplary Embodiment No.57. The morphic form of any of the preceding Exemplary Embodiments, wherein the sulfate salt comprises Compound No.1 and sulfuric acid present at a ratio of about 2:1.

[0919] Exemplary Embodiment No.58. The morphic form of any of the preceding Exemplary Embodiments, wherein Form E is characterized by an XRPD profile substantially similar to that shown in FIG.33.

[0920] Exemplary Embodiment No.59. The morphic form of any of the preceding Exemplary Embodiments, wherein Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) at 65.9 ± 20°C (e.g., 65.9 ± 10 °C (e.g., 65.9 ± 5 °C (e.g., 65.9 ± 4 °C (e.g., 65.9 ± 3 °C (e.g., 65.9 ± 2 °C (e.g., 65.9 ± 1 °C (e.g., 65.9 ± 0.5 °C))))))); optionally, wherein Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) at 65.9 °C.

[0921] Exemplary Embodiment No.60. The morphic form of any of the preceding Exemplary Embodiments, wherein Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) at 200 ± 20°C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))); optionally, wherein Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) at 200 °C.

[0922] Exemplary Embodiment No.61. The morphic form of any of the preceding Exemplary Embodiments, wherein Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 19.3 ± 2.0 J / g (e.g., 19.3 ± 1.5 J / g (e.g., 19.3 ± 1.0 J / g (e.g., 19.3 ± 0.8 J / g (e.g., 19.3 ± 0.6 J / g (e.g., 19.3 ± 0.4 J / g (e.g., 19.3 ± 0.2 J / g (e.g., 19.3 ± 0.1 J / g))))))); optionally, wherein Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 19.3 J / g.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0923] Exemplary Embodiment No.62. The morphic form of any of the preceding Exemplary Embodiments, wherein Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 64.3 ± 6.5 J / g (e.g., 64.3 ± 4.0 J / g (e.g., 64.3 ± 2.0 J / g (e.g., 64.3 ± 1.0 J / g (e.g., 64.3 ± 0.8 J / g (e.g., 64.3 ± 0.6 J / g (e.g., 64.3 ± 0.4 J / g (e.g., 64.3 ± 0.2 J / g))))))); optionally, wherein Form E is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 64.3 J / g; optionally, wherein Form E is characterized by a DSC profile substantially similar to that shown in FIG.34.

[0924] Exemplary Embodiment No.63. The morphic form of any of the preceding Exemplary Embodiments, wherein Form E shows a weight loss of from about 0.05% to about 4.5%, at a temperature ranging from about 33 ± 20 °C (e.g., 33 ± 10 °C (e.g., 33 ± 5 °C (e.g., 33 ± 4 °C (e.g., 33 ± 3 °C (e.g., 33 ± 2 °C (e.g., 33 ± 1 °C (e.g., 33 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form E shows a weight loss of about 1.3%, at a temperature ranging from about 33 °C to about 100 °C, as measured by TGA; optionally, wherein Form E is characterized by a TGA profile substantially similar to that shown in FIG.35.

[0925] Exemplary Embodiment No.64. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form F, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0926] Exemplary Embodiment No.65. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form F of a phosphate salt of Compound No.1.

[0927] Exemplary Embodiment No.66. The morphic form of any of the preceding Exemplary Embodiments, wherein the phosphate salt comprises Compound No.1 and phosphoric acid present at a ratio of about 1:1.

[0928] Exemplary Embodiment No.67. The morphic form of any of the preceding Exemplary Embodiments, wherein the phosphate salt comprises Compound No.1 and phosphoric acid present at a ratio of about 1:2.

[0929] Exemplary Embodiment No.68. The morphic form of any of the preceding Exemplary Embodiments, wherein the phosphate salt comprises Compound No.1 and phosphoric acid present at a ratio of about 2:1.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0930] Exemplary Embodiment No.69. The morphic form of any of the preceding Exemplary Embodiments, wherein Form F is characterized by an XRPD profile substantially similar to that shown in FIG.37.

[0931] Exemplary Embodiment No.70. The morphic form of any of the preceding Exemplary Embodiments, wherein Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) at 72.2 ± 20°C (e.g., 72.2 ± 10 °C (e.g., 72.2 ± 5 °C (e.g., 72.2 ± 4 °C (e.g., 72.2 ± 3 °C (e.g., 72.2 ± 2 °C (e.g., 72.2 ± 1 °C (e.g., 72.2 ± 0.5 °C))))))); optionally, wherein Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) at 72.2 °C.

[0932] Exemplary Embodiment No.71. The morphic form of any of the preceding Exemplary Embodiments, wherein Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) at 159 ± 20°C (e.g., 159 ± 10 °C (e.g., 159 ± 5 °C (e.g., 159 ± 4 °C (e.g., 159 ± 3 °C (e.g., 159 ± 2 °C (e.g., 159 ± 1 °C (e.g., 159 ± 0.5 °C))))))); optionally, wherein Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) at 159 °C.

[0933] Exemplary Embodiment No.72. The morphic form of any of the preceding Exemplary Embodiments, wherein Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 64.4 ± 6.5 J / g (e.g., 64.4 ± 5.0 J / g (e.g., 64.4 ± 4.0 J / g (e.g., 64.4 ± 3.0 J / g (e.g., 64.4 ± 2.0 J / g (e.g., 64.4 ± 1.0 J / g (e.g., 64.4 ± 0.8 J / g (e.g., 64.4 ± 0.5 J / g))))))); optionally, wherein Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 64.4 J / g.

[0934] Exemplary Embodiment No.73. The morphic form of any of the preceding Exemplary Embodiments, wherein Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 33.6 ± 3.5 J / g (e.g., 33.6 ± 3.0 J / g (e.g., 33.6 ± 2.5 J / g (e.g., 33.6 ± 2.0 J / g (e.g., 33.6 ± 1.5 J / g (e.g., 33.6 ± 1.0 J / g (e.g., 33.6 ± 0.5 J / g (e.g., 33.6 ± 0.3 J / g))))))); optionally, wherein Form F is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 33.6 J / g; optionally, wherein Form F is characterized by a DSC profile substantially similar to that shown in FIG.38.

[0935] Exemplary Embodiment No.74. The morphic form of any of the preceding Exemplary Embodiments, wherein Form F shows a weight loss of from about 0.5% to about 7.5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g.,Attorney Docket No. ASET-042 / 001WO 325190-2274 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form F shows a weight loss of about 3.6%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA; optionally, wherein Form F is characterized by a TGA profile substantially similar to that shown in FIG.39.

[0936] Exemplary Embodiment No.75. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form G, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0937] Exemplary Embodiment No.76. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form G of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0938] Exemplary Embodiment No.77. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form G of a salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0939] Exemplary Embodiment No.78. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form G of a phosphate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0940] Exemplary Embodiment No.79. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form G of a phosphate salt of Compound No.1.

[0941] Exemplary Embodiment No.80. The morphic form of any of the preceding Exemplary Embodiments, wherein the phosphate salt comprises Compound No.1 and phosphoric acid present at a ratio of about 1:1.

[0942] Exemplary Embodiment No.81. The morphic form of any of the preceding Exemplary Embodiments, wherein the phosphate salt comprises Compound No.1 and phosphoric acid present at a ratio of about 1:2.

[0943] Exemplary Embodiment No.82. The morphic form of any of the preceding Exemplary Embodiments, wherein the phosphate salt comprises Compound No.1 and phosphoric acid present at a ratio of about 2:1.

[0944] Exemplary Embodiment No.83. The morphic form of any of the preceding Exemplary Embodiments, wherein Form G is characterized by an XRPD profile substantially similar to that shown in FIG.41.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0945] Exemplary Embodiment No.84. The morphic form of any of the preceding Exemplary Embodiments, wherein Form G is characterized by a DSC curve having an endothermic signal (e.g., peak) at 75.1 ± 20°C (e.g., 75.1 ± 10 °C (e.g., 75.1 ± 5 °C (e.g., 75.1 ± 4 °C (e.g., 75.1 ± 3 °C (e.g., 75.1 ± 2 °C (e.g., 75.1 ± 1 °C (e.g., 75.1 ± 0.5 °C))))))); optionally, wherein Form G is characterized by a DSC curve having an endothermic signal (e.g., peak) at 75.1 °C.

[0946] Exemplary Embodiment No.85. The morphic form of any of the preceding Exemplary Embodiments, wherein Form G is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 58.4 ± 6.0 J / g (e.g., 58.4 ± 5.0 J / g (e.g., 58.4 ± 4.0 J / g (e.g., 58.4 ± 3.0 J / g (e.g., 58.4 ± 2.0 J / g (e.g., 58.4 ± 1.5 J / g (e.g., 58.4 ± 1.0 J / g (e.g., 58.4 ± 0.5 J / g))))))); optionally, wherein Form G is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 58.4 J / g; optionally, wherein Form G is characterized by a DSC profile substantially similar to that shown in FIG.42.

[0947] Exemplary Embodiment No.86. The morphic form of any of the preceding Exemplary Embodiments, wherein Form G shows a weight loss of from about 2.0% to about 7.5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form G shows a weight loss of about 4.1%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA; optionally, wherein Form G is characterized by a TGA profile substantially similar to that shown in FIG.43.

[0948] Exemplary Embodiment No.87. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form H, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0949] Exemplary Embodiment No.88. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form H of a mesylate salt of Compound No.1.

[0950] Exemplary Embodiment No.89. The morphic form of any of the preceding Exemplary Embodiments, wherein the mesylate salt comprises Compound No.1 and methanesulfonic acid present at a ratio of about 1:1.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0951] Exemplary Embodiment No.90. The morphic form of any of the preceding Exemplary Embodiments, wherein the mesylate salt comprises Compound No.1 and methanesulfonic acid present at a ratio of about 1:2.

[0952] Exemplary Embodiment No.91. The morphic form of any of the preceding Exemplary Embodiments, wherein the mesylate salt comprises Compound No.1 and methanesulfonic acid present at a ratio of about 2:1.

[0953] Exemplary Embodiment No.92. The morphic form of any of the preceding Exemplary Embodiments, wherein Form H is characterized by an XRPD profile substantially similar to that shown in FIG.45.

[0954] Exemplary Embodiment No.93. The morphic form of any of the preceding Exemplary Embodiments, wherein Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) at 72.4 ± 20°C (e.g., 72.4 ± 10 °C (e.g., 72.4 ± 5 °C (e.g., 72.4 ± 4 °C (e.g., 72.4 ± 3 °C (e.g., 72.4 ± 2 °C (e.g., 72.4 ± 1 °C (e.g., 72.4 ± 0.5 °C))))))); optionally, wherein Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) at 72.4 °C.

[0955] Exemplary Embodiment No.94. The morphic form of any of the preceding Exemplary Embodiments, wherein Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) at 163 ± 20°C (e.g., 163 ± 10 °C (e.g., 163 ± 5 °C (e.g., 163 ± 4 °C (e.g., 163 ± 3 °C (e.g., 163 ± 2 °C (e.g., 163 ± 1 °C (e.g., 163 ± 0.5 °C))))))); optionally, wherein Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) at 163 °C.

[0956] Exemplary Embodiment No.95. The morphic form of any of the preceding Exemplary Embodiments, wherein Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 49.3 ± 5.0 J / g (e.g., 49.3 ± 4.5 J / g (e.g., 49.3 ± 4.0 J / g (e.g., 49.3 ± 3.5 J / g (e.g., 49.3 ± 3.0 J / g (e.g., 49.3 ± 2.5 J / g (e.g., 49.3 ± 2.0 J / g (e.g., 49.3 ± 1.0 J / g))))))); optionally, wherein Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 49.3 J / g.

[0957] Exemplary Embodiment No.96. The morphic form of any of the preceding Exemplary Embodiments, wherein Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 59.1 ± 6.0 J / g (e.g., 59.1 ± 4.0 J / g (e.g., 59.1 ± 3.0 J / g (e.g., 59.1 ± 2.0 J / g (e.g., 59.1 ± 1.5 J / g (e.g., 59.1 ± 1.0 J / g (e.g., 59.1 ± 0.5 J / g (e.g., 59.1 ± 0.3 J / g)))))));Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein Form H is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 59.1 J / g; optionally, wherein Form H is characterized by a DSC profile substantially similar to that shown in FIG.46.

[0958] Exemplary Embodiment No.97. The morphic form of any of the preceding Exemplary Embodiments, wherein Form H shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form H shows a weight loss of about 2.4%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA; optionally, wherein Form H is characterized by a TGA profile substantially similar to that shown in FIG.47.

[0959] Exemplary Embodiment No.98. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form I, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0960] Exemplary Embodiment No.99. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form I of Compound No.1, a salt thereof, a solvate thereof, or a hydrate thereof.

[0961] Exemplary Embodiment No.100. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form I of a salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0962] Exemplary Embodiment No.101. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form I of a besylate salt of Compound No.1, a solvate thereof, or a hydrate thereof.

[0963] Exemplary Embodiment No.102. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form I of a besylate salt of Compound No.1.

[0964] Exemplary Embodiment No.103. The morphic form of any of the preceding Exemplary Embodiments, wherein the besylate salt comprises Compound No.1 and benzenesulfonic acid present at a ratio of about 1:1.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0965] Exemplary Embodiment No.104. The morphic form of any of the preceding Exemplary Embodiments, wherein the besylate salt comprises Compound No.1 and benzenesulfonic acid present at a ratio of about 1:2.

[0966] Exemplary Embodiment No.105. The morphic form of any of the preceding Exemplary Embodiments, wherein the besylate salt comprises Compound No.1 and benzenesulfonic acid present at a ratio of about 2:1.

[0967] Exemplary Embodiment No.106. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by an X-ray powder diffraction(“XRPD”) pattern comprising signals (e.g., peaks) at 12.4±0.2, 16.6±0.2, and 23.4±0.2 °2(e.g., 12.4±0.1, 16.6±0.1, and 23.4±0.1 °2 (e.g., 12.4, 16.6, and 23.4 °2 )) using Cu Kradiation; optionally, wherein the XRPD pattern of Form I further comprises at least one signal(e.g., peak) selected from 19.3±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 19.3±0.1, 26.3±0.1, and27.2±0.1 °2 (e.g., 19.3, 26.3, and 27.2 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form I further comprises at least two signals(e.g., peaks) selected from 19.3±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 19.3±0.1, 26.3±0.1,and 27.2±0.1 °2 (e.g., 19.3, 26.3, and 27.2 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form I further comprises signals (e.g.,peaks) at 19.3±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 19.3±0.1, 26.3±0.1, and 27.2±0.1 °2(e.g., 19.3, 26.3, and 27.2 °2 )) using Cu K radiation.

[0968] Exemplary Embodiment No.107. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by an X-ray powder diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 12.4±0.2,16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 12.4±0.1, 16.6±0.1, 19.3±0.1,23.4±0.1, 26.3±0.1, and 27.2±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6 °2 )) usingCu K radiation;optionally, wherein the XRPD pattern of Form I comprises at least four signals (e.g.,peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2, and 27.2±0.2 °2(e.g., 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1, and 27.2±0.1 °2 (e.g., 6.7, 12.1,15.1, 17.5, 24.2, and 24.6 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form I comprises at least five signals (e.g.,peaks) selected from 12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2, and 27.2±0.2 °2(e.g., 12.4±0.1, 16.6±0.1, 19.3±0.1, 23.4±0.1, 26.3±0.1, and 27.2±0.1 °2 (e.g., 6.7, 12.1,15.1, 17.5, 24.2, and 24.6 °2 )) using Cu K radiation;Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein the XRPD pattern of Form I comprises signals (e.g., peaks) at12.4±0.2, 16.6±0.2, 19.3±0.2, 23.4±0.2, 26.3±0.2, and 27.2±0.2 °2 (e.g., 12.4±0.1, 16.6±0.1,19.3±0.1, 23.4±0.1, 26.3±0.1, and 27.2±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6°2 )) using Cu K radiation.

[0969] Exemplary Embodiment No.108. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by an XRPD pattern substantially similar to that shown in FIG.11 or FIG.49.

[0970] Exemplary Embodiment No.109. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in Table 3.

[0971] Exemplary Embodiment No.110. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 233 ± 20°C (e.g., 233 ± 10 °C (e.g., 233 ± 5 °C (e.g., 233 ± 4 °C (e.g., 233 ± 3 °C (e.g., 233 ± 2 °C (e.g., 233 ± 1 °C (e.g., 233 ± 0.5 °C))))))); optionally, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 233 °C.

[0972] Exemplary Embodiment No.111. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 128 ± 20°C (e.g., 128 ± 10 °C (e.g., 128 ± 5 °C (e.g., 128 ± 4 °C (e.g., 128 ± 3 °C (e.g., 128 ± 2 °C (e.g., 128 ± 1 °C (e.g., 128 ± 0.5 °C))))))); optionally, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 128 °C.

[0973] Exemplary Embodiment No.112. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 235 ± 20°C (e.g., 235 ± 10 °C (e.g., 235 ± 5 °C (e.g., 235 ± 4 °C (e.g., 235 ± 3 °C (e.g., 235 ± 2 °C (e.g., 235 ± 1 °C (e.g., 235 ± 0.5 °C))))))); optionally, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) at 235 °C.

[0974] Exemplary Embodiment No.113. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 96 ± 9 J / g (e.g., 96 ± 8 J / g (e.g., 96 ± 7 J / g (e.g., 96 ± 6 J / g (e.g., 96 ± 5 J / g (e.g., 96 ± 4 J / g (e.g., 96 ± 2 J / g (e.g., 96 ± 1 J / g)))))));Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 96 J / g.

[0975] Exemplary Embodiment No.114. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 40 ± 4 J / g (e.g., 40 ± 3 J / g (e.g., 40 ± 2 J / g (e.g., 40 ± 1 J / g (e.g., 40 ± 0.75 J / g (e.g., 40 ± 0.5 J / g (e.g., 40 ± 0.2 J / g (e.g., 40 ± 0.1 J / g))))))); optionally, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 40 J / g.

[0976] Exemplary Embodiment No.115. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 88 ± 9 J / g (e.g., 88 ± 8 J / g (e.g., 88 ± 7 J / g (e.g., 88 ± 6 J / g (e.g., 88 ± 5 J / g (e.g., 88 ± 4 J / g (e.g., 88 ± 2 J / g (e.g., 88 ± 1 J / g))))))); optionally, wherein Form I is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 88 J / g; optionally, wherein Form I is characterized by a DSC profile substantially similar to those shown in FIGs.12 or 50.

[0977] Exemplary Embodiment No.116. The morphic form of any of the preceding Exemplary Embodiments, wherein Form I shows a weight loss of from about 0.1% to about 2%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 230 ± 20 °C (e.g., 230 ± 10 °C (e.g., 230 ± 5 °C (e.g., 230 ± 4 °C (e.g., 230 ± 3 °C (e.g., 230 ± 2 °C (e.g., 230 ± 1 °C (e.g., 230 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form I shows a weight loss of about 0.5%, at a temperature ranging from about 34 °C to about 230 °C, as measured by TGA; optionally, wherein Form I is characterized by a TGA profile substantially similar to those shown in FIG.13 or FIG.51.

[0978] Exemplary Embodiment No.117. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form J, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0979] Exemplary Embodiment No.118. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form J of a tosylate salt of Compound No.1.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0980] Exemplary Embodiment No.119. The morphic form of any of the preceding Exemplary Embodiments, wherein the tosylate salt comprises Compound No.1 and p- toluenesulfonic acid present at a ratio of about 1:1.

[0981] Exemplary Embodiment No.120. The morphic form of any of the preceding Exemplary Embodiments, wherein the tosylate salt comprises Compound No.1 and p- toluenesulfonic acid present at a ratio of about 1:2.

[0982] Exemplary Embodiment No.121. The morphic form of any of the preceding Exemplary Embodiments, wherein the tosylate salt comprises Compound No.1 and p- toluenesulfonic acid present at a ratio of about 2:1.

[0983] Exemplary Embodiment No.122. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J is characterized by an X-ray powder diffraction(“XRPD”) pattern comprising signals (e.g., peaks) at 6.7±0.2, 12.1±0.2, and 15.1±0.2 °2(e.g., 6.7±0.1, 12.1±0.1, and 15.1±0.1 °2 (e.g., 6.7, 12.1, and 15.1 °2 )) using Cu Kradiation; optionally, wherein the XRPD pattern of Form J further comprises at least one signal(e.g., peak) selected from 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 17.5±0.1, 24.2±0.1, and24.6±0.1 °2 (e.g., 17.5, 24.2, and 24.6 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form J further comprises at least two signals(e.g., peaks) selected from 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 17.5±0.1, 24.2±0.1,and 24.6±0.1 °2 (e.g., 17.5, 24.2, and 24.6 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form J further comprises signals (e.g.,peaks) at 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2(e.g., 17.5, 24.2, and 24.6 °2 )) using Cu K radiation.

[0984] Exemplary Embodiment No.123. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J is characterized by an X-ray powder diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 6.7±0.2,12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 6.7±0.1, 12.1±0.1, 15.1±0.1,17.5±0.1, 24.2±0.1, and 24.6±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6 °2 )) usingCu K radiation;optionally, wherein the XRPD pattern of Form J comprises at least four signals (e.g.,peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g.,6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5,24.2, and 24.6 °2 )) using Cu K radiation;Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein the XRPD pattern of Form J comprises at least five signals (e.g.,peaks) selected from 6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g.,6.7±0.1, 12.1±0.1, 15.1±0.1, 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5,24.2, and 24.6 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form J comprises signals (e.g., peaks) at6.7±0.2, 12.1±0.2, 15.1±0.2, 17.5±0.2, 24.2±0.2, and 24.6±0.2 °2 (e.g., 6.7±0.1, 12.1±0.1,15.1±0.1, 17.5±0.1, 24.2±0.1, and 24.6±0.1 °2 (e.g., 6.7, 12.1, 15.1, 17.5, 24.2, and 24.6°2 )) using Cu K radiation.

[0985] Exemplary Embodiment No.124. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J is characterized by an XRPD pattern substantially similar to those shown in FIG.15 or FIG.54.

[0986] Exemplary Embodiment No.125. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in Table 4.

[0987] Exemplary Embodiment No.126. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) at 204 ± 20°C (e.g., 204 ± 10 °C (e.g., 204 ± 5 °C (e.g., 204 ± 4 °C (e.g., 204 ± 3 °C (e.g., 204 ± 2 °C (e.g., 204 ± 1 °C (e.g., 204 ± 0.5 °C))))))); optionally, wherein Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) at 204 °C.

[0988] Exemplary Embodiment No.127. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 76 ± 8 J / g (e.g., 76 ± 7 J / g (e.g., 76 ± 6 J / g (e.g., 76 ± 5 J / g (e.g., 76 ± 4 J / g (e.g., 76 ± 3 J / g (e.g., 76 ± 2 J / g (e.g., 76 ± 1 J / g))))))); optionally, wherein Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 76 J / g.

[0989] Exemplary Embodiment No.128. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) at 205 ± 20°C (e.g., 205 ± 10 °C (e.g., 205 ± 5 °C (e.g., 205 ± 4 °C (e.g., 205 ± 3 °C (e.g., 205 ± 2 °C (e.g., 205 ± 1 °C (e.g., 205 ± 0.5 °C))))))); optionally, wherein Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) at 205 °C.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0990] Exemplary Embodiment No.129. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 62 ± 6 J / g (e.g., 62 ± 5 J / g (e.g., 62 ± 4 J / g (e.g., 62 ± 3 J / g (e.g., 62 ± 2 J / g (e.g., 62 ± 1 J / g (e.g., 62 ± 0.75 J / g (e.g., 62 ± 0.5 J / g))))))); optionally, wherein Form J is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 62 J / g; optionally, wherein Form J is characterized by a DSC profile substantially similar to those shown in FIG.16 or FIG.55.

[0991] Exemplary Embodiment No.130. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J shows a weight loss of from about 0.1% to about 2%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form J shows a weight loss of about 0.7%, at a temperature ranging from about 34 °C to about 200 °C, as measured by TGA.

[0992] Exemplary Embodiment No.131. The morphic form of any of the preceding Exemplary Embodiments, wherein Form J shows a weight loss of from about 0.1% to about 2.5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 200 ± 20 °C (e.g., 200 ± 10 °C (e.g., 200 ± 5 °C (e.g., 200 ± 4 °C (e.g., 200 ± 3 °C (e.g., 200 ± 2 °C (e.g., 200 ± 1 °C (e.g., 200 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form J shows a weight loss of about 0.9%, at a temperature ranging from about 34 °C to about 200 °C, as measured by TGA; optionally, wherein Form J is characterized by a TGA profile substantially similar to those shown in FIG.17 or FIG.56.

[0993] Exemplary Embodiment No.132. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form K, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[0994] Exemplary Embodiment No.133. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form K of a maleate salt of Compound No.1.Attorney Docket No. ASET-042 / 001WO 325190-2274

[0995] Exemplary Embodiment No.134. The morphic form of any of the preceding Exemplary Embodiments, wherein the maleate salt comprises Compound No.1 and maleic acid present at a ratio of about 1:1.

[0996] Exemplary Embodiment No.135. The morphic form of any of the preceding Exemplary Embodiments, wherein the maleate salt comprises Compound No.1 and maleic acid present at a ratio of about 1:2.

[0997] Exemplary Embodiment No.136. The morphic form of any of the preceding Exemplary Embodiments, wherein the maleate salt comprises Compound No.1 and maleic acid present at a ratio of about 2:1.

[0998] Exemplary Embodiment No.137. The morphic form of any of the preceding Exemplary Embodiments, wherein Form K is characterized by an XRPD profile substantially similar to that shown in FIG.58.

[0999] Exemplary Embodiment No.138. The morphic form of any of the preceding Exemplary Embodiments, wherein Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) at 57.1 ± 20°C (e.g., 57.1 ± 10 °C (e.g., 57.1 ± 5 °C (e.g., 57.1 ± 4 °C (e.g., 57.1 ± 3 °C (e.g., 57.1 ± 2 °C (e.g., 57.1 ± 1 °C (e.g., 57.1 ± 0.5 °C))))))); optionally, wherein Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) at 57.1 °C.

[1000] Exemplary Embodiment No.139. The morphic form of any of the preceding Exemplary Embodiments, wherein Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) at 121 ± 20°C (e.g., 121 ± 10 °C (e.g., 121 ± 5 °C (e.g., 121 ± 4 °C (e.g., 121 ± 3 °C (e.g., 121 ± 2 °C (e.g., 121 ± 1 °C (e.g., 121 ± 0.5 °C))))))); optionally, wherein Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) at 121 °C.

[1001] Exemplary Embodiment No.140. The morphic form of any of the preceding Exemplary Embodiments, wherein Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 12.9 ± 1.5 J / g (e.g., 12.9 ± 1.3 J / g (e.g., 12.9 ± 1.0 J / g (e.g., 12.9 ± 0.8 J / g (e.g., 12.9 ± 0.6 J / g (e.g., 12.9 ± 0.4 J / g (e.g., 12.9 ± 0.2 J / g (e.g., 12.9 ± 0.1 J / g))))))); optionally, wherein Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 12.9 J / g.

[1002] Exemplary Embodiment No.141. The morphic form of any of the preceding Exemplary Embodiments, wherein Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 91.9 ± 10 J / g (e.g., 91.9Attorney Docket No. ASET-042 / 001WO 325190-2274 ± 8 J / g (e.g., 91.9 ± 6 J / g (e.g., 91.9 ± 5 J / g (e.g., 91.9 ± 4 J / g (e.g., 91.9 ± 3 J / g (e.g., 91.9 ± 2 J / g (e.g., 91.9 ± 1 J / g))))))); optionally, wherein Form K is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 91.9 J / g; optionally, wherein Form K is characterized by a DSC profile substantially similar to that shown in FIG.59.

[1003] Exemplary Embodiment No.142. The morphic form of any of the preceding Exemplary Embodiments, wherein Form K shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 80 ± 20 °C (e.g., 80 ± 10 °C (e.g., 80 ± 5 °C (e.g., 80 ± 4 °C (e.g., 80 ± 3 °C (e.g., 80 ± 2 °C (e.g., 80 ± 1 °C (e.g., 80 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form K shows a weight loss of about 2.0%, at a temperature ranging from about 34 °C to about 80 °C, as measured by TGA.

[1004] Exemplary Embodiment No.143. The morphic form of any of the preceding Exemplary Embodiments, wherein Form K shows a weight loss of from about 8% to about 25%, at a temperature ranging from about 80 ± 20 °C (e.g., 80 ± 10 °C (e.g., 80 ± 5 °C (e.g., 80 ± 4 °C (e.g., 80 ± 3 °C (e.g., 80 ± 2 °C (e.g., 80 ± 1 °C (e.g., 80 ± 0.5 °C))))))) to about 250 ± 20 °C (e.g., 250 ± 10 °C (e.g., 250 ± 5 °C (e.g., 250 ± 4 °C (e.g., 250 ± 3 °C (e.g., 250 ± 2 °C (e.g., 250 ± 1 °C (e.g., 250 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form K shows a weight loss of about 15%, at a temperature ranging from about 80 °C to about 250 °C, as measured by TGA; optionally, wherein Form K is characterized by a TGA profile substantially similar to that shown in FIG.60.

[1005] Exemplary Embodiment No.144. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form L, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[1006] Exemplary Embodiment No.145. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form L of a fumarate salt of Compound No.1.

[1007] Exemplary Embodiment No.146. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:1.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1008] Exemplary Embodiment No.147. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:2.

[1009] Exemplary Embodiment No.148. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 2:1.

[1010] Exemplary Embodiment No.149. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L is characterized by an X-ray powder diffraction(“XRPD”) pattern comprising signals (e.g., peaks) at 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2(e.g., 12.5±0.1, 15.6±0.1, and 27.0±0.1 °2 (e.g., 12.5, 15.6, and 27.0 °2 )) using Cu Kradiation; optionally, wherein the XRPD pattern of Form L further comprises at least one signal(e.g., peak) selected from 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2 (e.g., 12.5±0.1, 15.6±0.1, and27.0±0.1 °2 (e.g., 12.5, 15.6, and 27.0 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form L further comprises at least twosignals (e.g., peaks) selected from 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2 (e.g., 12.5±0.1,15.6±0.1, and 27.0±0.1 °2 (e.g., 12.5, 15.6, and 27.0 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form L further comprises signals (e.g.,peaks) at 12.5±0.2, 15.6±0.2, and 27.0±0.2 °2 (e.g., 12.5±0.1, 15.6±0.1, and 27.0±0.1 °2(e.g., 12.5, 15.6, and 27.0 °2 )) using Cu K radiation.

[1011] Exemplary Embodiment No.150. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L is characterized by an X-ray powder diffraction (“XRPD”) pattern comprising at least three signals (e.g., peaks) selected from 12.0±0.2,14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2 (e.g., 12.0±0.1, 14.5±0.1, 15.6±0.1,18.7±0.1, 27.0±0.1, and 27.2±0.1 °2 (e.g., 12.0, 14.5, 15.6, 18.7, 27.0, and 27.2 °2 )) usingCu K radiation;optionally, wherein the XRPD pattern of Form L comprises at least four signals (e.g.,peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2(e.g., 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1, and 27.2±0.1 °2 (e.g., 12.0, 14.5,15.6, 18.7, 27.0, and 27.2 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form L comprises at least five signals (e.g.,peaks) selected from 12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2(e.g., 12.0±0.1, 14.5±0.1, 15.6±0.1, 18.7±0.1, 27.0±0.1, and 27.2±0.1 °2 (e.g., 12.0, 14.5,15.6, 18.7, 27.0, and 27.2 °2 )) using Cu K radiation;Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein the XRPD pattern of Form L comprises signals (e.g., peaks) at12.0±0.2, 14.5±0.2, 15.6±0.2, 18.7±0.2, 27.0±0.2, and 27.2±0.2 °2 (e.g., 12.0±0.1, 14.5±0.1,15.6±0.1, 18.7±0.1, 27.0±0.1, and 27.2±0.1 °2 (e.g., 12.0, 14.5, 15.6, 18.7, 27.0, and 27.2°2 )) using Cu K radiation.

[1012] Exemplary Embodiment No.151. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L is characterized by an XRPD pattern substantially similar those shown in FIG.20 or FIG.62.

[1013] Exemplary Embodiment No.152. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L is characterized by an XRPD pattern comprising signals (e.g., peaks) at approximately the positions shown in Table 5.

[1014] Exemplary Embodiment No.153. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) at 195 ± 20°C (e.g., 195 ± 10 °C (e.g., 195 ± 5 °C (e.g., 195 ± 4 °C (e.g., 195 ± 3 °C (e.g., 195 ± 2 °C (e.g., 195 ± 1 °C (e.g., 195 ± 0.5 °C))))))); optionally, wherein Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) at 195 °C.

[1015] Exemplary Embodiment No.154. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 111 ± 11 J / g (e.g., 111 ± 10 J / g (e.g., 111 ± 8 J / g (e.g., 111 ± 6 J / g (e.g., 111 ± 4 J / g (e.g., 111 ± 3 J / g (e.g., 111 ± 2 J / g (e.g., 111 ± 1 J / g))))))); optionally, wherein Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 111 J / g.

[1016] Exemplary Embodiment No.155. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) at 196 ± 20°C (e.g., 196 ± 10 °C (e.g., 196 ± 5 °C (e.g., 196 ± 4 °C (e.g., 196 ± 3 °C (e.g., 196 ± 2 °C (e.g., 196 ± 1 °C (e.g., 196 ± 0.5 °C))))))); optionally, wherein Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) at 196 °C.

[1017] Exemplary Embodiment No.156. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 99 ± 10 J / g (e.g., 99 ± 9 J / g (e.g., 99 ± 8 J / g (e.g., 99 ± 6 J / g (e.g., 99 ± 4 J / g (e.g., 99 ± 3 J / g (e.g., 99 ± 2 J / g (e.g., 99 ± 1 J / g)))))));Attorney Docket No. ASET-042 / 001WO 325190-2274 optionally, wherein Form L is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 99 J / g; optionally, wherein Form L is characterized by a DSC profile substantially similar to those shown in FIG.21 or FIG.63.

[1018] Exemplary Embodiment No.157. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L shows a weight loss of from about 0.1% to about 2%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 180 ± 20 °C (e.g., 180 ± 10 °C (e.g., 180 ± 5 °C (e.g., 180 ± 4 °C (e.g., 180 ± 3 °C (e.g., 180 ± 2 °C (e.g., 180 ± 1 °C (e.g., 180 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form L shows a weight loss of about 0.8%, at a temperature ranging from about 34 °C to about 180 °C, as measured by TGA.

[1019] Exemplary Embodiment No.158. The morphic form of any of the preceding Exemplary Embodiments, wherein Form L shows a weight loss of from about 0.05% to about 2%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 185 ± 20 °C (e.g., 185 ± 10 °C (e.g., 185 ± 5 °C (e.g., 185 ± 4 °C (e.g., 185 ± 3 °C (e.g., 185 ± 2 °C (e.g., 185 ± 1 °C (e.g., 185 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form L shows a weight loss of about 0.5%, at a temperature ranging from about 34 °C to about 185 °C, as measured by TGA; optionally, wherein Form L is characterized by a TGA profile substantially similar to those shown in FIG.22 or FIG.64.

[1020] Exemplary Embodiment No.159. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form M, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[1021] Exemplary Embodiment No.160. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form M of a fumarate salt of Compound No.1.

[1022] Exemplary Embodiment No.161. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:1.

[1023] Exemplary Embodiment No.162. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:2.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1024] Exemplary Embodiment No.163. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 2:1.

[1025] Exemplary Embodiment No.164. The morphic form of any of the preceding Exemplary Embodiments, wherein Form M is characterized by an XRPD profile substantially similar to that shown in FIG.66.

[1026] Exemplary Embodiment No.165. The morphic form of any of the preceding Exemplary Embodiments, wherein Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) at 54.0 ± 20°C (e.g., 54.0 ± 10 °C (e.g., 54.0 ± 5 °C (e.g., 54.0 ± 4 °C (e.g., 54.0 ± 3 °C (e.g., 54.0 ± 2 °C (e.g., 54.0 ± 1 °C (e.g., 54.0 ± 0.5 °C))))))); optionally, wherein Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) at 54.0 °C.

[1027] Exemplary Embodiment No.166. The morphic form of any of the preceding Exemplary Embodiments, wherein Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) at 125 ± 20°C (e.g., 125 ± 10 °C (e.g., 125 ± 5 °C (e.g., 125 ± 4 °C (e.g., 125 ± 3 °C (e.g., 125 ± 2 °C (e.g., 125 ± 1 °C (e.g., 125 ± 0.5 °C))))))); optionally, wherein Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) at 125 °C.

[1028] Exemplary Embodiment No.167. The morphic form of any of the preceding Exemplary Embodiments, wherein Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 26.1 ± 2.5 J / g (e.g., 26.1 ± 2.0 J / g (e.g., 26.1 ± 1.5 J / g (e.g., 26.1 ± 1.0 J / g (e.g., 26.1 ± 0.8 J / g (e.g., 26.1 ± 0.6 J / g (e.g., 26.1 ± 0.4 J / g (e.g., 26.1 ± 0.2 J / g))))))); optionally, wherein Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 26.1 J / g.

[1029] Exemplary Embodiment No.168. The morphic form of any of the preceding Exemplary Embodiments, wherein Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 34.9 ± 3.5 J / g (e.g., 34.9 ± 3.0 J / g (e.g., 34.9 ± 2.5 J / g (e.g., 34.9 ± 2.0 J / g (e.g., 34.9 ± 1.5 J / g (e.g., 34.9 ± 1.0 J / g (e.g., 34.9 ± 0.5 J / g (e.g., 34.9 ± 0.3 J / g))))))); optionally, wherein Form M is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 34.9 J / g; optionally, wherein Form M is characterized by a DSC profile substantially similar to that shown in FIG.67.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1030] Exemplary Embodiment No.169. The morphic form of any of the preceding Exemplary Embodiments, wherein Form M shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form M shows a weight loss of about 1.6%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA; optionally, wherein Form M is characterized by a TGA profile substantially similar to that shown in FIG.68.

[1031] Exemplary Embodiment No.170. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form N, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[1032] Exemplary Embodiment No.171. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form N of a fumarate salt of Compound No.1.

[1033] Exemplary Embodiment No.172. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:1.

[1034] Exemplary Embodiment No.173. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 1:2.

[1035] Exemplary Embodiment No.174. The morphic form of any of the preceding Exemplary Embodiments, wherein the fumarate salt comprises Compound No.1 and fumaric acid present at a ratio of about 2:1.

[1036] Exemplary Embodiment No.175. The morphic form of any of the preceding Exemplary Embodiments, wherein Form N is characterized by an XRPD profile substantially similar to that shown in FIG.70.

[1037] Exemplary Embodiment No.176. The morphic form of any of the preceding Exemplary Embodiments, wherein Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) at 62.0 ± 20°C (e.g., 62.0 ± 10 °C (e.g., 62.0 ± 5 °C (e.g., 62.0 ± 4 °C (e.g., 62.0 ± 3 °C (e.g., 62.0 ± 2 °C (e.g., 62.0 ± 1 °C (e.g., 62.0 ± 0.5 °C))))))); optionally, wherein Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) at 62.0 °C.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1038] Exemplary Embodiment No.177. The morphic form of any of the preceding Exemplary Embodiments, wherein Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) at 107 ± 20°C (e.g., 107 ± 10 °C (e.g., 107 ± 5 °C (e.g., 107 ± 4 °C (e.g., 107 ± 3 °C (e.g., 107 ± 2 °C (e.g., 107 ± 1 °C (e.g., 107 ± 0.5 °C))))))); optionally, wherein Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) at 107 °C.

[1039] Exemplary Embodiment No.178. The morphic form of any of the preceding Exemplary Embodiments, wherein Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 37.8 ± 3.8 J / g (e.g., 37.8 ± 3.4 J / g (e.g., 37.8 ± 3.0 J / g (e.g., 37.8 ± 2.5 J / g (e.g., 37.8 ± 2.0 J / g (e.g., 37.8 ± 1.5 J / g (e.g., 37.8 ± 1.0 J / g (e.g., 37.8 ± 0.5 J / g))))))); optionally, wherein Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 37.8 J / g.

[1040] Exemplary Embodiment No.179. The morphic form of any of the preceding Exemplary Embodiments, wherein Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 22.1 ± 2.5 J / g (e.g., 22.1 ± 2.0 J / g (e.g., 22.1 ± 1.5 J / g (e.g., 22.1 ± 1.0 J / g (e.g., 22.1 ± 0.8 J / g (e.g., 22.1 ± 0.6 J / g (e.g., 22.1 ± 0.4 J / g (e.g., 22.1 ± 0.2 J / g))))))); optionally, wherein Form N is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 22.1 J / g; optionally, wherein Form N is characterized by a DSC profile substantially similar to that shown in FIG.71.

[1041] Exemplary Embodiment No.180. The morphic form of any of the preceding Exemplary Embodiments, wherein Form N shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 110 ± 20 °C (e.g., 110 ± 10 °C (e.g., 110 ± 5 °C (e.g., 110 ± 4 °C (e.g., 110 ± 3 °C (e.g., 110 ± 2 °C (e.g., 110 ± 1 °C (e.g., 110 ± 0.5 °C))))))), as measured by TGA.; optionally, wherein Form N shows a weight loss of about 1.8%, at a temperature ranging from about 34 °C to about 110 °C, as measured by TGA; optionally, wherein Form N is characterized by a TGA profile substantially similar to that shown in FIG.72.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1042] Exemplary Embodiment No.181. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form O, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

[1043] Exemplary Embodiment No.182. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form O of a L-tartrate salt of Compound No.1.

[1044] Exemplary Embodiment No.183. The morphic form of any of the preceding Exemplary Embodiments, wherein the L-tartrate salt comprises Compound No.1 and L- tartaric acid present at a ratio of about 1:1.

[1045] Exemplary Embodiment No.184. The morphic form of any of the preceding Exemplary Embodiments, wherein the L-tartrate salt comprises Compound No.1 and L- tartaric acid present at a ratio of about 1:2.

[1046] Exemplary Embodiment No.185. The morphic form of any of the preceding Exemplary Embodiments, wherein the L-tartrate salt comprises Compound No.1 and L- tartaric acid present at a ratio of about 2:1.

[1047] Exemplary Embodiment No.186. The morphic form of any of the preceding Exemplary Embodiments, wherein Form O is characterized by an XRPD profile substantially similar to that shown in FIG.74.

[1048] Exemplary Embodiment No.187. The morphic form of any of the preceding Exemplary Embodiments, wherein Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) at 52.7 ± 20°C (e.g., 52.7 ± 10 °C (e.g., 52.7 ± 5 °C (e.g., 52.7 ± 4 °C (e.g., 52.7 ± 3 °C (e.g., 52.7 ± 2 °C (e.g., 52.7 ± 1 °C (e.g., 52.7 ± 0.5 °C))))))); optionally, wherein Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) at 52.7 °C.

[1049] Exemplary Embodiment No.188. The morphic form of any of the preceding Exemplary Embodiments, wherein Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) at 129 ± 20°C (e.g., 129 ± 10 °C (e.g., 129 ± 5 °C (e.g., 129 ± 4 °C (e.g., 129 ± 3 °C (e.g., 129 ± 2 °C (e.g., 129 ± 1 °C (e.g., 129 ± 0.5 °C))))))); optionally, wherein Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) at 129 °C.

[1050] Exemplary Embodiment No.189. The morphic form of any of the preceding Exemplary Embodiments, wherein Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 24.5 ± 2.5 J / g (e.g., 24.5Attorney Docket No. ASET-042 / 001WO 325190-2274 ± 2.0 J / g (e.g., 24.5 ± 1.5 J / g (e.g., 24.5 ± 1.0 J / g (e.g., 24.5 ± 0.8 J / g (e.g., 24.5 ± 0.6 J / g (e.g., 24.5 ± 0.4 J / g (e.g., 24.5 ± 0.2 J / g))))))); optionally, wherein Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 24.5 J / g.

[1051] Exemplary Embodiment No.190. The morphic form of any of the preceding Exemplary Embodiments, wherein Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 34.8 ± 3.5 J / g (e.g., 34.8 ± 3.0 J / g (e.g., 34.8 ± 2.5 J / g (e.g., 34.8 ± 2.0 J / g (e.g., 34.8 ± 1.5 J / g (e.g., 34.8 ± 1.0 J / g (e.g., 34.8 ± 0.5 J / g (e.g., 34.8 ± 0.3 J / g))))))); optionally, wherein Form O is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 34.8 J / g; optionally, wherein Form O is characterized by a DSC profile substantially similar to that shown in FIG.75.

[1052] Exemplary Embodiment No.191. The morphic form of any of the preceding Exemplary Embodiments, wherein Form O shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form O shows a weight loss of about 1.6%, at a temperature ranging from about 34 °C to about 100 °C, as measured by TGA.

[1053] Exemplary Embodiment No.192. The morphic form of any of the preceding Exemplary Embodiments, wherein Form O shows a weight loss of from about 0.3% to about 2.5%, at a temperature ranging from about 100 ± 20 °C (e.g., 100 ± 10 °C (e.g., 100 ± 5 °C (e.g., 100 ± 4 °C (e.g., 100 ± 3 °C (e.g., 100 ± 2 °C (e.g., 100 ± 1 °C (e.g., 100 ± 0.5 °C))))))) to about 140 ± 20 °C (e.g., 140 ± 10 °C (e.g., 140 ± 5 °C (e.g., 140 ± 4 °C (e.g., 140 ± 3 °C (e.g., 140 ± 2 °C (e.g., 140 ± 1 °C (e.g., 140 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form O shows a weight loss of about 1.0%, at a temperature ranging from about 100 °C to about 140 °C, as measured by TGA; optionally, wherein Form O is characterized by a TGA profile substantially similar to that shown in FIG.76.

[1054] Exemplary Embodiment No.193. The morphic form of Exemplary Embodiment Nos.1 or 2, wherein the morphic form is Form P, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1055] Exemplary Embodiment No.194. The morphic form of any of the preceding Exemplary Embodiments, wherein the morphic form is Form P of a L-malate salt of Compound No.1.

[1056] Exemplary Embodiment No.195. The morphic form of any of the preceding Exemplary Embodiments, wherein the L-malate salt comprises Compound No.1 and L-malic acid present at a ratio of about 1:1.

[1057] Exemplary Embodiment No.196. The morphic form of any of the preceding Exemplary Embodiments, wherein the L-malate salt comprises Compound No.1 and L-malic acid present at a ratio of about 1:2.

[1058] Exemplary Embodiment No.197. The morphic form of any of the preceding Exemplary Embodiments, wherein the L-malate salt comprises Compound No.1 and L-malic acid present at a ratio of about 2:1.

[1059] Exemplary Embodiment No.198. The morphic form of any of the preceding Exemplary Embodiments, wherein Form P is characterized by an XRPD profile substantially similar to that shown in FIG.78.

[1060] Exemplary Embodiment No.199. The morphic form of any of the preceding Exemplary Embodiments, wherein Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) at 109 ± 20°C (e.g., 109 ± 10 °C (e.g., 109 ± 5 °C (e.g., 109 ± 4 °C (e.g., 109 ± 3 °C (e.g., 109 ± 2 °C (e.g., 109 ± 1 °C (e.g., 109 ± 0.5 °C))))))); optionally, wherein Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) at 109 °C.

[1061] Exemplary Embodiment No.200. The morphic form of any of the preceding Exemplary Embodiments, wherein Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) at 169 ± 20°C (e.g., 169 ± 10 °C (e.g., 169 ± 5 °C (e.g., 169 ± 4 °C (e.g., 169 ± 3 °C (e.g., 169 ± 2 °C (e.g., 169 ± 1 °C (e.g., 169 ± 0.5 °C))))))); optionally, wherein Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) at 169 °C.

[1062] Exemplary Embodiment No.201. The morphic form of any of the preceding Exemplary Embodiments, wherein Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 57.5 ± 6.0 J / g (e.g., 57.5 ± 5.0 J / g (e.g., 57.5 ± 4.0 J / g (e.g., 57.5 ± 3.0 J / g (e.g., 57.5 ± 2.0 J / g (e.g., 57.5 ± 1.5 J / g (e.g., 57.5 ± 1.0 J / g (e.g., 57.5 ± 0.5 J / g))))))); optionally, wherein Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 57.5 J / g.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1063] Exemplary Embodiment No.202. The morphic form of any of the preceding Exemplary Embodiments, wherein Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of about 21.5 ± 2.5 J / g (e.g., 21.5 ± 2.0 J / g (e.g., 21.5 ± 1.5 J / g (e.g., 21.5 ± 1.0 J / g (e.g., 21.5 ± 0.8 J / g (e.g., 21.5 ± 0.6 J / g (e.g., 21.5 ± 0.4 J / g (e.g., 21.5 ± 0.2 J / g))))))); optionally, wherein Form P is characterized by a DSC curve having an endothermic signal (e.g., peak) associated with an enthalpy of 21.5 J / g; optionally, wherein Form P is characterized by a DSC profile substantially similar to that shown in FIG.79.

[1064] Exemplary Embodiment No.203. The morphic form of any of the preceding Exemplary Embodiments, wherein Form P shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 34 ± 20 °C (e.g., 34 ± 10 °C (e.g., 34 ± 5 °C (e.g., 34 ± 4 °C (e.g., 34 ± 3 °C (e.g., 34 ± 2 °C (e.g., 34 ± 1 °C (e.g., 34 ± 0.5 °C))))))) to about 130 ± 20 °C (e.g., 130 ± 10 °C (e.g., 130 ± 5 °C (e.g., 130 ± 4 °C (e.g., 130 ± 3 °C (e.g., 130 ± 2 °C (e.g., 130 ± 1 °C (e.g., 130 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form P shows a weight loss of about 2.1%, at a temperature ranging from about 34 °C to about 130 °C, as measured by TGA.

[1065] Exemplary Embodiment No.204. The morphic form of any of the preceding Exemplary Embodiments, wherein Form P shows a weight loss of from about 15% to about 30%, at a temperature ranging from about 130 ± 20 °C (e.g., 130 ± 10 °C (e.g., 130 ± 5 °C (e.g., 130 ± 4 °C (e.g., 130 ± 3 °C (e.g., 130 ± 2 °C (e.g., 130 ± 1 °C (e.g., 130 ± 0.5 °C))))))) to about 300 ± 20 °C (e.g., 300 ± 10 °C (e.g., 300 ± 5 °C (e.g., 300 ± 4 °C (e.g., 300 ± 3 °C (e.g., 300 ± 2 °C (e.g., 300 ± 1 °C (e.g., 300 ± 0.5 °C))))))), as measured by TGA; optionally, wherein Form P shows a weight loss of about 21%, at a temperature ranging from about 130 °C to about 300 °C, as measured by TGA; optionally, wherein Form P is characterized by a TGA profile substantially similar to that shown in FIG.80.

[1066] Exemplary Embodiment No.205. The morphic form of any one of the preceding Exemplary Embodiments, which is at least 90, 95, 96, 97, 98, or 99% pure.

[1067] Exemplary Embodiment No.206. A combination comprising: an amorphous form of Compound No.1, a salt thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a polymer.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1068] Exemplary Embodiment No.207. A composition comprising the combination of Exemplary Embodiment No.206.

[1069] Exemplary Embodiment No.208. The composition of Exemplary Embodiment No. 207, wherein the polymer comprises a copolymer of N-vinylpyrrolidone and vinyl acetate.

[1070] Exemplary Embodiment No.209. The composition of any one of the preceding Exemplary Embodiments, wherein the polymer is sold as PVP VA64.

[1071] Exemplary Embodiment No.210. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by a Tg as measured by mDSC at about 106 °C.

[1072] Exemplary Embodiment No.211. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.91.

[1073] Exemplary Embodiment No.212. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an Tg as measured by mDSC at about 107 °C.

[1074] Exemplary Embodiment No.213. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.96.

[1075] Exemplary Embodiment No.214. The composition of any one of the preceding Exemplary Embodiments, wherein the composition shows a weight loss of from about 2.5% to about 10%, at a temperature ranging from about 33 ± 20 °C to about 100 ± 20 °C, as measured by TGA.

[1076] Exemplary Embodiment No.215. A composition comprising the combination of Exemplary Embodiment No.207, wherein the polymer comprises hydroxypropyl methylcellulose.

[1077] Exemplary Embodiment No.216. The composition of any one of the preceding Exemplary Embodiments, wherein the polymer is sold as HPMC ASMG.

[1078] Exemplary Embodiment No.217. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by a Tg as measured by mDSC at about 102 °C.

[1079] Exemplary Embodiment No.218. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.92.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1080] Exemplary Embodiment No.219. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by a Tg as measured by mDSC at about 91 °C.

[1081] Exemplary Embodiment No.220. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.99.

[1082] Exemplary Embodiment No.221. The composition of any one of the preceding Exemplary Embodiments, wherein the composition shows a weight loss of from about 0.5% to about 5%, at a temperature ranging from about 32 ± 20 °C to about 100 ± 20 °C, as measured by TGA.

[1083] Exemplary Embodiment No.222. The composition of any one of the preceding Exemplary Embodiments, wherein the polymer is sold as HPMC E3.

[1084] Exemplary Embodiment No.223. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by a Tg as measured by mDSC at about 104 °C.

[1085] Exemplary Embodiment No.224. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.93.

[1086] Exemplary Embodiment No.225. The composition of any one of the preceding Exemplary Embodiments, wherein the composition shows a weight loss of from about 0.5% to about 5%, at a temperature ranging from about 33 ± 20 °C to about 100 ± 20 °C, as measured by TGA.

[1087] Exemplary Embodiment No.226. A composition comprising the combination of Exemplary Embodiment No.207, wherein the polymer comprises a polymethacrylate-based copolymer.

[1088] Exemplary Embodiment No.227. The composition of any one of the preceding Exemplary Embodiments, wherein the polymer is sold as Eudragit®E100.

[1089] Exemplary Embodiment No.228. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by a Tg as measured by mDSC at about 48 °C.

[1090] Exemplary Embodiment No.229. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.94.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1091] Exemplary Embodiment No.230. The composition of any one of the preceding Exemplary Embodiments, wherein the composition shows a weight loss of from about 0.1% to about 5%, at a temperature ranging from about 33 ± 20 °C to about 100 ± 20 °C, as measured by TGA.

[1092] Exemplary Embodiment No.231. The composition of any one of the preceding Exemplary Embodiments, wherein the polymer is sold as Eudragit®L100-55.

[1093] Exemplary Embodiment No.232. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by a Tg as measured by mDSC at about 181 °C.

[1094] Exemplary Embodiment No.233. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.95.

[1095] Exemplary Embodiment No.234. The composition of any one of the preceding Exemplary Embodiments, wherein the composition shows a weight loss of from about 0.5% to about 10%, at a temperature ranging from about 32 ± 20 °C to about 100 ± 20 °C, as measured by TGA.

[1096] Exemplary Embodiment No.235. A composition comprising the combination of Exemplary Embodiment No.207, wherein the polymer comprises a polyvinyl caprolactam– polyvinyl acetate–polyethylene glycol graft copolymer.

[1097] Exemplary Embodiment No.236. The composition of any one of the preceding Exemplary Embodiments, wherein the polymer is sold as Soluplus®.

[1098] Exemplary Embodiment No.237. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by a Tg as measured by mDSC at about 72 °C.

[1099] Exemplary Embodiment No.238. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.97.

[1100] Exemplary Embodiment No.239. The composition of any one of the preceding Exemplary Embodiments, wherein the polymer is sold as Kollidon®12 PF.

[1101] Exemplary Embodiment No.240. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by a Tg as measured by mDSC at about 107 °C.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1102] Exemplary Embodiment No.241. The composition of any one of the preceding Exemplary Embodiments, wherein the composition is characterized by an mDSC profile substantially similar to that shown in FIG.98.

[1103] Exemplary Embodiment No.242. Use of the morphic form of any one of the preceding Exemplary Embodiments in the manufacture of a medicament for treating or preventing cancer in a subject.

[1104] Exemplary Embodiment No.243. A combination comprising: (i) the morphic form of any one of the preceding Exemplary Embodiments and (ii) one or more inhibitors of the MAPK pathways.

[1105] Exemplary Embodiment No.244. A method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising: (i) the morphic form of any one of the preceding Exemplary Embodiments, and (ii) one or more inhibitors of the MAPK pathways.

[1106] Exemplary Embodiment No.245. A combination comprising: (i) the morphic form of any one of the preceding Exemplary Embodiments, and (ii) one or more inhibitors of the MAPK pathways, for treating or preventing cancer in a subject.

[1107] Exemplary Embodiment No.246. Use of a combination comprising: (i) the morphic form of any one of the preceding Exemplary Embodiments, and (ii) one or more inhibitors of the MAPK pathways, in the manufacture of a medicament for treating or preventing cancer in a subject.

[1108] Exemplary Embodiment No.247. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject is a human.

[1109] Exemplary Embodiment No.248. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is characterized by at least one oncogenic mutation in the BRAF gene.

[1110] Exemplary Embodiment No.249. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is characterized by at least one oncogenic variant of B-Raf.

[1111] Exemplary Embodiment No.250. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject has at least one oncogenic mutation in the BRAF gene.

[1112] Exemplary Embodiment No.251. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1113] Exemplary Embodiment No.252. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the oncogenic mutation of B- Raf is any of the B-Raf mutations put forth in Table 6.

[1114] Exemplary Embodiment No.253. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the oncogenic variant of B- Raf can be any of the B-Raf variants put forth in Table 7.

[1115] Exemplary Embodiment No.254. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is characterized by at least one oncogenic mutation in the KRAS gene.

[1116] Exemplary Embodiment No.255. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is characterized by at least one oncogenic variant of K-Ras.

[1117] Exemplary Embodiment No.256. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject has at least one oncogenic mutation in the KRAS gene.

[1118] Exemplary Embodiment No.257. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of K-Ras.

[1119] Exemplary Embodiment No.258. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is characterized by at least one oncogenic mutation in the NRAS gene.

[1120] Exemplary Embodiment No.259. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is characterized by at least one oncogenic variant of N-Ras.

[1121] Exemplary Embodiment No.260. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject has at least one oncogenic mutation in the NRAS gene.

[1122] Exemplary Embodiment No.261. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of N-Ras.

[1123] Exemplary Embodiment No.262. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is characterized by at least one oncogenic mutation in the NF1 gene.Attorney Docket No. ASET-042 / 001WO 325190-2274

[1124] Exemplary Embodiment No.263. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is characterized by at least one oncogenic variant of NF1.

[1125] Exemplary Embodiment No.264. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject has at least one oncogenic mutation in the NF1 gene.

[1126] Exemplary Embodiment No.265. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of NF1.

[1127] Exemplary Embodiment No.266. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is a carcinoma, a lymphoma, a blastoma, a sarcoma, a leukemia, a brain cancer, a breast cancer, a blood cancer, a bone cancer, a lung cancer, a skin cancer, a liver cancer, an ovarian cancer, a bladder cancer, a renal cancer, a kidney cancer, a gastric cancer, a thyroid cancer, a pancreatic cancer, an esophageal cancer, a prostate cancer, a cervical cancer, a uterine cancer, a stomach cancer, a soft tissue cancer, a laryngeal cancer, a small intestine cancer, a testicular cancer, an anal cancer, a vulvar cancer, a joint cancer, an oral cancer, a pharynx cancer or a colorectal cancer.

[1128] Exemplary Embodiment No.267. The method, morphic form, combination, or use of any one of the preceding Exemplary Embodiments, wherein the cancer is adrenocortical carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma, endocervical adenocarcinoma, ...

Claims

Attorney Docket No. ASET-042 / 001WO 325190-2274 CLAIMS What is claimed is:

1. A morphic form of Compound No.1:a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof.

2. The morphic form of claim 1, wherein the morphic form is a crystalline form.

3. The morphic form of claim 1 or 2, wherein the morphic form is Form A, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

4. The morphic form of any of the preceding claims, wherein Form A is characterized by an X-ray powder diffraction (“XRPD”) pattern comprising signals (e.g., peaks) at 13.2±0.2,22.3±0.2, and 25.3±0.2 °2 (e.g., 13.2±0.1, 22.3±0.1, and 25.3±0.1 °2 (e.g., 13.2, 22.3, and25.3 °2 )) using Cu K radiation.

5. The morphic form of any of the preceding claims, wherein the XRPD pattern of Form A further comprises at least one signal (e.g., peak) selected from 12.8±0.2, 18.5±0.2, 19.4±0.2,and 24.8±0.2 °2 (e.g., 12.8±0.1, 18.5±0.1, 19.4±0.1, and 24.8±0.1 °2 (e.g., 12.8, 18.5, 19.4,and 24.8 °2 )) using Cu K radiation;optionally, wherein the XRPD pattern of Form A further comprises at least two signals(e.g., peaks) selected from 12.8±0.2, 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 12.8±0.1,18.5±0.1, 19.4±0.1, and 24.8±0.1 °2 (e.g., 12.8, 18.5, 19.4, and 24.8 °2 ))using Cu Kradiation; optionally, wherein the XRPD pattern of Form A further comprises signals (e.g., peaks)at 12.8±0.2, 18.5±0.2, 19.4±0.2, and 24.8±0.2 °2 (e.g., 12.8±0.2, 18.5±0.1, 19.4±0.1, and24.8±0.1 °2 (e.g., 12.8, 18.5, 19.4, and 24.8 °2 )) using Cu K radiation.

6. The morphic form of claim 1 or 2, wherein the morphic form is Form B, the solvateAttorney Docket No. ASET-042 / 001WO 325190-2274 thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

7. The morphic form of claim 1 or 2, wherein the morphic form is Form C, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

8. The morphic form of claim 1 or 2, wherein the morphic form is Form D, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

9. The morphic form of claim 1 or 2, wherein the morphic form is Form E, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

10. The morphic form of claim 1 or 2, wherein the morphic form is Form F, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

11. The morphic form of claim 1 or 2, wherein the morphic form is Form G, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

12. The morphic form of claim 1 or 2, wherein the morphic form is Form H, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

13. The morphic form of claim 1 or 2, wherein the morphic form is Form I, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

14. The morphic form of claim 1 or 2, wherein the morphic form is Form J, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

15. The morphic form of claim 1 or 2, wherein the morphic form is Form K, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

16. The morphic form of claim 1 or 2, wherein the morphic form is Form L, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

17. The morphic form of claim 1 or 2, wherein the morphic form is Form M, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.Attorney Docket No. ASET-042 / 001WO 325190-2274 18. The morphic form of claim 1 or 2, wherein the morphic form is Form N, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

19. The morphic form of claim 1 or 2, wherein the morphic form is Form O, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

20. The morphic form of claim 1 or 2, wherein the morphic form is Form P, the solvate thereof, the hydrate thereof, or the pharmaceutically acceptable salt thereof.

21. A combination comprising: an amorphous form of Compound No. 1, a salt thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a polymer. A composition comprising the combination of claim 21.

23. The composition of claim 22, wherein the polymer comprises a copolymer of N- vinylpyrrolidone and vinyl acetate.

24. The composition of claim 22, wherein the polymer comprises hydroxypropyl methylcellulose.

25. The composition of claim 22, wherein the polymer comprises a polymethacrylate- based copolymer.

26. The composition of claim 22, wherein the polymer comprises a polyvinyl caprolactam– polyvinyl acetate–polyethylene glycol graft copolymer.

27. The composition of any one of the preceding claims, wherein the composition is prepared by a method comprising mixing Form A of Compound No. 1 with one or more solvents.

28. The composition of any one of the preceding claims, wherein the composition isAttorney Docket No. ASET-042 / 001WO 325190-2274 prepared by a method comprising mixing Form A of Compound No.1 with a polymer.

29. The composition of any one of the preceding claims, wherein the XRPD profile of the composition is substantially similar to one or more of the XRPD profiles shown in FIG.

100.

30. Use of the morphic form of any one of the preceding claims in the manufacture of a medicament for treating or preventing cancer in a subject.

31. A combination comprising: (i) the morphic form of any one of the preceding claims and (ii) one or more inhibitors of the MAPK pathways.

32. A method of treating or preventing cancer in a subject, the method comprising administering to the subject a combination comprising: (i) the morphic form of any one of the preceding claims, and (ii) one or more inhibitors of the MAPK pathways.

33. A combination comprising: (i) the morphic form of any one of the preceding claims, and (ii) one or more inhibitors of the MAPK pathways, for treating or preventing cancer in a subject.

34. Use of a combination comprising: (i) the morphic form of any one of the preceding claims, and (ii) one or more inhibitors of the MAPK pathways, in the manufacture of a medicament for treating or preventing cancer in a subject.

35. The method, morphic form, combination, or use of any one of the preceding claims, wherein the subject has at least one oncogenic mutation in the BRAF gene.

36. The method, morphic form, combination, or use of any one of the preceding claims, wherein the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of B-Raf.

37. The method, morphic form, combination, or use of any one of the preceding claims, wherein the subject has at least one oncogenic mutation in the KRAS gene.

38. The method, morphic form, combination, or use of any one of the preceding claims,Attorney Docket No. ASET-042 / 001WO 325190-2274 wherein the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of K-Ras.

39. The method, morphic form, combination, or use of any one of the preceding claims, wherein the subject has at least one oncogenic mutation in the NRAS gene.

40. The method, morphic form, combination, or use of any one of the preceding claims, wherein the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of N-Ras.

41. The method, morphic form, combination, or use of any one of the preceding claims, wherein the subject has at least one oncogenic mutation in the NF1 gene.

42. The method, morphic form, combination, or use of any one of the preceding claims, wherein the subject has at least one tumor and / or cancerous cell that expresses an oncogenic variant of NF1.

43. The method, morphic form, combination, or use of any one of the preceding claims, wherein the cancer is a carcinoma, a lymphoma, a blastoma, a sarcoma, a leukemia, a brain cancer, a breast cancer, a blood cancer, a bone cancer, a lung cancer, a skin cancer, a liver cancer, an ovarian cancer, a bladder cancer, a renal cancer, a kidney cancer, a gastric cancer, a thyroid cancer, a pancreatic cancer, an esophageal cancer, a prostate cancer, a cervical cancer, a uterine cancer, a stomach cancer, a soft tissue cancer, a laryngeal cancer, a small intestine cancer, a testicular cancer, an anal cancer, a vulvar cancer, a joint cancer, an oral cancer, a pharynx cancer or a colorectal cancer.

44. The method, morphic form, combination, or use of any one of the preceding claims, wherein the cancer is insensitive or resistant to treatment with one or more inhibitors of the MAPK pathways.

45. The method, morphic form, combination, or use of any one of the preceding claims, wherein the cancer is insensitive or resistant to treatment with a BRAF inhibitor, a MEK inhibitor, or a combination thereof.

Images